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Zusammenfassung 
Zusätzlich zu den tropentypischen Erkrankungen werden die afrikanischen Länder südlich der Sahara 
von einer disproportionalen Ausbreitung des Human Immunodeficiency Virus (HIV) geplagt. In einer 
Region, die ohnehin mehr als andere unter Infektionserkrankungen leidet, wurde schon lange 
diskutiert, ob chronische Wurmerkrankungen zu einer erhöhten Suszeptibilität für HIV führen 
könnten. Helmintheninfektionen werden häufig bereits in der Kindheit erworben und können 
unbehandelt über Jahre im menschlichen Körper verbleiben. Da Helmintheninfektionen somit zeitlich 
der Lebensphase mit erhöhtem Risiko für den Erwerb einer HIV-Infektion vorausgehen, könnten sie 
für die HIV Epidemiologie eine Rolle spielen. Trotz vieler Hinweise, die diese Hypothese unterstützen, 
blieb der Beweis über lange Jahre aus. In der vorliegenden Habilitationsarbeit werden Daten einer 
großen prospektiven Studie in der Normalbevölkerung Süd-West-Tansanias ausgewertet und der 
Einfluss verschiedener Helminthen auf die Empfänglichkeit für eine HIV-Infektion untersucht. Die 
Infektion mit W. bancrofti, dem Erreger der lymphatischen Filariose (LF), die trotz adäquater 
Behandlung lange im menschlichen Körper bleibt, zeigte einen signifikanten Einfluss auf die HIV 
Inzidenz. Der Vergleich von Filarien-Infizierten mit nicht-Infizierten zeigt ein 3,2-fach erhöhtes Risiko 
für die HIV-Ansteckung bei den 14 bis 25-Jährigen, ein 2,4-fach erhöhtes Risiko für die 25 bis 45-
Jährigen, und ein 1,2-fach erhöhtes Risiko für die über 45-Jährigen. Mehrere Konsequenzen können 
aus den Ergebnissen gezogen werden: Das erhöhte Risiko für den Erwerb einer HIV-Infektion kann 
sehr wahrscheinlich reduziert werden durch schnellere Elimination des Wurmes aus dem befallenen 
menschlichen Körper mit bereits verfügbaren moderneren Therapieschemata. Damit könnte ein 
erheblicher Beitrag zur HIV Prävention geleistet werden, der bislang nicht propagiert wurde. Die 
weiteren Untersuchungen zu HIV-Risikofaktoren in der Studienpopulation deckten auf, dass die 
verschiedenen Altersgruppen unterschiedlich empfänglich für diese Faktoren sind. Dies sollte bei 
Präventionsmaßnahmen berücksichtigt werden, die auf Zielgruppen zurechtgeschnitten werden. Es 
wurden innerhalb der großen prospektiven Studie auch intestinale Nematoden untersucht, die 
keinen signifikanten Einfluss auf die HIV Inzidenz zeigten. Interessant sind auch weitere Analysen, die 
versuchen die Hintergründe für die gesteigerte HIV Inzidenz zu beleuchten. Es wurden 
Veränderungen der Immunaktivierung und der Rezeptorbeladung der T-Helferzellen gefunden, die 
insbesondere bei Patienten infiziert mit W. bancrofti, aber nicht bei den mit intestinalen Helminthen 
Infizierten auftraten.  
Die extreme Verbreitung des HI-Virus in den Ländern im südlichen Afrika hat zur Folge, dass andere 
Infektionen aber auch bösartige Erkrankungen in diesen Regionen an Häufigkeit zunehmen. Eine der 
häufigsten Ko-Infektionen in diesen Ländern ist die Tuberkulose (TB). Eine zügige und korrekte 
Diagnose und Therapie ist erschwert durch die paucibazilläre Natur, in der TB bei den HIV-Ko-
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infizierten vorliegt. Mit zwei neueren diagnostischen Methoden, den Interferon-gamma-Release 
Assays (IGRA) sowie wie der Untersuchung des Lipoarabinomannan (LAM) habe ich mich näher 
befasst. LAM ist ein Teil der Zellwand von Mykobakterien und im Urin von Tuberkulosepatienten 
nachweisbar Die Verfügbarkeit von Urin und der unkomplizierte Testablauf machen diesen Test 
attraktiv. Die Studien der letzten Jahre hatten aber sehr schwankende Spezifitäten und recht niedrige 
Sensitivitäten gezeigt, was die Begeisterung über diese neue Testmethode dann doch begrenzt hat. 
Wir konnten in den hier beigelegten Studien in Tansania einiges zur Klärung der wechselhaften 
Spezifität beitragen. Die Sensitivität dieses Tests ist sehr unterschiedlich bei Personen mit bzw. ohne 
HIV-Infektion. Bei stark immunkompromittierten HIV-Infizierten werden tolerable Sensitivitäten 
erreicht, die diesen Test sinnvoll erscheinen lassen. Ebenfalls interessant als alternative diagnostische 
Möglichkeit für Tuberkulose sind die sogenannten Interferon-gamma Release Assays (IGRA). Wie der 
Tuberkulin-Haut-Test (TST) messen die IGRAs die spezifische Immunantwort gegen M. tuberculosis 
und zeigen eine aktive oder latente Tuberkulose an. Im Gegensatz zum Tuberkulin-Haut-Test 
reagieren die IGRAs nicht falsch positiv, bei Personen die mit dem BCG- Impfstoff geimpft wurden, 
oder die mit anderen (nicht-tuberkulösen) Mykobakterien (NTM) Kontakt hatten und sind somit 
erheblich spezifischer. Sie haben im Vergleich mit dem TST ebenfalls den großen Vorteil, dass sie 
korrekt negative Befunde unterscheiden können von einer immunkompromittierten Situation in 
denen die Tests nicht aussagefähig sind. Die HIV-Infektion führt sehr früh bereits zu einem Verlust 
der TB-spezifischen Gedächtniszellen. Dies beeinflusst die Interpretation eines positiven IGRAs bei 
den HIV/TB-Ko-infizierten und kann diagnostisch benutzt werden.  
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1 Einleitung 
Die durch HIV ausgelöste Epidemie nahm ihren Ursprung im Westen Afrikas [1], und breitete sich 
dann global aus. Molekularepidemiologische Methoden legen eine Speziestransmission vom 
Schimpansen auf den  Menschen bereits um 1920  nahe [1], aber erst 1981 trat das hierdurch 
ausgelöste Acquired Immunodeficiency Syndrom (AIDS) in das Blickfeld der Öffentlichkeit. Circa 78 
Millionen Menschen wurden bislang infiziert, circa die Hälfte der Infizierten verstarb. Von den 36,7 
Millionen Menschen, die zurzeit mit HIV infiziert sind [2], leben circa zweidrittel in Afrika südlich der 
Sahara. Schon lange wurden die Ursachen der disproportionalen Verbreitung des HI-Virus in dieser 
Region hinterfragt [3]. 
 
Abbildung 1: Geschätzte HIV Prävalenz in 15-49 jährigen in afrikanischen Ländern südlich der Sahara in 1984, 1989, 1994, 
1999 (aus dem Artikel: The global impact of HIV/AIDS, Peter Piot, Michael Bartos, Peter D. Ghys, Neff Walker and Bernhard 
Schwartländer, Nature 410, 968-973 (19 April 2001) 
Im Vergleich zu anderen Kontinenten, in denen die Ausbreitung von HIV erheblich langsamer verlief, 
leiden viele Menschen in afrikanischen Ländern an weiteren Infektionserkrankungen, wie z.B. 
Tuberkulose oder Wurmerkrankungen Es wurde daher bereits früh nach einer möglichen Rolle 
anderer Infektionen für die HIV Inzidenz und Pathogenese gefragt. Bentwich et al. formulierten 1995 
die Hypothese, dass eine durch Wurminfektionen hervorgerufene Immunaktivierung sowohl die Rate 
der HIV-Neu-Infektionen, als auch den Krankheitsverlauf beeinflussen könnte [4-6]. Umgekehrt ist 
bekannt, dass die HIV-Infektion die Häufigkeit und den Verlauf anderer Infektionen verändern kann; 
Beispiele sind die opportunistischen Infektionen. 
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Das Thema dieser Habilitation sind die Interaktionen von HIV und anderen tropentypischen 
Infektionserregern. Dabei wird sowohl auf die Epidemiologie verschiedener Erreger und die 
eventuelle gegenseitige Beeinflussung, als auch auf die diagnostischen Schwierigkeiten unter dem 
Einfluss von HIV eingegangen.  
 
HIV und die dadurch ausgelöste Erkrankung AIDS haben sich  rasend schnell global ausgebreitet. 
Nach der Erstbeschreibung 1981 nahm die Zahl der weltweit Infizierten stetig zu. Massive 
Bemühungen zur Prävention der Übertragung haben in den letzten Jahren zu einer Stagnation der 
Zahlen geführt. Die Übertragung des Virus erfolgt über Blut, sexuelle Kontakte und von Mutter-zu-
Kind. Präventionsmaßnahmen beinhalten Aufklärung über die Übertragungswege, Kondome, 
Zirkumzision sowie die antiretrovirale Therapie (ART) der Infizierten. Eine wirksame Impfung gegen 
HIV ist bislang trotz vieler Bemühungen nicht verfügfügbar. Weltweit waren in 2016 circa 50% der 
Infizierten mit ART behandelt, circa 77% der schwangeren Frauen erhielten eine Therapie zur 
Verhinderung der Mutter-zu-Kind-Übertragung. Die Zahl der Neuansteckungen liegt seit 2010 
weltweit jährlich bei circa 2 Millionen und hat sich seit 2010 trotz massiver Anstrengungen nicht 
verringert. Weitere Informationen und mögliche Maßnahmen zur Prävention der HIV Infektion sind 
daher von großem Interesse. 
Die sogenannten “durch-Erde-übertragenen Würmer“ (soil transmitted helminths) (STH), Ascaris 
lumbricoides und Hakenwürmer (Ancylostoma duodenale und Necator americanus) sowie Trichuris 
trichiura sind abhängig von verschiedenen Umweltfaktoren. Innerhalb des Menschen wandern 
sowohl der Spulwurm (Ascaris lumbricoides), als auch die Hakenwürmer durch den Körper und 
passieren dabei mehrere Organe. Im Gegensatz dazu wird der Peitschenwurm (Trichuris trichiura) 
oral aufgenommen und verbleibt im Intestinaltrakt, in dem auch der Weg der anderen beiden 
Nematoden letztendlich mündet. Die Diagnostik der Helminthen erfolgt durch Untersuchungen des 
Stuhls. Die Behandlung der intestinalen Nematoden erfolgt mit Albendazol. 
Eine Infektion mit dem Blut- und Gewebe-Nematoden Wuchereria bancrofti führt zur lymphatischen 
Filariose. Zirka 120 Millionen Menschen weltweit sind von dieser Erkrankung betroffen, circa ein 
Drittel von Ihnen leidet unter den Folgeerscheinungen, einer Elephantiasis oder einer Hydrozele [7, 
8]. Im Gegensatz zu den intestinalen Nematoden wird W. bancrofti von Mücken übertragen. Diese 
nehmen die im Blut befindlichen Mikrofilarien auf, und übertragen nach circa 14 Tagen eine 
infektiöse Larve auf den Menschen. Seit dem Jahr 2000 versucht die Global Alliance for Eliminating 
Lymphatic Filariasis (GAELF) diese Erkrankung zu bekämpfen. Jedoch wirken die in Afrika benutzten 
Medikamente nur auf die Mikrofilarien, und verhindern somit die Transmission auf weitere 
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Menschen. Auf die adulten Würmer, die circa 12-12 Jahre im menschlichen Körper leben, wirken sie 
allerdings kaum.  
Die Tuberkulose ist weiterhin eine global weit verbreitete Erkrankung. Es wird geschätzt, dass circa 2 
Milliarden Menschen „latent“ mit Mykobakterium tuberculosis infiziert sind und circa 9 Millionen an 
einer aktiven Erkrankung erleiden. Seit der HIV Epidemie hat sich die Ausbreitung der Tuberkulose 
noch mal verstärkt. Die „latente“ TB Infektion hatte früher eine Wahrscheinlichkeit von circa 5% sich 
innerhalb des Lebens des Betroffenen in eine aktive Erkrankung zu verwandeln. Bei einer Ko-
Infektion mit HIV rechnet man mit circa 5% aktiven Tuberkulosen pro Jahr. Die TB hat sich damit zu 
einer der wichtigsten opportunistischen Infektionen (OI) der HIV Infektion entwickelt. Sie kann 
bereits in einem frühen Stadium der HIV-Infektion auftreten, wenn andere OI noch vom 
Immunsystem kontrolliert werden. Dies liegt an dem frühen Eliminieren von TB-spezifischen CD4-
Zellen [9, 10]. Eine aktive TB-Infektion ist bei Vorliegen einer HIV-Ko-Infektion schwerer zu 
diagnostizieren, weil die „Goldstandards“ der Diagnostik, wie Sputum-Ausstrich, Mykobakterien 
Kultur weniger sensitiv sind. Der Ausstrich, der circa 10.000 Bazillen pro ml Sputum braucht, aber 
auch die Kultur, die mit 10-100 vermehrungsfähigen Bazillen auskommt, tragen bei HIV-Infizierten 
erheblich seltener zur Diagnose bei, da die Erkrankung oft paucibazillär verläuft. Dies führt zu 
erheblichen Schwierigkeiten eine Tuberkulose sicher zu erkennen und zeitnah eine Behandlung zu 
beginnen  
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2 Zielsetzung:  
Diese Habilitation basiert auf zwei Studienbereichen:  
(i) der Untersuchungen zu epidemiologischen Parametern innerhalb einer sorgfältig randomisierten 
Kohorte (EMINI, SOLF) mit den folgenden Schwerpunkten:;  
• Beschreibung der Prävalenz und Inzidenz verschiedener Helmintheninfektionen und HIV, 
sowie der Untersuchung von Risikofaktoren für die jeweiligen Erkrankungen in einer großen 
prospektiven Kohorte der Normalbevölkerung in Süd-West-Tansania. 
• Analyse des Einflusses der HIV-Infektion auf die unterschiedlichen Helminthen. 
• Analyse des Einflusses einer vorbestehenden Helminthen-Erkrankung auf die HIV-Inzidenz.  
(ii) der Untersuchungen von erkrankten Kindern, die mit dem Verdacht auf eine aktive 
Tuberkulose in das Krankenhaus kamen (ADAT) mittels unterschiedlicher TB diagnostischer 
Methoden mit den folgenden Schwerpunkten:; 
• Untersuchung der Sensibilität und Spezifität des Lipoarabinomannan Testes, sowie 
verschiedener Interferon-gamma Release Assays für die Diagnose der Tuberkulose bei 
Kindern.  
• Analyse eines Einfluss der HIV-Infektion auf die tuberkulosespezifische Diagnostik.  
Des Weiteren gingen Erfahrungen und Probleme in der Diagnostik in einer auf die Entdeckung und 
Beschreibung des frühen Stadiums der HIV-Infektion spezialisierten Studie (RV 217) in diese 
Zusammenfassung ein.  
 
3 Wissenschaftliche Projekte 
Es werden Daten von 9 publizierten PubMed gelisteten Artikel, an denen ich beteiligt war für diese 
Habilitation zusammengefasst. Die Daten hierfür wurden in folgenden Studien gesammelt.  
ADAT (Active Detection of Active Tuberculosis), eine Studie in Tansania, durchgeführt 2008-10,  in 
der Kinder von 1-14 Jahren mit Verdacht auf Tuberkulose untersucht und behandelt wurden.  
(Rolle: Co-Investigatorin, Datenanalyse) 
 
EMINI (Evaluate and Monitor the Impact of New Interventions), eine großangelegte 
Bevölkerungsstudie, durchgeführt 2006-11, die 10% der Bewohner von neun ausgewählten Distrikten 
der Region Mbeya, Tansania, auf HIV, TB, Malaria und Helminthen untersucht hat (Abb.1) 
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(Rolle: Labormanagerin, Datenanalyse) 
 
WHIS (Worm HIV Interaction Study), eine Studie (Amendement zu EMINI, 2009-12), die an 
ausgewählten erwachsenen Patienten die Interaktion zwischen HIV und Helminthen untersucht. Es 
wurden verschiedene T-Zell-Subpopulationen, sowie Aktivierungsmarker. 
 
(Rolle:, gemeinsame Auswertungen und Veröffentlichungen, Überlappung der Ergebnisse mit SOLF) 
SOLF (Surveillance of Lymphatic Filariasis), eine Studie (Amendement zu EMINI, 2009-12), die die 
Prävalenz der lymphatischen Filariose vor und nach zwei Zyklen einer Massenbehandlung in einer der 
EMINI-Distrikte untersucht hat. Es wurde die gesamte Population des Distriktes über fünf Jahre 
untersucht. (Rolle: Antragstellerin, Projektleiterin) 
 
RV 217 (syn. ECHO Early Infection HIV Cohort Study, Beginn 2009) Studie zur „HIV-Prevalence, 
Incidence, Cohort Retention, and Host Genetics and viral Diversity in Cohorts in East Africa and 
Thailand” (Rolle: Clinical Research Coordinator) 
 
Studienort 
Die Projekte wurden im Mbeya Medical Research Centre (MMRC) des National Institutes for Medical 
Research (NIMR) in Mbeya Tansania durchgeführt. Sie fanden unter der Leitung von Prof. Michael 
Hölscher, Direktor der Abteilung Tropenmedizin des Klinikum der Universität München, (LMU) und 
Leonard Maboko (vormaliger Direktor des NIMR-MMRC) statt. Die ersten beiden Projekte (ADAT und 
EMINI) wurden von Prof. Michael Hölscher initiiert. Bei der ADAT-Studie war ich für die Durchführung 
und Qualitätskontrolle des Quantiferon-TB-Gold und des Lipoarabinomannan Tests verantwortlich. 
Die beiden Projekte SOLF und WHIS waren sogenannte Ergänzungs-Studien die innerhalb der 
Population der EMINI-Studie durchgeführt wurden. Ich habe die SOLF Studie beim 
Bundesministerium für Bildung und Forschung (BMBF) beantragt und war als Projektleiterin für das 
Training, die Durchführung und die Auswertungen zuständig. Die Studie zur Erforschung der frühen 
HIV-Infektion (RV217) wurde von Dr. Merlin Robb vom Walter Reed Army Institute konzipiert und in 
5 Ländern durchgeführt. Als klinische Koordinatorin war ich an der Protokollentwicklung und 
während der ersten zwei Jahre an der Rekrutierung und Betreuung von Studienteilnehmern beteiligt.  
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Abbildung 1: Die Region Mbeya liegt im Südwesten Tansania und grenzt an Malawi und Zambia. Das 
schwarze Viereck deutet das Gebiet der EMINI Studie an, das rechts vergrößert dargestellt wurde. Im 
rechten Bild sind die neun Gebiete der EMINI-Studie eingezeichnet. Diese unterscheiden sich 
geographisch erheblich, sodass verschiedene Umweltfaktoren in der Analyse erfasst und verglichen 
werden konnten. Mit dem roten Viereck ist das Gebiet Kyela, in welchem die Substudie SOLF 
stattfand, gekennzeichnet. 
 
 
3 Diskussion der eigenen Arbeiten:  
HIV Infektion, Probleme der Diagnostik, Frühe Infektionsphase 
Low specificity of determine HIV1/2 RDT using whole blood in south west Tanzania. Kroidl I, Clowes P, 
Mwalongo W, Maganga L, Maboko L, Kroidl AL, Geldmacher C, Machibya H, Hoelscher M, Saathoff E. 
PLoS One. 2012;7(6):e39529. doi: 10.1371/journal.pone.0039529. 
Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. Robb ML, Eller LA, 
Kibuuka H, Rono K, Maganga L, Nitayaphan S, Kroon E, Sawe FK, Sinei S, Sriplienchan S, Jagodzinski 
LL, Malia J, Manak M, de Souza MS, Tovanabutra S, Sanders-Buell E, Rolland M, Dorsey-Spitz J, Eller 
MA, Milazzo M, Li Q, Lewandowski A, Wu H, Swann E, O'Connell RJ, Peel S, Dawson P, Kim JH, Michael 
NL; RV 217 Study Team (Kroidl I,…).N Engl J Med. 2016 Jun 2;374(22):2120-30. doi: 
10.1056/NEJMoa1508952. 
Zwei der hier beigelegten Artikel beschäftigen sich mit der HIV-Infektion ohne begleitende Ko-
Infektion. Eine großangelegte Studie „EMINI“ wurde in der Normalbevölkerung durchgeführt und 
war dazu gedacht, die Prävalenz von verschiedenen Infektionserkrankungen zu beschreiben. Für HIV 
konnte zusätzlich die Anzahl der Neuinfektionen über die 4 Jahre, in der die Studie durchgeführt 
wurde, beschrieben werden. Der Algorithmus zur Diagnostik der HIV-Infektion bei mehr als 18.000 
Studienteilnehmern aus 4200 Haushalten sah zunächst einen sogenannten „rapid-diagnostic test“ 
(RDT), entsprechend der nationalen tansanischen Guidelines vor. Alle positiven Ergebnisse wurden 
mittels ELISA und/oder Western Blot bestätigt. Um die Verschwiegenheit über das Testergebnis für 
die einzelnen Haushaltsmitglieder zu wahren, wurden alle HIV-Tests aus konserviertem Blut im 
Zentrallabor durchgeführt, aber zusätzlich Zelte der mobilen freiwilligen Beratungs- und 
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Testungseinheit („voluntary counseling and testing“, VCT) für jeden Studienteilnehmer zu Verfügung 
gestellt. Sehr schnell stellte sich heraus, dass es eine hohe Anzahl von falsch positiven RDT 
Ergebnissen gab, insbesondere bei Kindern. Dies hatte bereits zu Besorgnis geführt, da Kinder von 
HIV negativen Eltern unerwartet HIV positiv getestet wurden. Es stellte sich jedoch heraus, dass der 
vom Staat Tansania gewählt RDT extrem sensitiv, aber wenig spezifisch war, und insbesondere bei 
Verwendung von Vollblut viele falsch positive Ergebnisse lieferte. Da die Blutabnahme bei kleineren 
Kindern vom Forschungsteam nicht genügend geübt worden war, wurde bei diesen meistens nur 
Fingerbeerenblut genommen, statt eine Venenpunktion durchzuführen. Die Nachtestungen ergaben, 
dass tatsächlich alle Ergebnisse, die zu Zweifeln geführt hatten, auf falsch positiven RDT Ergebnissen 
beruhten und diese häufiger bei Fingerbeerenblut (Vollblut), als bei Serumproben vorkamen. Diese 
Ergebnisse wurden frühzeitig mit dem tansanischen Gesundheitssystem besprochen und die 
Guidelines bezüglich der Wahl bzw. Kombination der HIV-Teste daraufhin auch geändert. 
 
Die Ergebnisse der EMINI Studie, insbesondere die Ergebnisse der Testung für die HIV-Prävalenz und 
Inzidenz in den neun Studiengebieten wurden im Mbeya Medical Research Centre benötigt, weil 
weitere Studien zu HIV durchgeführt werden sollten. Es wurde eine HIV Prävalenz von 6,9% in der 
Studienpopulation gemessen. Die HIV-Prävalenzen betrugen 1,6% in der Altersgruppe 0-15 Jahre, 
12,4% in der Altersgruppe 15-49 Jahre, und 6,8% in der Altersgruppe über 50 Jahre. Die HIV-Inzidenz 
betrug 1,35 auf 100 Personenjahren (95% KI 1,10-1,64).  
Verschiedene Sponsoren hatten in der Region HIV-Impfstudien geplant. Zusätzlich führte das Walter-
Reed-Army-Institute eine Studie zur frühen HIV Infektion durch, an der ich als klinische Forschungs-
Koordinatorin für Tansania beteiligt war. Ziel der RV 217 (ECHO) Studie war es, die frühe HIV 
Infektion zu beschreiben, in einer Phase, in der die üblichen Tests noch negativ sind. Dies dient der 
Erfassung von typischen Symptomen in der frühen Phase, sowie auch der Sammlung von Blutproben, 
um unterschiedliche immunologische Reaktionen, die für den späteren Verlauf der chronischen HIV 
wichtig sind, zu erfassen. In diese Studie wurden Personen mit hohem Risiko für eine HIV-Infektion, 
aber bislang negativen HIV Test eingeschlossen. Mehr als 2.000 Personen mit hohem Risiko einer 
HIV-Infektion wurden in Tansania, Kenia, Uganda und Thailand über mehrere Jahre zweimal 
wöchentlich auf eine neue HIV-Infektion untersucht. Eine spezielle, hochsensitive semiquantitative 
DNA Nachweis-Methode namens APTIMA ermöglichte, HIV-Neuansteckungen schon bei sehr 
geringen Konzentrationen von circa 20 HIV-RNA-Kopien pro Milliliter Plasma nachzuweisen. 
Insgesamt wurden durch diese Nachweismethode 112 Personen nur wenige Tage nach der Infektion 
mit dem HI-Virus identifiziert. Bei diesen HIV-Infektionen im extrem frühen Stadium waren 
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durchschnittlich fünf Tage vom letzten negativen bis zum ersten positiven Bluttest vergangen. So 
konnte erstmalig der Zeitraum zwischen Infektion und dem Höchstwert der Viruslast genauer 
beschrieben werden, in dem es zur Ausbreitung von Zelltypen kommt, die entscheidend für den 
weiteren Verlauf der HIV-Infektion sind. Die Zeit vom ersten Nachweis der HIV-RNA bis zum Peak der 
Viruslast betrug im Mittel 13 Tage. Zwischen Maximalwert und dem Tiefstwert der Viruslast, dem 
sogenannten Set-point, wurden wiederum 31 Tage gemessen. Der weitere Krankheitsverlauf des HIV-
infizierten Patienten wird vom Set-point bestimmt, denn die Höhe der Viruslast bleibt nach Erreichen 
des Set-points für eine lange Zeit gleich. Die Höhe der Viruslast zu diesem Zeitpunkt entscheidet über 
einen raschen oder eher langsamen Verlauf der HIV-Infektion. Informationen über Interaktionen 
zwischen dem Immunsystem und dem Virus, die die Höhe des Set-points beeinflussen könnten, sind 
daher von außerordentlicher Relevanz. Eine Analyse derart früher Zeitpunkte nach der Ansteckung ist 
bislang einzigartig, da frühere Studien nur Patienten einschlossen, die bereits Symptome aufwiesen 
oder sich schon mehrere Wochen zuvor angesteckt hatten. Inzwischen wurden Ergänzungsstudien 
begonnen, die die Auswirkung einer sehr früh antiretroviralen Behandlung auf den Langzeitverlauf 
untersuchen.  
 
Helminthen und HIV 
Im Jahr 2009 betrug die HIV-Prävalenz innerhalb der gesamten EMINI Studie 6,9%, dabei wiesen die 
einzelnen Studienregionen Prävalenzen zwischen 3,6% und 9.7% auf. Ab 2009 wurde in der EMINI 
Studie auch Stuhl und Urinproben gesammelt, um auf S. haematobium, S. mansoni, die intestinalen 
Helminthen Ascaris lumbricoides, Hakenwurm (Necator americanus und Ancylostoma duodenale) 
sowie Trichuris trichiura zu untersuchen. Als Ergänzungsstudie kam dann noch die Untersuchungen 
für Wuchereria bancrofti hinzu, nachdem in einer der EMINI-Studienregionen Patienten mit 
klinischen Zeichen der lymphatischen Filariose bemerkt worden waren. Drei der hier angegebenen 
Publikationen beschäftigen sich mit intestinalen Helminthen, zwei weitere mit der lymphatischen 
Filariose. Bei circa 60% der untersuchten Studienteilnehmer wurden ein oder mehrere 
unterschiedliche  Helmintheninfektionen festgestellt. Die neun Regionen der EMINI Studie waren 
geographisch unterschiedlich gelegen. So war es nicht unerwartet, dass sowohl die HIV-Prävalenz, 
aber auch die Verteilung der Helminthen sehr unterschiedlich war. Im Prinzip waren vier der 
studierten Regionen relevant von Wurminfektionen betroffen, die anderen fünf nur sehr wenig. Es 
gab genau eine Studienregion, in der alle untersuchten Helminthenarten zu finden waren. Bei den 
folgenden Untersuchungen gab es teilweise Auswertungen der gesamten Studienpopulation, zum 
Teil aber auch Analysen getrennt für einzelne Regionen. Dies ist insbesondere beim Vergleich 
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zwischen HIV-infizierten und HIV-negativen Studienteilnehmern wichtig, da ansonsten ein 
verfälschtes Bild eines möglichen Einflusses entstehen könnte. Es wurden von unserer Gruppe 
bereits Auswertungen zu Ascaris lumbricoides, Hakenwurminfektionen, Trichuris trichiura (PloS One, 
in press) und W. bancrofti veröffentlicht. Da alle Diagnosen zu einer medikamentösen Therapie des 
jeweiligen Studienteilnehmers führten, konnten hauptsächlich Querschnitts-Untersuchungen 
durchgeführt werden, da bei gutem Therapieerfolg keine längeren Zeiten der Infektion mit einem 
intestinalen Helminthen definiert werden konnten.  
 
Querschnitts (cross-sectionale) Untersuchungen zu Helminthen 
Ascaris lumbricoides infection and its relation to environmental factors in the Mbeya region of 
Tanzania, a cross-sectional, population-based study. Schüle SA, Clowes P, Kroidl I, Kowuor DO, Nsojo 
A, Mangu C, Riess H, Geldmacher C, Laubender RP, Mhina S, Maboko L, Löscher T, Hoelscher M, 
Saathoff E. PLoS One. 2014 Mar 18;9(3):e92032. doi: 10.1371/journal.pone.0092032. 
(Trichuris trichiura Infection and Its Relation to Environmental Factors in Mbeya Region, Tanzania: A 
Cross-Sectional, Population-Based Study. Kirsi Marjaana Manz, M.Sc.; Petra Clowes; Inge Kroidl; 
Dickens O Kowuor; Christof Geldmacher; Nyanda E Ntinginya; Leonard Maboko; Michael Hoelscher; 
Elmar Saathoff. PONE-D-16-48704.in press) 
Hookworm infection and environmental factors in Mbeya region, Tanzania: a cross-sectional, 
population-based study. Riess H, Clowes P, Kroidl I, Kowuor DO, Nsojo A, Mangu C, Schüle SA, 
Mansmann U, Geldmacher C, Mhina S, Maboko L, Hoelscher M, Saathoff E. PLoS Negl Trop Dis. 2013 
Sep 5;7(9):e2408. doi: 10.1371/journal.pntd.0002408. 
Infektionen mit Ascaris lumbricoides kamen hauptsächlich in 3 Regionen der EMINI Studie vor 
(Ruanda 8.5%, Isongole 16.8%, Kyela 25.2 % Prävalenz). Die anderen sechs Regionen der EMINI-
Studie lagen unter 1% in der Prävalenz für A. lumbricoides. Eine Infektion mit dieser Wurm Spezies 
war in der multivariaten Analyse positiv assoziiert mit Faktoren wie Dichte der Vegetation, 
Regenmenge und Umgebungstemperaturen. Der Peitschenwurm Trichuris trichiura kam fast 
ausschließlich in dem Distrikt Kyela vor, es waren dort 26.6% der Studienteilnehmer infiziert. Eine 
Infektion war positiv assoziiert mit der Dichte der Vegetation, aber negativ mit der Regenmenge.   
Die HIV-Prävalenz in den drei Studienregionen, in denen die Ascaris Infektion hauptsächlich vorkam, 
war mit 9.17%, 9.74%, 9.19%, respektive, sehr ähnlich. Bezogen auf alle drei Regionen gemeinsam 
konnten wir bei der HIV-negativen Subgruppe Ascaris Prävalenzen von 18.9%, und bei der HIV-
positiven Subgruppe von 15.2 % darstellen, und fanden somit keinen signifikanten Unterschied 
(p=0.210). Berücksichtigt man den Einfluss von Alter und Geschlecht in einer multivariaten 
logistischen Regression waren die Unterschiede noch geringer (p=0.62). Sehr ähnliche Befunde 
fanden wir für Trichuris trichiura. Da dieser fast ausschließlich in dem Distrikt Kyela vorkam, konnte 
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auch nur in diesem Distrikt eine Relation zu HIV untersucht werden. Im Gegensatz zu A. lumbricoides, 
der einen zweiten Peak der Prävalenz im Erwachsenenalter hat, kommt T. trichiura hauptsächlich bei 
Kindern vor (Abb. 2). Die univariate Analyse suggeriert ein selteneres Vorkommen dieses Helminthen 
bei HIV-infizierten Personen, da die HIV Prävalenz bei Kindern und Jugendlichen niedrig war und erst 
ab dem 20. Lebensjahr signifikant anstieg. In der multivariaten Analyse, die auch Alter und 
Geschlecht berücksichtigte war dann aber kein Unterschied mehr zu sehen (p=0.975).  
     
Abb 2: Abbildungen aus den jeweiligen o.g. Veröffentlichungen zur Altersverteilung der Helminthen 
in der EMINI-Studie. Die grauen Balken geben die Anzahl der Studienteilnehmer in der jeweiligen 
Altersgruppe an. Die roten Linien repräsentieren die Helminthen Prävalenz der verschiedenen 
Altersgruppen, links für die Spulwürmer, mittige die Peitschenwürmer, sowie rechts für die 
Hakenwürmer.  
Die Hakenwürmer wurden interessanterweise hauptsächlich in den beiden Regionen mit der 
höchsten und der niedrigsten HIV Prävalenz gefunden. Die Analyse sowohl der einzelnen Regionen, 
als auch der gesamten EMINI Kohorte zeigte keinen signifikanten Einfluss von Hakenwürmern auf die 
Hiv Inzidenz oder Prävalenz.  
Die hier beschriebenen Helmintheninfektionen werden hauptsächlich in der Kindheit erworben, je 
nach Art des Wurmes gibt es aber hohe Infektionsraten auch bei den Erwachsenen, z.B. bei den 
Hakenwürmern. In den meisten Fällen kann man davon ausgehen, dass Wurminfektionen in einem 
früheren Lebensabschnitt erworben werden, als eine HIV-Infektion. Bei allen Querschnitts-
Betrachtungen ist aber zu berücksichtigen, dass es natürlich für den Einzelfall nicht gesichert  ist, 
welche Infektion primär aufgetreten ist, und welche folgte. Hierfür sind prospektive Studien nötig. 
Für die meisten Helmintheninfektionen gestaltete sich dies schwierig. Die im oberen Text 
beschriebenen Helminthen wurden alle nach den Richtlinien der WHO therapiert, d.h. mit Albendazol 
gegen die intestinalen Helminthen, mit üblicherweise recht guten Erfolgsraten. Eine prospektive 
Untersuchung des Einflusses dieser Helminthen auf die HIV Inzidenz erwies sich daher als schwierig, 
da ein Zeitraum in dem der Einfluss einer Helmintheninfektion untersucht werden könnte, so nicht zu 
definieren war. Eine weitere Helminthenart die als Ergänzung der EMINI Studie in der Region Kyela 
untersucht wurde war die Blut-und Gewebsnematode Wuchereria bancrofti. Im Unterschied zu den 
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intestinalen Nematoden befinden sich die adulten Würmer im lymphatischen System, die zur 
weiteren Übertragung nötigen Mikrofilarien im Blut. Ein Regierungsprogramm begann die 
Behandlung gegen diesen Erreger im Jahr 2009, also nachdem der EMINI Survey bereits 3 Jahre 
durchgeführt worden war. Wir führten daher retrospektiv Untersuchungen zur Bestimmung der 
Prävalenz vor Behandlung (Proben von 2007, 2008 und 2009), aber auch in den zwei Jahren nach 
Durchführung der Massenhandlung (2010, 2011) durch, um den Therapieerfolg unabhängig zu 
überprüfen. Die von den afrikanischen Ländern gewählten Präparate Albendazol und Ivermectin 
töten die Mikrofilarien sehr gut, und verhindern damit die weitere Transmission des Erregers. Die 
adulten Würmer leben jedoch unbeeinträchtigt von diesen Präparaten circa 10-12 Jahre im 
menschlichen Körper. Der Nachweis einer Infektion mit W. bancrofti gelingt durch eine 
Blutuntersuchung, die ein Antigen des adulten Wurmes nachweist. Wir hatten die Möglichkeit 
Zeiträume zu definieren in denen eine W. bancrofti Infektion vorlag (positiver Antigenbefund am 
Anfang und am Ende des Beobachtungszeitraumes).  
 
Untersuchungen zum Einfluss von HIV auf LF 
Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in 
Individuals with HIV Co-infection in Southwest-Tanzania. Kroidl I, Saathoff E, Maganga L, Clowes P, 
Maboko L, Hoerauf A, Makunde WH, Haule A, Mviombo P, Pitter B, Mgeni N, Mabuye J, Kowuor D, 
Mwingira U, Malecela MN, Löscher T, Hoelscher M. PLoS Negl Trop Dis. 2016 Apr 12;10(4):e0004618. 
doi: 10.1371/journal.pntd.0004618  
 
In einer der neun Studienregionen von EMINI (Kyela) fielen bei den klinischen Untersuchungen 
Lymphödeme der Extremitäten auf, wie sie z.B. bei Infektionen mit W. bancrofti vorkommen. Für 
diese circa 2500 Teilnehmer wurde in den  bereits gewonnenen Plasmaproben auf das zirkulierende 
Filarienantigen (CFA) untersucht, welches von dem adulten Wurm von W. bancrofti stammt. Der 
große Vorteil dieser Untersuchungsmethode ist, dass die CFA-Mengen keiner zirkadianen Rhythmik 
unterliegen, wie z.B. die Mikrofilarien, die nur nachts im Blut vorkommen. Im Jahr 2009 wurde die 
Prävalenz der LF in der EMINI-Studienregion Kyela untersucht und lag bei 24.8%. Dabei hatten Kinder 
unter 10 Jahren eine sehr geringe Infektionsrate von unter 3%, Erwachsene lagen bei circa 40%. Es 
wurde alterstratifiziert der Einfluss einer HIV-Ko-infektion auf die LF-Prävalenz untersucht. Des 
Weiteren wurde analysiert, ob die HIV-Erkrankung eine Veränderung der LF-Inzidenz bewirkt, oder 
die Ansprechrate  unter Therapie verändert ist. Für keine der formulierten Fragestellungen war ein 
signifikanter Einfluss der  HIV-Erkrankung nachzuweisen. 
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Untersuchungen zum Einfluss von LF auf HIV  
Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort 
study. Kroidl I, Saathoff E, Maganga L, Makunde WH, Hoerauf A, Geldmacher C, Clowes P, Maboko L, 
Hoelscher M. Lancet. 2016 Oct 15;388(10054):1912-1920. doi: 10.1016/S0140-6736(16)31252-1.  
Die EMINI Studie hat über einen Zeitraum von fünf Jahren circa 2500 Teilnehmer pro Studienregion 
im Alter zwischen 0 und 94 Jahren jährlich einmal aufgesucht und untersucht. Dies erlaubte 
Berechnungen von Neuinfektionen für die HIV Erkrankung. In dem Distrikt Kyela, in dem die 
lymphatische Filariose getestet wurde, konnte daher der Einfluss dieser chronischen Wurminfektion 
auf die HIV Inzidenz untersucht werden. Die Auswertung für HIV Risikofaktoren beschränkte sich auf 
Personen über 14 Jahre, um verschiedene HIV Übertragungswege, und damit unterschiedliche 
Faktoren, die ein Risiko darstellen könnten, nicht zu vermischen. Bei 1055 initial HIV negativen 
Personen aus der Studienregion Kyela, die älter als 14 Jahre waren, wurden die jährlich gesammelten 
Plasmaproben auf eine Infektion mit W. bancrofti und auf eine neu erworbene HIV-Infektion 
untersucht. In 2626 Personenjahren konnten 32 neu aufgetretene HIV-Infektionen diagnostiziert 
werden. Das Risiko einer HIV-Infektion war mehr als zweifach erhöht bei den LF infizierten (1,91 Fälle 
im Vergleich zu 0,8 Fällen pro 100 Personenjahre, Inzidenz Rate Ratio (IRR) 2,38; das 95% KI= 1,08-
4,37). Es wurden drei Alterscluster getrennt untersucht. Der Vergleich von Filarien-Infizierten mit 
nicht-Infizierten ein 3,2-fach erhöhtes Risiko für die HIV-Ansteckung bei den 14 bis 25-Jährigen, ein 
2,4-fach erhöhtes Risiko für die 25 bis 45-Jährigen, und ein 1,2-fach erhöhtes Risiko für die über 45-
Jährigen (Abb. 5).  
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Abb.5 Die HIV Inzidenzen in den verschiedenen Altersgruppen bei LF-Infizierten (rote Balken) und LF-
Uninfizierten (blaue Balken). Die Zahlen unter der Graphik geben Anzahl der Personenjahre und die 
in dieser Zeit dokumentierten HIV-Neuinfektionen an. Es gab eine Neuinfektion im Kleinkindesalter, 
am ehesten durch Stillen. In der Phase zwischen 6 und 14 Jahren wurde keine HIV-Neuinfektion 
dokumentiert. In den Altersgruppen 14-25 Jahre und 25 bis 45 Jahre zeigten die LF-Infizierten ein 3 
bzw. 2,4 fach erhöhtes Risiko für eine HIV Infektion. 
Des Weiteren wurde die Kohorte auf andere, üblicherweise beschriebene Risikofaktoren für HIV 
untersucht, um eine mögliche Beeinflussung zu identifizieren. Dabei fiel auf, dass es Faktoren mit 
erheblich größerem Einfluss für die HIV-Infektion gibt, z.B. das Zusammenleben mit einem HIV-
Infizierten Partner (12.8-fach erhöhtes Risiko für eine HIV-Neuinfektion, linke Seite von Abb. 6). Es 
gab auch schützende Faktoren mit einem Risikofaktor unterhalb der 1-er Marke (siehe rechte Seite 
von Abb. 6)  
 
Abb. 6: Risikofaktoren für HIV. Links eine Gesamt-Darstellung, im rechten Teil der Graphik wurde der 
Risikobereich 0-3 vergrößert dargestellt, um feine Unterschiede besser darstellen zu können. Es 
wurden Risiken beschrieben, wie z.B. das Zusammenleben mit einem HIV-Infizierten Partner oder der 
Ehezustand „geschieden oder getrennt“ im Vergleich zu „Verheirateten“. Es wurden aber auch 
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schützende Faktoren, mit einem Risiko kleiner als 1 (all Balken unterhalb der roten Linie im rechten 
Bild) festgestellt.  
Die Analyse der 3 Alterscluster (Adoleszenten: 14-25 Jahre, junge Erwachsene 25-45 Jahre, und ältere 
Erwachsene über 45 Jahre) ergab, dass eine Infektion mit W. bancrofti der wichtigste Risikofaktor für 
den Erwerb einer HIV-Infektion unter den Adoleszenten darstellt. Andere HIV-Risikofaktoren spielten 
eine relevante Rolle bei den Erwachsenen über 25 Jahren Abb.7.  
Abbildung 7: Die Faktoren, die auf ihr Risikopotential für den Erwerb einer HIV Infektion untersucht 
wurden sind unterschiedlich wichtig in den verschiedenen Altersclustern.  
Als nächsten Schritt untersuchten wir die verschiedensten HIV-Risiko-Faktoren, ob sie die erhöhte 
HIV Inzidenz, die für die mit W. bancrofti-Infizierten gesehen wurde, beeinflussen könnten. Hiermit 
wurde geklärt, ob der beobachtete Einfluss der LF-Infektion auf die HIV Inzidenz sich durch andere 
Faktoren erklären lässt, oder ob es sich hierbei um einen eigenständigen Faktor handelt. Dazu 
wurden mehrere multivariate Analysen durchgeführt, die jeweils den LF-Status, die Altersgruppen, 
das Geschlecht sowie den zusätzlichen HIV-Risikofaktor beinhalteten. Die untersuchten Faktoren 
waren der eheliche Zustand, die Anzahl der sexuellen Partner, das Zusammenleben mit einem HIV-
infizierten Partner, Religionszugehörigkeit, Schulbildung, Beruf, zusätzliche Infektion mit anderen 
Helminthen, Kondombenutzung, Zirkumzision, Art der Kontrazeption, und mehr. Bei keiner der 
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durchgeführten Analysen wurde der Einfluss der LF-Infektion auf das Risiko einer HIV-Neuinfektion 
beeinträchtigt. Das Risiko blieb immer signifikant erhöht.  
Diese Ergebnisse sind von außerordentlicher Relevanz. Zum einen gelang zum ersten Mal der 
Nachweis in einer prospektiven Studie, dass eine vorstehende Wurmerkrankung, die völlig anders 
übertragen wird und mit sexuellen Praktiken und Vorlieben nicht zu tun hat, das Risiko für den 
Erwerb einer HIV-Infektion erhöht. Zum anderen wurde die Rolle von HIV-Risikofaktoren in den 
verschiedenen Altersgruppen beschrieben. Einige der HIV-Risikofaktoren, die bereits Eingang in die 
Präventivmedizin gefunden haben, sind noch nicht von Relevanz in diesem jungen Alter. In diesem 
Alter haben andere Faktoren, z.B. die LF-Infektion eine größere Wichtigkeit. Diese Erkenntnisse 
bieten verschiedenste Ansatzmöglichkeiten für eine Verbesserung der HIV-Prävention.  
 
HIV und Tuberkulose 
Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. Kroidl I, 
Clowes P, Reither K, Mtafya B, Rojas-Ponce G, Ntinginya EN, Kalomo M, Minja LT, Kowuor D, Saathoff 
E, Kroidl A, Heinrich N, Maboko L, Bates M, O'Grady J, Zumla A, Hoelscher M, Rachow A. Eur Respir J. 
2015 Sep;46(3):761-70. doi: 0.1183/09031936.00003315. 
Reasons for false-positive lipoarabinomannan ELISA results in a Tanzanian population. Kroidl I, 
Clowes P, Mwakyelu J, Maboko L, Kiangi A, Rachow A, Reither K, Jung J, Nsojo A, Saathoff E, 
Hoelscher M. Scand J Infect Dis. 2014 Feb;46(2):144-8. doi: 10.3109/00365548.2013.853133. 
QuantiFERON®-TB gold in-tube performance for diagnosing active tuberculosis in children and adults 
in a high burden setting. Rose MV, Kimaro G, Nissen TN, Kroidl I, Hoelscher M, Bygbjerg IC, Mfinanga 
SG, Ravn P. PLoS One. 2012;7(7):e37851.  
Drei der hier vorgelegten Arbeiten befassen sich mit der Diagnostik der Tuberkulose. Im Rahmen 
meiner Tätigkeit in Tansania war ich auch für die Durchführung und Beurteilung neuer Diagnostika 
zuständig. Im Allgemeinen führt die HIV-Erkrankung zu einer erschwerten Beurteilbarkeit von z.B. 
serologischen Untersuchungen. Auch die Sputum-Diagnostik für Tuberkulose ist deutlich weniger 
sensitiv bei Vorliegen einer Ko-infektion mit HIV. Diese Einschränkung trifft nicht zu für den Test auf 
Lipoarabinomannan (LAM), einen Bestandteil der Zellwand von Mykobakterien. Im Gegenteil, LAM ist 
im Urin von Tuberkulosepatienten deutlich besser nachweisbar bei HIV-Ko-infizierten Patienten, im 
Vergleich zu den ausschließlich an TB erkrankten Patienten. Dies konnten wir in einer pädiatrischen 
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Studie in Tansania bestätigen (ADAT). Bei HIV-negativen TB-Patienten wird die Durchführung des 
LAM Tests daher überhaupt nicht mehr empfohlen. Im Gegensatz dazu stehen die Interferon-Gamma 
Release Assays, die ein funktionierendes Immunsystem brauchen um ein aussagekräftiges Ergebnis 
zu produzieren. Drei verschiedene IGRAs (Quantiferon TB-Gold, T-Spot.TB und ein in-house ELISPOT) 
wurden in der ADAT-Studie getestet und mit dem konventionellen Tuberkulin –Haut-Test (TST) 
verglichen. Es konnte allgemein eine etwas bessere Sensitivität bei HIV negativen Patienten im 
Vergleich zu den mit HIV-infizierten demonstriert werden. Für beide Gruppen konnten die IGRAs 
jedoch empfohlen werden. Die ELISPOT Techniken und der Quantiferon TB Gold waren deutlich 
besser als der Tuberkulin Skin Test, sowohl bei HIV-positiven, als auch bei HIV-negativen 
Studienteilnehmern. Es gab einige weitere interessante Aspekte. Bei den IGRAs gibt es 
Untersuchungen, die nicht auswertbar sind, weil die positive Testkontrolle keine ausreichenden 
Werte erzielt hat. Diese nicht auswertbaren Tests für TB sind signifikant assoziiert mit 
Mangelernährung und Mortalität. Es sollte deshalb nach kurzer Zeit eine Wiederholung des IGRA 
durchgeführt werden, um zu einem auswertbaren Ergebnis zu kommen. In dieser Hinsicht, sind die 
IGRAs dem konventionellen Hauttest deutlich überlegen, denn dieser kann nicht zwischen „korrekt“ 
negativen Ergebnissen und dem geschilderten Problem unterscheiden. 
Einen weiteren interessanten Aspekt boten die Verlaufsuntersuchungen der Patienten der ADAT-
Studie, die 12 Monate nach Beginn der TB-Therapie durchgeführt wurden. Bei HIV-negativen 
Menschen bleiben nach einer erfolgreichen TB-Therapie immer TB-spezifische CD 4 Zellen zurück, die 
nach Stimulation mit TB-spezifischen Antigenen Interferon-gamma produzieren. Es ist daher anhand 
eines IGRA-Ergebnisses unmöglich zu sagen, ob die TB ausgeheilt ist. Dies ist anders bei HIV-positiven 
Patienten, die keine antiretrovirale Therapie bekommen. Bei dieser Subgruppe von Patienten 
verschwanden die TB-spezifischen CD4 Zellen unter Therapie, sodass die meisten von Ihnen circa 12 
Monate nach Therapie Beginn einen negativen IGRA aufwiesen. (diese Auswertungen sind bislang 
nur auf der Welt-TB-Konferenz vorgetragen, Veröffentlichung geplant). Dieses Phänomen kann 
diagnostisch genutzt werden.  
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4 Einordnung der eigenen Studienergebnisse in die Literatur 
Der mögliche Einfluss von chronischen Infektionen auf die Empfänglichkeit für HIV wurde lange 
diskutiert. Breits in den 1990iger Jahren fiel bei Querschnittsstudien an äthiopischen Immigranten in 
Israel auf, dass es eine Korrelation zwischen Helminthen Prävalenz und HIV gab [4-6, 11-15]. Auch in-
vitro Studien deuteten auf eine erhöhte Suszeptibilität der T-Zellen von Helminthen-infizierten 
Personen hin [16, 17]. Prospektive Studien zum weiteren Beweis der Hypothese wurden 
durchgeführt, brachten aber keine schlüssigen Ergebnisse. Das mag auch daran liegen, dass die 
meisten Helminthen mit einer einmaligen Therapie gut zu behandeln sind und somit ein langfristiger 
Einfluss schwer zu untersuchen ist. Der Nachweis einer erhöhten HIV Inzidenz bei Wurminfizierten 
gelang nun erstmalig bei einer Infektion mit W. bancrofti [18], bei den weiteren untersuchten 
Helminthen war kein Zusammenhang mit HIV dokumentiert worden. Nur wenige Studien hatten sich 
bereits mit der Ko-infektion der lymphatischen Filariose und HIV befasst, bislang auch nur in 
Querschnittsbeobachtungen. Nielsen et al. hatte 2006 eine positive Assoziation zwischen LF und HIV 
beschrieben [19], konnte dies aber in Folgestudien nicht unterlegen [20]. Kein Unterschied in der 
Prävalenz und der Wurmlast war in Querschnittsstudien in Indien [21] und Malawi [22] gesehen 
worden. Auch die Behandlung der LF war gleichermaßen erfolgreich bei HIV Infizierten [23, 24]. Dies 
konnten wir in unseren Auswertungen bestätigen [25].  
Die Ergebnisse bezüglich der durch Filarien erhöhten HIV-Inzidenz haben weitere Forschungsansätze 
zu Folge. In Kooperation mit der ebenfalls in Mbeya durchgeführten WHIS Studie konnten bereits 
Analysen zu T-Zellaktivierungsmarkern und weiteren Faktoren, die eine Rolle spielen könnten, 
durchgeführt werden (Auswertungen laufen zurzeit). Die WHIS Studie hatte unterschiedliche Level 
von Aktivierung bei Trichuris trichiura- im Vergleich mit Hakenwurm-Infizierten beschrieben [26, 27]. 
Ob die beobachtete erhöhte HIV Inzidenz bei LF-Infizierten sich auf ein regionalübliches Niveau 
zurück entwickelt und somit die LF-Therapie als Präventions-Maßnahme gegen HIV anzusehen ist, ist 
ein weiteres Studienfeld. LF gehört zu den so genannten „neglected tropical diseases“ (NTD). Die 
Therapie bzw. Elimination dieser Erkrankung könnte forciert werden, um damit als Nebeneffekt die 
HIV-Inzidenz zu senken. Eine Reihe von Studien hat in den letzten Jahren die Wirksamkeit von 
Medikamenten, bzw. Medikamentenkombinationen auch gegen den adulten Wurm von W. bancrofti 
getestet [28-33]. Diese bieten die Möglichkeit W.bancrofti nach circa 6-12 Monaten, statt den 12 
Jahren, aus dem menschlichen Körper zu eliminieren und somit das erhöhte Risiko für HIV erheblich 
schneller zu reduzieren. Studien mit dieser Fragestellung sind in Planung.  
Bezüglich der Untersuchung der neuen Diagnostika im Bereich der TB-HIV Interaktion konnten wir 
einen wertvollen Betrag zur Wertigkeit des LAM Testes leisten. Die LAM Testes waren in der Literatur 
sehr unterschiedlich bewertet worden [34-37]. Wir konnten maßgeblich zur Beschreibung von 
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Problemen bei der Diagnostik [38] und weitere Informationen zur Sensibilität und Spezifität bei 
richtigem Gebrauch beitragen [39]. Eine Besonderheit bei der Tuberkulose HIV-Ko-Infektion ist der 
Verlust von TB spezifischen T-Helferzellen, solange keine aktive TB vorliegt, oder die HIV Infektion mit 
antiretroviraler Medikation therapiert wird. Dies wurde von unserem Institut beschrieben [9, 10] und 
wird in der weiteren Untersuchung von HIV/TB Ko-Infizierten genauer untersucht [40, 41]. Weitere 
Studien zum prospektiven Wert der IGRAs bei ART naiven HIV-Infizierten Individuen sind im Gange 
(AFRICOS-Studie). 
 
 
 
 
5 Abkürzungen 
95% KI  95% Konfidenzintervall 
ADAT  Akkronym der Studie: „Active Detection of Active Tuberculosis” 
AIDS  Acquired Immune Deficiency Syndrom 
ART  Antiretroviral Treatment 
CD4   Synonym für T-Helferzellen (Cluster of Differentiation 4) 
CIH  Center for International Health an der Universität München 
ECHO  Akkronym der Studie: „Early HIV Infection”= RV 217 
EMINI  Akkronym der Studie: „Evatuating and Monitoring the Impact of New Interventions 
HIV  Human Immunodeficiency Virus 
IGRA  Interferon Gamma Release Assay 
IRR  Incidence Rate Ratio 
LAM  Lipoarabinomannan 
LF  Lymphatische Filariose 
MMRC  Mbeya Medical Research Centre 
NTD  Neglected Tropical Diseases 
OI  Opportunistische Infektion 
RV 217   Akkronym der Studie: „Early Infection HIV Cohort”==ECHO 
SOLF  Akkronym der Studie: „Surveillance Of Lymphatic Filariasis” 
STH  Soil Transmitted Helminths 
TB  Tuberkulose 
TST  Tuberculin Skin Test 
WHIS  Akkronym der Studie: „Worms-HIV-Interaction-Study” 
VCT  Voluntary Counseling and Testing 
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Effect of Wuchereria bancrofti infection on HIV incidence in 
southwest Tanzania: a prospective cohort study 
Inge Kroidl, Elmar Saathof, Lucas Maganga, Williams H Makunde, Achim Hoerauf, Christof Geldmacher, Petra Clowes, Leonard Maboko, 
Michael Hoelscher
Summary
Background The past decades have seen an ongoing controversial debate about whether the immune activation induced 
by helminths has an effect on the susceptibility of individuals to HIV. In view of this, we assessed the effect of lymphatic 
filariasis, a chronic helminth disease elicited by Wuchereria bancrofti, on HIV incidence in southwest Tanzania.
Methods In this population-based cohort study, we enrolled a geographically stratified randomly chosen sample of 
about 10% of the households in nine distinct sites in southwest Tanzania. All household members present were 
followed up and tested for HIV and circulating filarial antigen, an indicator of W bancrofti adult worm burden. Our 
main outcome of interest was HIV incidence in participants with or without lymphatic filariasis.
Findings Between May 29, 2006, and June 16, 2011, we enrolled 4283 households with roughly 18 000 participants. Of 
these, 2699 individuals from Kyela district participated in at least one round of the EMINI study. In the 1055 initially 
HIV-negative adolescents and adults with clearly defined lymphatic filariasis status, 32 new HIV infections were 
observed in 2626 person-years. HIV incidence in lymphatic filariasis-positive participants (1·91 cases per 
100 person-years) was significantly higher than the incidence in lymphatic filariasis-negative participants (0·80 cases 
per 100 person-years). The age-adjusted and sex-adjusted incidence rate ratio was 2·17 (95% CI 1·08–4·37, p=0·0300). 
Lymphatic filariasis status remained an independent and significantly relevant risk factor for HIV infection when 
controlled for other known risk factors such as sexual behaviour and socioeconomic factors.
Interpretation To our knowledge, this is the first prospective study demonstrating a significantly increased risk of 
acquiring HIV for lymphatic filariasis-infected individuals. Immunological studies and interventional treatment 
studies that eliminate the adult worms and not only the microfilaria are needed to follow up on the results presented.
Funding European Union as part of EuropAid; German Ministry of Education and Research; German Center for 
Infection Research. 
Introduction
The disproportionately high prevalence of HIV in 
communities of sub-Saharan Africa has led to the 
hypothesis that concomitant parasitic infections might 
increase the risk of HIV transmission.1,2 The foundation 
of this premise has been based on cross-sectional studies 
of Ethiopian immigrants in Israel since correlations were 
observed between the prevalence of helminth and HIV 
infections.3 An underlying mechanism for this 
occurrence is that the immune milieu induced by 
helminth infections could facilitate HIV acquisition.4 In 
those participants who were predominantly infected with 
soil-transmitted helminths, immunological changes 
were characterised by a dominant T-helper-2 cell response 
and broad T-cell activation.5,6 Moreover, an increased 
susceptibility for HIV in peripheral blood mononuclear 
cells of these immigrants was found through in vitro 
experimentation.7
Further support that helminths affect HIV susceptibility 
stems from several cross-sectional studies8 that 
have reported a positive association of urogenital 
schistosomiasis with HIV prevalence. By contrast with 
soil and vector-transmitted helminths, infections with 
Schistosoma haematobium are located in the urogenital 
tract and it seems that the disruption of the mucosal 
barrier is the prevailing factor for increased susceptibility 
to the virus.9 With regards to filarial nematode infections, 
no studies have addressed the effect on HIV incidence in 
endemic communities. Lymphatic filariasis is a chronic 
helminth disease that infects 120 million people 
worldwide and is elicited by Wuchereria bancrofti or 
Brugia species.10 Adult worms reside in the lymphatic 
system for many years, producing the transmission 
life-stage microfilariae. Although most individuals with 
lymphatic filariasis remain asymptomatic, presenting 
either patent (with microfilariae) or latent (without 
microfilariae) states,11 some patients do develop severe 
pathology (hydrocele or lymphoedema).12 Mass drug 
administration programmes focus on the interruption of 
transmission with drugs that target microfilariae. An 
interesting facet of filarial nematodes is the requirement 
of the endosymbiont Wolbachia spp for their survival and 
reproduction. Indeed, this has become the Achilles’ heel 
of filariae because treatment with tetracyclines is 
additionally macrofilaricidal and can revert and improve 
pathology.13 Before larger treatment programmes started 
in 2001, lymphatic filariasis was present in most of the 
21 regions of Tanzania, with a reported prevalence in 
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Articles
coastal regions of up to 44% (799 of 1829 in Tanga, 
Tanzania).14 In the southern regions of Tanzania, mass 
drug administration programmes began in 2009. With 
regards to HIV, several governmental surveys have 
documented prevalence.15 The third population-based 
Tanzanian HIV/AIDS and Malaria Indicator Survey 
2011/2012 found a countrywide HIV prevalence of 5% in 
Tanzanian adults between 15 and 49 years of age, and a 
9% prevalence for the same age group in the Mbeya 
region. Possible effects of lymphatic filariasis infection 
on the prevalence or pathology of HIV have been 
previously studied.16–19 A large cross-sectional prevalence 
study in northern Tanzania reported an increased HIV 
prevalence in individuals infected with W bancrofti.17 
However, a follow-up study in the same group did not 
support this association.16 Recent studies18,20 from Malawi 
and Tanzania reported no evidence that HIV infection 
affected lymphatic filariasis epidemiology. Because no 
prospective study focusing on HIV susceptibility in 
individuals with lymphatic filariasis has been published 
to date, we did a large cohort study in individuals from 
the Mbeya region of Tanzania, an area highly endemic 
for both diseases.15 
Methods 
Study design and participants
The EMINI study was a population-based cohort study 
done to assess and monitor the effect of future 
interventions done in the area of infectious disease 
control (eg, HIV, tuberculosis, malaria, neglected tropical 
diseases). We enrolled a geographically stratified random 
sample of about 10% of the households in nine distinct 
sites. There were no exclusion criteria except for 
unwillingness to participate or to donate a biological 
sample. The overarching aim of the cohort was to 
describe the epidemiology of HIV, tuberculosis, malaria, 
and other infectious diseases and to generate baseline 
data for the planning and conduct of future randomised 
trials. Following the advice of the local and international 
ethical boards that approved the study, reporting of HIV 
results and medical care was offered by an independent 
team on a voluntary and anonymous basis. To ensure 
privacy, the study team remained masked to any HIV 
data. Surveillance data of lymphatic filariasis were 
generated as part of a substudy of EMINI (SOLF) that 
was initiated in 2009 to describe the effect of mass drug 
administration (ivermectin and albendazole) on filarial 
prevalence in the general population of Kyela region 
between 2009 and 2011. Filarial antigen testing was done 
on all participants of EMINI in the Kyela district at all 
visits on stored samples. Although the number of 
included households remained unchanged over the 
years, the family members participating in the study 
varied. The EMINI and SOLF studies were approved by 
both the National Ethical Committee/Medical Research 
Coordinating Committee of the National Institute for 
Medical Research, Tanzania, and the Mbeya Medical 
Research and Ethics Committee. All adult participants 
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Research in context
Evidence before the study
We searched PubMed on April 15, 2016, for studies published in 
English using the search terms “lymphatic filariasis”, “Wuchereria 
bancrofti”, and “HIV” with no restrictions on publication date. 
We found few manuscripts describing co-infections of both 
diseases, which have been cited and discussed in this 
manuscript. Helminth infections have been suggested as one of 
the factors driving the HIV/AIDS epidemic in sub-Saharan Africa. 
However, not many studies have examined the interaction of 
W bancrofti, a mosquito-transmitted filarial nematode, and HIV, 
and all of them have focused on already co-infected individuals. 
A cross-sectional study in north Tanzania suggested a higher 
HIV prevalence in W bancrofti-positive individuals, but a follow-
up study of the same group did not provide evidence for an 
interaction of lymphatic filariasis with HIV. Recent reports from 
India, Zimbabwe, and south Tanzania did not show any 
difference in lymphatic filariasis prevalence or circulating filarial 
antigen levels in HIV-positive compared with HIV-negative 
individuals. However, none of the published reports focused on 
the effect of lymphatic filariasis on HIV transmission.
Added value of the study
The risk for HIV infection is determined by multiple factors, 
most of which are behavioural. This study describes an 
increased HIV infection risk caused by a helminth infection 
(lymphatic filariasis). Our findings open up new opportunities 
for prevention, especially in the high-HIV-risk group of young 
adults in developing countries. Furthermore they support the 
primarily laboratory-based hypothesis that an immune-
activated host is more receptive for HIV infection, which if 
investigated further might improve our understanding of the 
physiopathology during primary HIV infection.
Implications of all the available evidence
The adult worm of W bancrofti lives for 10–12 years in the 
lymphatic system and is not killed by single-dose treatment. 
By contrast, it takes up to 10 years of annual mass treatment to 
produce a lasting reduction in lymphatic filariasis prevalence in 
an affected area. Lymphatic filariasis eradication programmes in 
the past decade have focused on the reduction of transmission 
but made only limited efforts to cure W bancrofti infection, 
although recently an active therapy has become available. 
Lymphatic filariasis, together with other helminth infections, 
belongs to the 17 neglected diseases as defined by WHO. Our 
findings add another argument to push neglected diseases, 
in this case filarial infection, into the focus of global strategies, 
as they create not only morbidity but in addition generate an 
increased risk of acquiring HIV.
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provided written informed consent before enrolment in 
the study. Parents provided consent for children younger 
than 18 years of age and children above the age of 12 years 
signed their own assent form, together with their parents’ 
consent.
Procedures
In five annual surveys the households were visited by the 
study team and all household members present at that 
time answered a structured questionnaire and donated 
blood, urine, stool, and sputum (if suspected for 
tuberculosis). Unused samples were stored for further 
analysis. Additionally, participants were interviewed to 
accumulate data on sociodemographic and behavioural 
factors. Interview data were collected with handheld 
computers and downloaded into an Access database on 
return to the institute. The characterisation of the 
socioeconomic status is described in the appendix. 
Laboratory data were recorded on paper, double entered 
into an Access database, and then compared with the 
original to check for discrepancies. Results for the ELISA 
tests for Lymphatic filariasis and HIV were directly 
imported into the database.
A commercially available ELISA (Og4C3 serum ELISA, 
TropBio, Townsville, Australia) was used to detect the 
circulating filarial antigen in 100 µL of the collected sera 
(appendix).20 HIV screening was done with a rapid diagnostic 
test (Determine HIV 1/2 test, Abbott Laboratories, Abbott 
Park, IL, USA, in 2007; HIV 1/2 STAT-PAK Dipstick Assay, 
Chembio Diagnostics Systems, Medford, NY, USA, in 2008; 
and SD-Bioline HIV-1/2 3·0, Standard Diagnostics, Kyonggi-
do, South Korea, from 2009 to 2011). All positive rapid test 
results were confirmed with an ELISA HIV test (Enzygnost 
Anti HIV 1/2 Plus, DADE-Behring, Marburg, Germany) and 
subsequent western blot (MPD HIV Blot 2.2, MP 
Biomedicals, Geneva, Switzerland) if results were discordant. 
Negative rapid diagnostic tests from the previous annual 
survey, which again showed a negative rapid diagnostic test 
result in the following survey, were regarded as confirmed 
negative. For all HIV incident cases, the negative result of 
the previous year was confirmed by an ELISA HIV test, 
according to the above described testing algorithm. For 
children younger than 2 years, HIV testing was done by 
nucleic acid amplification test (PCR, Amplicor, Roche, 
Randburg, South Africa) with EDTA plasma.21
To measure HIV incidence and related variables, we 
used observation periods to define exposure time—ie, the 
time between two consecutive visits for the same 
participant (observation period) was only considered as 
exposure time if the participant both had an HIV result at 
the beginning and at the end of the respective period and 
if the result at the beginning was negative. Univariable 
and multivariable models included person-time for 
observation periods with defined lymphatic filariasis 
status until the earliest of the following points: the end of 
follow-up after about 4 years, the date when the participant 
was last visited, or the estimated date of HIV 
seroconversion, taken as the midpoint between the last 
negative and the first positive HIV test result.
Outcomes
Our main outcome of interest was HIV incidence in 
participants with or without lymphatic filariasis. For 
lymphatic filariasis, we used a conservative status 
definition which excluded observation periods where the 
lymphatic filariasis status changed during the period, 
meaning that we only retained periods with stable 
lymphatic filariasis status where lymphatic filariasis test 
results at the beginning and at the end were either both 
positive or both negative. To test the results obtained 
with the above conservative lymphatic filariasis status 
definition for robustness, we also used a more liberal 
Person-years HIV 
incidence
Incidence per 
100 person-years
Univariable model* Multivariable model†
IRR (95% CI) p value IRR (95% CI) p value
Lymphatic filariasis status
Negative 1632 13 0·80 1 ·· 1 ··
Positive 994 19 1·91 2·38 (1·17–4·84) 0·0163 2·17 (1·08–4·37) 0·0300
Sex
Female 1333 18 1·35 1 ·· 1 ··
Male 1293 14 1·08 0·80 (0·40– 1·62) 0·5416 0·78 (0·38– 1·57) 0·4801
Age (years)
14 to <25* 1095 7 0·64 1 ·· 1 ··
25 to <45 758 19 2·51 3·87 (1·62–9·22) 0·0023 3·49 (1·46– 8·38) 0·0050
≥45 773 6 0·78 1·21 (0·41–3·63) 0·7302 1·01 (0·32–3·19) 0·9824
Socioeconomic rank (per unit) ·· ·· ·· 0·96 (0·84–1·10) 0·5577 0·95 (0·84– 1·08) 0·4738
Univariable and multivariable results from log binomial regression models with robust variance estimates to adjust for within-person clustering only in person-periods with 
stable lymphatic filariasis status. Socioeconomic rank was calculated based on the participant’s household according to socioeconomic status score, calculated from various proxy 
variables. IRR=incidence rate ratio. *Univariable results are from analysing each variable in a separate model. †Multivariable results including all variables shown.
Table 1: Association of lymphatic filariasis status and other covariates with HIV incidence
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definition, which used the maximum binary lymphatic 
filariasis result that had been obtained for each 
participant over the whole course of the study, meaning 
that participants with at least one positive lymphatic 
filariasis result were regarded as positive for lymphatic 
filariasis according to this definition.
Statistical analysis
Our primary analysis used log binomial regression models 
to assess the association of stable lymphatic filariasis 
infection with HIV incidence univariably and adjusted for 
sex, age, and socioeconomic status. Robust variance 
estimates were used to adjust for within-participant 
clustering and person-time was accounted for by including 
its natural logarithm as an offset into the model. Lymphatic 
filariasis infection status, age, and other covariates that 
were subject to change over time were included in our 
analyses as time-varying covariates.
To examine the potentially confounding effect of other 
known risk factors for HIV infection (eg, sex, marital 
status, living with a discordant partner, male 
circumcision, etc), we analysed the unadjusted 
association of HIV incidence with each of these risk 
factors separately for each age group to identify potential 
differences in these associations at different ages. 
Furthermore, we ran separate binomial regression 
models with the same specifications as previously 
mentioned that each included lymphatic filariasis 
infection status, age, and only one of these risk factors 
respectively.
To examine the results of the primary analysis (table 1) 
for robustness, we used the Cox proportional-hazards 
model to estimate hazard ratios (HRs; appendix) with the 
conservative stable lymphatic filariasis status definition, 
using robust variance estimates adjusted for within-
participant clustering. A Kaplan-Meier plot was used to 
visualise the cumulative HIV incidence during the 
course of the study. Furthermore we estimated 
univariable and multivariable log binomial regression 
models with similar specifications as the main model, 
but with the more liberal maximum lymphatic filariasis 
status definition (appendix). Observations where HIV 
incidence or lymphatic filariasis status could not be 
ascertained were excluded from subsequent analyses 
(figure 1).
Regarding covariates used in the main model (table 1), 
sex and age information was available for every participant. 
Household socioeconomic status information was 
available for all participants and for most of the five 
annual visits. If this information was missing for one of 
the visits we used the information from the previous 
visit, or, if this was unavailable, from the following visit. 
Since all other covariates which were used in additional 
analyses (tables 2, 3; appendix) were categorical, we 
created a separate category for missing values which was 
included in our analyses. Stata/SE software, version 14.1 
was used for all statistical analyses and to draw graphs.
2626 person-years of 1055 initially HIV-negative 
participants aged ≥14 years with identical 
lymphatic filariasis result at start and end 
of person-period (conservative model)
1143 participants excluded
1013 person-years from participants with 
<2 lymphatic filariasis results
130 person-years from participants with 
change in lymphatic filariasis status
2890 person-years of participants aged 
<14 years were not included in the main
analysis 
2699 participants received circulating filarial 
antigen and HIV testing
444 excluded
224 participants initially HIV positive
208 HIV-negative participants without 
follow-up result
12 HIV-negative participants without 
valid lymphatic filariasis result
6658 person-years of 2255 initially HIV-negative 
participants with at least one lymphatic 
filariasis result
3768 person-years of 1334 initially HIV-negative 
participants aged ≥14 years with at least 
one lymphatic filariasis result (liberal model)
Figure 1: Flow chart showing study participants with person-years and 
exclusion criteria for defining the liberal and conservative case models for 
lymphatic filariasis
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Figure 2: HIV incidence by age and lymphatic filariasis status (conservative definition)
For each age group the person-years and number of incident cases are given for the lymphatic filariasis-negative 
and lymphatic filariasis-positive groups. For the age group of 6 to <14 years, no incident cases were noted for both 
groups despite the high number of person-years.
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. ES, IK, and MH had full access to 
all the data in the study and IK and MH had final 
responsibility for the decision to submit for publication. 
Results
The EMINI study was conducted between May 29, 2006, 
and June 26, 2011. We enrolled 4283 households with 
roughly 18 000 participants. At the Kyela site, about 88% 
of participants of each previous year were followed up in 
the consecutive year. Kyela was visited five times between 
Feb 16, 2007, and June 10, 2011 (once a year). 
2699 individuals from Kyela district participated in at 
least one round of the EMINI study (figure 1). 51% of 
participants were female, and the overall median age of 
the cohort was 15·4 years (IQR 7·2–31·1). 224 (8%) 
participants tested positive for HIV and were excluded 
from the analysis. The HIV age distribution was typical 
for a medium-high incidence country before introduction 
of antiretroviral therapy, with peak incidence in the 
reproductive age group (appendix).20 The prevalence of 
lymphatic filariasis infection was 26% (691 of 2673), with 
a low prevalence in young children (13 [3%] of 489 
children younger than 6 years), rising rapidly to an 
average prevalence of 41% (520 of 1280) in HIV-negative 
and 37% (72 of 193) in HIV-positive individuals older 
than 14 years. Valid lymphatic filariasis results and at 
least one follow-up HIV result were obtained from 
2255 initially HIV-negative participants. The participants 
were followed up for 1–4 years (mean 2·95; SD 0·997), 
leading to 6658 person-years of observation, during 
which 48 study participants seroconverted to HIV 
(figure 1).
Three different age clusters were distinguished 
representing different possible routes of HIV transmission 
(0 to <6 years, 6 to 14 years, and older than 14 years). 
Among infants and toddlers younger than 6 years 
(986 person-years), the group of potential transmission 
through breastfeeding, we observed four incident HIV 
infections, of which one was in an infant with lymphatic 
Aged 14 to <25 years Aged 25 to <45 years Aged ≥45 years
Person-
years
Incidence IRR (95% CI) Person-
years
Incidence IRR (95% CI) Person-
years
Incidence IRR (95% CI)
Lymphatic filariasis status during person-period
Negative* 769 0·39 1·00 439 1·60 1·00 424 0·71 1·00
Positive 325 1·23 3·16 (0·53– 21·5) 319 3·76 2·36 (0·86–7·06) 350 0·86 1·21 (0·16–9·05)
HIV status of spouse
HIV negative* 93 2·15 1·00 549 0·91 1·00 412 0·24 1·00
HIV positive 6 0·00 0·00 (0·00– 78·3) 51 11·87 13·04 (3·32–54·0) 24 12·34 50·77 (4·08–2665)
No spouse 963 0·52 0·24 (0·04–2·53) 130 4·62 5·07 (1·29–21·0) 279 0·72 2·95 (0·15–174)
Data missing/NA 32 0·00 0·00 (0·00–15·5) 28 7·21 7·92 (0·75–48·4) 59 0·00 0·00 (0·00–274)
Marital status
Never married 894 0·45 0·28 (0·05–1·88) 74 2·72 1·53 (0·16–7·01) 15 0·00 0·00 (0·00–46·3)
Married* 185 1·62 1·00 619 1·78 1·00 444 0·90 1·00
Divorced/seperated 13 0·00 0·00 (0·00–34·4) 32 12·41 6·99 (1·62–23·6) 30 3·38 3·76 (0·08–38)
Widowed 3 0·00 0·00 (0·00–147) 32 6·19 3·48 (0·38–16·0) 285 0·35 0·39 (0·01–3·94)
Number of sexual partners within the last year
None 29 0·00 0·00 (0·00–11·2) 20 10·22 5·17 (0·56–23·7) 201 0·50 1·33 (0·02–104)
One* 381 1·57 1·00 556 1·98 1·00 267 0·37 1·00
Two or more 83 0·00 0·00 (0·00–3·90) 155 3·86 1·95 (0·59–5·76) 67 4·45 11·90 (0·96–624)
Data missing/NA 602 0·17 0·11 (0·00–0·87) 27 0·00 0·00 (0·00–8·34) 237 0·42 1·13 (0·01–88·3)
Circumcised (male)
No* 561 0·53 1·00 286 2·10 1·00 293 1·37 1·00
Yes 57 0·00 0·00 (0·00–24) 73 1·37 0·65 (0·01–5·36) 23 0·00 0·00 (0·00–19·1)
NA (female) 476 0·84 1·57 (0·27–10·7) 399 3·01 1·43 (0·50–4·65) 457 0·44 0·32 (0·03–2·23)
Ever used condom (male)
No* 275 0·73 1·00 444 2·93 1·00 682 0·88 1·00
Yes 229 1·75 2·40 (0·34–26·6) 302 1·99 0·68 (0·21–1·92) 56 0·00 0·00 (0·00–10·3)
Missing/NA (female) 590 0·17 0·23 (0·00–4·48) 12 0·00 0·00 (0·00–12·0) 35 0·00 0·00 (0·00–16·8)
Unadjusted values were used for the IRR calculation. Socioeconomic rank was calculated based on the participant’s household according to socioeconomic status score, 
calculated from various proxy variables. IRR=incidence rate ratio per 100 person-years. NA=not applicable. *Reference strata.
Table 2: Influence of different factors on HIV incidence stratified by age
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filariasis. No seroconversions were observed in 
1904 person-years from individuals between 6 and 14 years 
of age. 44, presumably sexual, HIV transmissions 
occurred during 3768 person-years in 1334 adolescents 
and adults older than 14 years. For stringency, the primary 
analysis was only done for observation periods that had 
the same lymphatic filariasis result at the start and end of 
a period (figure 1). With use of the “conservative” lymphatic 
filariasis status definition, 2626 person-years from 
1055 individuals were analysed. Lymphatic filariasis-
negative individuals contributed 1632 person-years, 
lymphatic filariasis-positive individuals contributed 
994 person-years. Of the initially depicted 44 HIV 
infections in individuals older than 14 years, 32 occurred 
during the 2626 person-years with stable lymphatic 
filariasis status, 13 in lymphatic filariasis-negative (0·80 
cases per 100 person-years) and 19 in lymphatic filariasis-
positive individuals (1·91 cases per 100 person-years), 
suggesting a 2·38 times increased risk of HIV infection 
for individuals infected with W bancrofti compared to 
those who are uninfected (95% CI 1·17–4·84, p=0·0163; 
table 1).
Because our assessments focused on newly acquired 
HIV infections through sexual contact, we further 
categorised age into 14 years to older than 25 years, 
25 years to younger than 45 years, and older than 45 years, 
which reflects the personal situations of participants 
(eg, marital status). With use of these groups, we assessed 
the effect of factors describing sociodemographic status 
or sexual behaviour on HIV incidence (table 2, appendix). 
Although most of those factors were more relevant in the 
middle and older age groups, lymphatic filariasis 
infection was one of the most important risk factors in 
the early years (14–25 years) of sexual activity (risk ratio 
[RR] 3·16, 95% CI 0·53–21·5, p=0·0750; table 2, figure 2). 
In this age group, the increased incidence risk was also 
reflected by a more than doubled prevalence of HIV in 
individuals with lymphatic filariasis (12 [8%] of 147) 
compared with individuals without lymphatic filariasis 
(11 [4%] of 303; RR 2·25, 95% CI 1·02–4·97, p=0·0406; 
appendix).
To control for potential confounding factors, we 
estimated the association of HIV incidence with stable 
lymphatic filariasis status in a multivariable log 
binominal regression model adjusted for sex, age, and 
socioeconomic status (table 1). The adjusted incidence 
rate ratio was 2·17 (95% CI 1·08–4·37, p=0·0300). 
Additionally, separate binomial regression models were 
done that included lymphatic filariasis status, age, and 
one other of the risk factors for HIV. A significant effect 
on HIV incidence could be found for the factors “living 
with an HIV-positive partner”, “having more than one 
sex partner”, and “being divorced or separated” (table 2). 
Factors which had no significant effect on the HIV 
incidence were education, religion, and occupation 
(appendix), and being circumcised (for males) or use of 
condoms (table 2). Further analysis with separate 
Risk ratio 
lymphatic 
filariasis 
infection
p value for 
lymphatic 
filariasis 
infection
Years of 
exposure
Incident 
HIV 
infections
Risk ratio of the 
additional factor 
(95%CI)
p value
None (only adjusted 
for age)
2·20 0·0332 ·· ·· ·· ··
Spouse HIV status 2·39 0·0250
HIV negative* ·· ·· 1054 8 1·00 ··
HIV positive ·· ·· 81 9 12·88 (4·72–35·1) <0·0001
No spouse in 
household
·· ·· 1372 13 2·61 (0·82–8·33) 0·1051
Data missing/NA ·· ·· 118 2 3·80 (0·76–19·0) 0·1047
Marital status 2·14 0·0387 ·· ·· ·· ··
Never married ·· ·· 982 6 0·68 (0·17–2·76) 0·5867
Married* ·· ·· 1249 18 1·00 ··
Separated/divorced ·· ·· 75 5 4·48 (1·55–13·0) 0·0057
Widowed ·· ·· 320 3 1·15 (0·26–5·09) 0·8569
Number of sexual 
partners last year
2·07 0·0459 ·· ·· ·· ··
None 249 3 1·15 (0·26–5·04) 0·8521
One* ·· ·· 1204 18 1·00 ··
Two or more ·· ·· 306 9 1·88 (0·84–4·20) 0·1263
Data missing/NA ·· ·· 866 2 0·26 (0·05–1·24) 0·0899
Religion 2·17 0·0359
Christian* ·· ·· 2408 28 1·00 ··
Muslim ·· ·· 63 1 1·13 (0·15–8·53) 0·9079
Data missing/NA ·· ·· 155 3 1·93 (0·61–6·11) 0·2636
Education 2·06 0·0500  ·· ·· ·· ··
None ·· ·· 537 6 1·15 (0·41–3·22) 0·7917
Any primary* ·· ·· 1202 22 1·00 ··
Secondary and 
above
·· ·· 112 2 0·95 (0·22–4·18) 0·9507
Currently a student ·· ·· 774 2 0·20 (0·04–1·04) 0·0550
Occupation 2·03 0·0494 ·· ·· ·· ··
Farmer* ·· ·· 1719 28 1·00 ··
Student ·· ·· 671 0 † ··
Other ·· ·· 235 4 1·03 (0·36–3·00) 0·9533
Circumcised (male) 2·22 0·0286 ·· ·· ·· ··
No* ·· ·· 1139 13 1·00 ··
Yes ·· ·· 153 1 0·47 (0·06–3·36) 0·4482
NA (female) ·· ·· 1333 18 1·19 (0·58–2·44) 0·6426
Ever used condom 2·04 0·0544 ·· ·· ·· ··
No* ·· ·· 1401 21 1·00 ··
Yes ·· ·· 587 10 0·87 (0·41–1·87) 0·7242
Data missing/NA ·· ·· 637 1 0·14 (0·02–1·15) 0·0673
Used birth control 2·22 0·0272 ·· ·· ·· ··
None* ·· ·· 379 7 1·00 ··
Pill, injection, or 
implant 
·· ·· 421 9 0·78 (0·26–2·30) 0·6464
Other ·· ·· 93 1 0·43 (0·05–3·43) 0·4229
NA (male) ·· ·· 1293 14 0·53 (0·20–1·38) 0·1960
Data missing/NA ·· ·· 440 1 0·18 (0·02–1·57) 0·1203
Haematuria ever 2·20 0·0331 ·· ·· ·· ··
Negative* ·· ·· 2059 24 1·00 ··
Positive ·· ·· 566 8 1·08 (0·49–2·34) 0·8534
(Table 3 continues on next page)
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binominal regression models, which included lymphatic 
filariasis status and age with one of the risk factors 
(table 3) showed that lymphatic filariasis infection 
remained a stable risk factor for new HIV infections.
Furthermore, we used a Kaplan-Meier plot to examine 
whether the duration of lymphatic filariasis infection 
differentially affected the risk of HIV infection. 
Supporting the findings from the regression analysis, the 
Kaplan-Meier plot showed that the HIV-infection hazard 
continues to be increased in individuals with lymphatic 
filariasis over the duration of the study (figure 3). To 
check the results of our primary analysis (table 1) for 
robustness, we also applied a Cox proportional-hazard 
model (appendix) and another multivariable log binomial 
regression model using the more liberal lymphatic 
filariasis case definition (figure 1), where all 
44 HIV seroconversions, which occurred during 
3768 person-years in 1334 adolescents or adults, were 
included (appendix). Compared with the main dataset 
(table 1), both of these additional models showed similar, 
statistically significant findings, strengthening the 
primary result of a significantly increased risk for HIV 
acquisition in individuals with lymphatic filariasis.
Discussion
Our study shows a significantly increased risk of 
acquiring HIV in individuals infected with lymphatic 
filariasis. Our data were obtained in an area with high 
prevalence for both HIV and lymphatic filariasis infection 
at a time when antiretroviral treatment was not widely 
available, and mass drug administration only began in 
2009, affecting the last 2 years of the study.15,20 The most 
dominant association between lymphatic filariasis and 
HIV was in the adolescent group where more than a 
three-fold increase in HIV incidence was observed. This 
was also reflected in the HIV prevalence, which for this 
age group was significantly higher in those with 
lymphatic filariasis compared with those with no 
lymphatic filariasis. Although lymphatic filariasis 
infection was one of the most relevant risk factors in the 
years of first sexual activity, we show that known HIV 
risk factors such as marital status or the number of 
sexual partners are important for older adults.
A limitation of this study is its observational character, 
which precludes firm conclusions about the causal effect 
of lymphatic filariasis infection on HIV incidence. 
However, most conceivable confounders would have a 
socioeconomic dimension, which should have been 
apparent in our various models. We have carefully 
addressed possible confounding effects of major known 
risk factors for HIV and show that these factors did not 
have any effect on the influence of lymphatic filariasis on 
HIV incidence. Other limitations include missing 
lymphatic filariasis results for some individuals and 
losses to follow-up, which might both have biased our 
findings. However, we addressed this issue by using 
separate models with the conservative and the liberal 
lymphatic filariasis case definitions, which showed 
similar, statistically significant, results. The conservative 
model avoids bias that might be due to lymphatic 
filariasis misclassification, at the cost of introducing bias 
by excluding large amounts of person-time from analysis, 
whereas the “liberal” model makes full use of the 
available person-time, but introduces misclassification 
bias for the lymphatic filariasis exposure variable. 
The fact that both models are similar shows that our 
results are robust to both types of bias.
Potential causes for the increased HIV acquisition in 
individuals with lymphatic filariasis might exist in the 
interaction between the filarial parasite and the host’s 
immune system. Helminth infections have been 
postulated to modulate the level of systemic immune 
Risk ratio 
lymphatic 
filariasis 
infection
p value for 
lymphatic 
filariasis 
infection
Years of 
exposure
Incident 
HIV 
infections
Risk ratio of the 
additional factor 
(95%CI)
p value
(Continued from previous page)
Schistosoma 
haematobium ever†
2·20 0·0333 ·· ·· ·· ··
Negative* ·· ·· 2238 27 1·00
Positive ·· ·· 387 5 1·01 (0·39–2·62) 0·9840
Any intestinal 
nematode ever‡§
2·25 0·0290 ·· ·· ·· ··
Negative* ·· ·· 1139 18 1·00 ··
Positive ·· ·· 987 9 0·64 (0·28–1·46) 0·2842
Data missing ·· ·· 499 5 0·80 (0·30–2·15) 0·6577
All models included lymphatic filariasis infection, the respective risk factor, and age as covariates (results for age not 
shown). *Reference strata. †S haematobium eggs have been visualised at some timepoint during the study. All 
diagnosed infections have been treated with praziquantel. ‡Trichuris trichiura, Ascaris lumbricoides, or hookworm. 
§Infections with intestinal nematodes have been diagnosed through Kato Katz technique at some timepoint during 
the study. All diagnosed infections have been treated with albendazole.
Table 3: Effect of HIV risk factors on the association between lymphatic filariasis and HIV incidence
Number at risk
(incident)
Lymphatic
filariasis positive
Lymphatic
filariasis negative
0
396 (9)
659 (8)
1
374 (8)
615 (4)
2
321 (1)
486 (1)
3
132 (1)
222 (0)
4
90
146
Follow-up (years)
0
2·5
5·0
7·5
In
cid
en
t H
IV
 in
fe
ct
io
ns
 (%
)
Lymphatic filariasis positive
Lymphatic filariasis negative
Figure 3: Kaplan-Meier plot of HIV incidence by stable lymphatic filariasis status in participants older than 
14 years
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activation that could facilitate early viral 
dissemination.4,22,23 Individuals with lymphatic filariasis 
can present distinct clinical conditions, which differ 
regarding the activation status of the immune system. 
Patients with lymphoedema show an increased 
proinflammatory Th17 profile,12 whereas asymptomatic 
individuals display either T-cell hyporesponsiveness 
with high numbers of microfilariae, or increased 
immune responses in amicrofilaraemic individuals.11 
However, lymphatic filariasis is known to be associated 
with changes in the human immune system profile that 
could alleviate early HIV transmission events. For 
example, lymphatic filariasis infection-associated 
changes in the cytokine profile of peripheral blood 
mononuclear cells are linked to increased susceptibility 
to in-vitro HIV infection.24 Furthermore, because 
macrophage populations have differing potential to 
mediate the transmission of HIV-1 to CD4-positive 
T cells, further studies should investigate whether the 
expansion of such populations in individuals with 
lymphatic filariasis25 also facilitates HIV acquisition.
The effect of nematode infections on HIV transmission 
has been discussed for more than three decades. Previous 
cross-sectional studies that concentrated on coinfected 
individuals in Tanzania suggested an association,17 
although this could not be confirmed in follow-up 
studies.16,18,20,26 Despite the difficulties in conducting 
longitudinal studies to dissect the effect of filariae on 
HIV transmission, we have been able to follow a large 
cohort of individuals from a high HIV incident setting 
over several years and show for the first time a significant 
effect of an ongoing lymphatic filariasis infection on the 
acquisition of HIV.
To reduce the susceptibility to HIV, a change in 
lymphatic filariasis treatment recommendations 
might help. Commonly used dual combinations of drugs 
administered for mass drug administration 
(diethylcarbamazine, albendazole, or ivermectin) in 
lymphatic filariasis kill microfilariae but only partly affect 
adult worms. Treatment concepts that aim to kill adult 
worms, such as doxycycline27 or diethylcarbamazine, 
albendazole, and ivermectin in triple combination28 
(currently only used outside Africa because of contra-
indication of diethylcarbamazine in onchocerciasis) 
might more quickly diminish the described increased 
susceptibility to HIV. Future studies should address the 
question of whether antifilarial treatment reduces HIV 
incidence in individuals with lymphatic filariasis. If true, 
this would be an important instrument to reduce HIV-
infection in areas where lymphatic filariasis is prevalent.
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Abstract
Background
Annual mass treatment with ivermectin and albendazole is used to treat lymphatic filariasis
in many African countries, including Tanzania. In areas where both diseases occur, it is
unclear whether HIV co-infection reduces treatment success.
Methodology
In a general population study in Southwest Tanzania, individuals were tested for HIV and
circulating filarial antigen, an indicator ofWuchereria bancrofti adult worm burden, before
the first and after 2 consecutive rounds of anti-filarial mass drug administration.
Principle Findings
Testing of 2104 individuals aged 0–94 years before anti-filarial treatment revealed a preva-
lence of 24.8% for lymphatic filariasis and an HIV-prevalence of 8.9%. Lymphatic filariasis
was rare in children, but prevalence increased in individuals above 10 years, whereas a
strong increase in HIV was only seen above 18 years of age. The prevalence of lymphatic
filariasis in adults above 18 years was 42.6% and 41.7% (p = 0.834) in HIV-negatives and–
positives, respectively. Similarly, the HIV prevalence in the lymphatic filariasis infected
(16.6%) and uninfected adult population (17.1%) was nearly the same. Of the above 2104
individuals 798 were re-tested after 2 rounds of antifilarial treatment. A significant reduction
in the prevalence of circulating filarial antigen from 21.6% to 19.7% was found after treat-
ment (relative drop of 8.8%, McNemar´s exact p = 0.036). Furthermore, the post-treatment
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reduction of CFA positivity was (non-significantly) larger in HIV-positives than in HIV-nega-
tives (univariable linear regression p = 0.154).
Conclusion/Significance
In an area with a high prevalence for both diseases, no difference was found between HIV-
infected and uninfected individuals regarding the initial prevalence of lymphatic filariasis. A
moderate but significant reduction in lymphatic filariasis prevalence and worm burden was
demonstrated after two rounds of treatment with albendazole and ivermectin. Treatment
effects were more pronounced in the HIV co-infected subgroup, indicating that the effective-
ness of antifilarial treatment was not reduced by concomitant HIV-infection. Studies with
longer follow-up time could validate the observed differences in treatment effectiveness.
Author Summary
Parasite infections and HIV show large geographical overlap in sub-Saharan Africa and
could hence potentially interact in co-infected individuals. In a general-population study
conducted in Southwest Tanzania, we found high prevalence of both, lymphatic filariasis
and HIV, with 42.5% of the adult population infected withWuchereria bancrofti and
16.8% infected with HIV. Seven percent of the adults were infected with both pathogens.
When adjusting for age, there was no statistically significant difference in initial prevalence
or worm burden between HIV-positive and negative participants. For 798 individuals test
results for both diseases were available in 2009, before and in 2011, after 2 rounds of treat-
ment against lymphatic filariasis. Between 2009 and 2011, a significant drop of prevalence
and worm burden in infected individuals were observed, which was more pronounced in
the HIV co-infected subgroup. Hence, HIV co-infection does not seem to negatively affect
lymphatic filariasis treatment programmes.
Introduction
Lymphatic Filariasis (LF) is a mosquito-borne disease caused either byWuchereria bancrofti
which is distributed throughout the tropics, or Brugia malayi and Brugia timori, both limited
to Southeast-Asia. It is estimated that 120 million people world-wide are infected with one of
these pathogens, and 1 billion are at risk to acquire LF during their lifetime [1]. Before larger
treatment programmes started, LF was present in most of the 21 regions of Tanzania with up
to 63.8% of individuals testing positive for circulating filarial antigen, a marker for LF infection
[2]. Since the year 2000 the “Global Alliance to Eliminate Lymphatic Filariasis” uses annual
mass drug administration (MDA), with the aim to control and ultimately eliminate the disease
[3]. The campaign of the Tanzanian National Lymphatic Filariasis Elimination Programme
(NLEFP) commenced in 2001 in the coastal regions of Tanzania. In the Mbeya district in
Southwest-Tanzania the treatment programme started in October 2009 with the annual distri-
bution of albendazole (400mg) and ivermectin (150–200μg/kg). Ivermectin is considered to be
mainly microfilaricidal [4], for albendazole an effect on the release of intrauterine antigen com-
ponents of the adult worm was described [5]. Some studies report on the treatment effective-
ness of the combination of albendazole and ivermectin after 12-month: in Ghana a significant
reduction in circulating filarial antigen (CFA) levels but no measurable reduction of CFA
LF in HIV Co-infected Individuals
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prevalence was described in 370 individuals receiving both drugs [6, 7]. A longitudinal study
from Northern Tanzania showed only small reductions of CFA positivity after two annual
drug distributions (from 53.3% to 51.4%), but a significant drop to 44.9% and 19.6% after four
and seven years of treatment, respectively [8].
In South Western Tanzania, both LF and HIV are public health concerns. The HIV preva-
lence in the country has been documented in several national surveys [1, 9, 10]. The third pop-
ulation based Tanzanian HIV/AIDS and Malaria Indicator Survey in 20011/2012 (THMIS)
revealed a country-wide HIV prevalence of 5.1% in Tanzanian adults between the age of 15
and 49 years, and a prevalence of 9.0% for this age-group in Mbeya Region [10]. Large scale
distribution of antiretroviral (ART) drugs was initiated in Tanzania in 2005. At the time of our
study, ART was not widely available in Southwest Tanzania. [10–12].
Local differences in initial prevalence, coverage of treatment programs, co-infection with
other pathogens, etc. can all affect treatment success, thus careful surveillance of the programs
is necessary to control the infection. [1, 13–17]. Only few manuscripts focus specifically on the
possible interaction of HIV with LF and most of these use cross-sectional data [18–21]. Only
one recently published study investigates the treatment effectiveness of MDA drugs in HIV/LF
co-infected individuals [22], but focusses on changes in CD4 and HIV viral load after antifilar-
ial treatment in selected HIV-positive individuals. No study concentrated on the antifilarial
treatment effectiveness of MDA drugs in HIV/LF co-infected individuals.
Our study assesses LF prevalence in the Mbeya Region, before and after the governmental
eradication program reached the area and examines the potential impact of HIV co-infection
on LF treatment.
Methods
Study population and study design
Data were collected during the SOLF cohort-study (Surveillance of Lymphatic Filariasis, http://
www.mmrp.org/projects/basic-research/solf.html) in the Kyela district/Mbeya region in South-
west Tanzania which was conducted at the National Institute for Medical Research (NIMR)—
MbeyaMedical Research Centre (MMRC) between 2009 and 2011. The study was embedded
into the population based EMINI (Evaluation andMonitoring of the Impact ofNew Interven-
tions, http://www.mmrp.org/projects/cohort-studies/emini.html) cohort study, which was carried
out in 9 selected communities in the Mbeya region (Fig 1) from 2006 to 2011. More than 170,000
inhabitants from ~42,000 households of these communities were registered and 10% of house-
holds randomly selected to participate in the study. No additional households entered the surveil-
lance, but some new participants entered through birth or marriage into included household.
Ethical considerations
The SOLF study was approved by the Mbeya Medical Research and Ethics Committee and the
Tanzanian National Institute for Medical Research—Medical Research Coordinating Commit-
tee as an amendment to the EMINI cohort study. Prior to enrolment, each EMINI participant
had provided written informed consent regarding study participation. Parents consented for
their children below 18 years of age. In addition, children above the age of 12 years signed their
own assent form.
Data collection
Data and samples from participants in the Kyela site of the EMINI study were collected annu-
ally from 2007 until 2009. During the last two surveys (2010 and 2011) only half of the study
LF in HIV Co-infected Individuals
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households were visited in each year. During each visit, which took place between 8 am and 2
pm, blood, urine and stool samples were collected from each participant. Samples from 2,165
participants fromMarch 2009 were used to estimate the prevalence of LF directly before the
government treatment program commenced in Kyela in October 2009. In March 2011, 18
month after the first and 6 month after the second delivery of antifilarial treatment, samples
from 1,010 participants were used to evaluate treatment impact.
Sample processing
From each study participant, 2.7 ml of blood was collected during morning hours in EDTA
tubes and immediately stored at 4°C. Cells and plasma were separated within 24 hours and sub-
sequently stored at -80°C. All laboratory tests were performed at NIMR-MMRC, Mbeya
Tanzania.
HIV diagnosis
HIV testing was performed using the SD-Bioline HIV-1/2 3.0 (Standard Diagnostics, Kyonggi-
do, South Korea) rapid diagnostic test (RDT). Negative RDT results from one survey, followed
by another negative RDT result in a subsequent survey, were regarded as confirmed negative
and not further tested. All positive results were confirmed using an ELISA HIV test (Enzygnost
Anti HIV 1/2 Plus, DADE-Behring, Marburg, Germany), and tested by Western blot (MPD
HIV Blot 2.2, MP Biomedicals, Geneva, Switzerland) if discordant. For all HIV incident cases,
the negative result of the previous year, as well as the new positive results was confirmed by the
testing algorithm described above. For children below the age of two years, HIV testing was
done by PCR. Further details are described elsewhere [23]. Because confidential disclosure of
the HIV-status could not be ensured during household visits, we did not inform participants
about their HIV status. Instead they were offered voluntary counseling and testing by an
Fig 1. Study area. The study was conducted in the southwestern part of Tanzania (black rectangle). A general population study was performed in nine study
areas (black polygons). Data for this study were collected in Kyela (red rectangle) situated close to Lake Nyassa. (Globe Icon by Sev, https://openclipart.org).
doi:10.1371/journal.pntd.0004618.g001
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independent team, which was travelling with our study team, who provided referral to the local
care and treatment center, to everyone who was tested positive.
Filarial antigen testing
A commercially available ELISA (TropBio Og4C3 serum ELISA, Townsville, Australia) was
used to detect circulating filarial antigen (CFA) using 100 μl of the collected sera. The Og4C3
antibody detectsWuchereria bancrofti antigen with high specificity (98.5%) and no known
cross-reaction to Onchocerca volvulus, Brugia spp.,Mansonella, Dracunculus medinensis, Asca-
ris lumbricoides or Strongyloides stercoralis [24]. Sensitivity varies between 73% [25] and 100%
[26], but was found 97.9% in individuals carrying microfilariae [24]. CFA is secreted by fully
developedW. bancrofti adults and can be found at similar levels during day and night. Antigen
levels thus reflect theW. bancrofti worm burden. The measurement of CFA with the Trop Bio
ELISA is semi-quantitative; seven control tubes with standardized amounts of antigen are sup-
plied and allow an estimation of the filarial antigen levels in the analysed plasma according to
the measured optical density (OD). LF test results were considered negative, indeterminate or
positive if the OD was<0.2,0.2 and0.3, or>0.3 respectively.
Statistics
Statistical analyses were performed using Stata statistics software (version 14; Stata Corp.,
College Station, TX). Pearson´s chi-squared test was used to compare binominal outcomes
between groups and to compare CFA positivity before and after treatment in all participants.
McNemar´s exact test for paired data was used to compare CFA positivity before and after
treatment in those individuals who participated in both surveys. The non-parametric
Wilcoxon rank sum test was used to compare selected baseline characteristics of continuous
variables, since none of these was normally distributed. In order to examine the associa-
tion of LF infection with HIV status and other potentially important covariates we per-
formed uni- and multi-variable log link binomial regression analyses with robust variance
estimates.
Results
In March 2009, before the first national MDA commenced, valid CFA results were obtained
from 2,104 individuals (Table 1). Indeterminate results were found for the 61 of the tested
2,165 samples (2.8%). Their median age was 16.6 years (range 0–94, IQR: 8.8 to 34), and 51.0%
were female. Only 4 (1.6%) of the 245 children below the age of 5 years were CFA-positive; LF
prevalence started to rise in participants above 10 years and was 42.3% in adults above 18 years
of age (Fig 2). When including all age groups, 24.8% of the study population were CFA-positive
with a trend to higher prevalence in males (26.5%) than in females (23.1%, chi-squared
p = 0.074). In the adult population above 18 years the difference in CFA-positivity between
males (47.3%) and females (38.0%) was significant (chi-squared p = 0.003).
In March 2011, 18 months after the first MDA and six months after the second, ~50% of the
initially included households were revisited for interviews and blood sample collection. Some
scheduled participants were not found in 2011, and some new individuals had entered the vis-
ited households (see study population and design). In addition to an analysis where the data of
all participants form each Survey (= open cohort) are evaluated, which reflects more a cross
sectional design, a second analysis included only the 798 individuals who actively participated
in both years of the surveillance longitudinally (= closed cohort). The numbers of participants
is shown in Table 1. Of the 974 valid test results in 2011, 19.7% were CFA-positive, leading to a
calculated prevalence reduction of 5.1% (24.8% vs. 19.7%, chi-squared p = 0.002) when
LF in HIV Co-infected Individuals
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including all subjects who participated in at least one survey (Table 1, open cohort). In the
analysis of samples from 798 individuals who actively participated in both surveys (Table 1,
closed cohort), a lower prevalence reduction (21.6 to 19.7%, McNemar´s exact p = 0.036) was
measured (Fig 3).
Table 1. Study participants and LF prevalence in 2009 and 2011.
2009 2011
all n LF-positive n LF-prevalence % all n LF-positive n LF-prevalence %
open cohort
all* 2,104 521 24.8 974 192 19.7
HIV-negative 1,905 450 23.6 878 166 18.9
HIV-positive 187 69 36.9 91 25 27.5
closed cohort
all** 798 172 21.6 798 157 19.7
HIV-negative 723 151 20.9 723 140 19.4
HIV-positive 69 19 27.5 69 15 21.7
*12 individuals without valid HIV result
**6 individuals without valid HIV result
Data for all study participants from 2009 and 2011 are shown in the upper part of the table (= open cohort). Only 798 individuals participated in both years
of the surveillance (= closed cohort) their data are shown in the lower part.
doi:10.1371/journal.pntd.0004618.t001
Fig 2. Baseline CFA prevalence by age.Numbers of participants for each age group are given in parenthesis.
doi:10.1371/journal.pntd.0004618.g002
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At baseline the overall HIV prevalence in our study cohort was 8.9%, with a prevalence of
only 2.1% in children and adolescents below the age of 18 years, and a prevalence of 16.9% in
individuals18 years of age (Fig 3).
HIV-infection was more prevalent in female (10.7%), compared to male participants (7.1%,
chi-squared p = 0.003). Sixty-eight of the 968 adult individuals (7.0%) were infected with both
pathogens and among the whole group of 2,104 individuals 69 co-infections (= 3.3%) were
observed. The initial univariable analysis of the potential association of HIV with LF infection
showed a higher prevalence of LF in HIV-positive (36.9%); compared to HIV-negative individ-
uals (23.6%) (RR = 1.56, 95% CI = 1.26 to 1.94, p<0.001). But we already demonstrated that
HIV and LF are both less common in children than in adults, which confounds this association.
To further study the pattern of co-infection we analysed CFA positivity in HIV infected and
uninfected individuals stratified by age (Fig 4); in adults (> = 18 years) only; and in log-link
binomial multivariable regression adjusted for age and gender. None of these analyses showed
a significant association of LF infection with HIV, neither within the single age strata nor over-
all in the multivariable regression model where the influence of age and gender were con-
firmed, but where the adjusted RR for HIV was only 1.04 (Table 2). When only analysing data
from adults above 18, the CFA prevalence was 42.6% in the HIV-negative and 41.7% in the
HIV-positive subgroup (univariable log-link regression RR = 0.98, 95% CI = 0.80 to 1.20;
p = 0.84).
In order to compare antifilarial treatment success in the HIV-negative and positive sub-
groups we again performed two analysis: one for all tested individuals who participated in at
least one survey (open cohort using chi-squared testing), and one only for the individuals who
Fig 3. HIV prevalence by age.Numbers of participants for each age group are given in parenthesis (for 12 individuals no valid HIV result was available).
doi:10.1371/journal.pntd.0004618.g003
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participated in both surveys before and after treatment (closed cohort, using McNemar´s exact
test).
For the open cohort a CFA prevalence reduction from 23.6% to 18.9% (chi-squared
p = 0.015, relative drop = 19.7%) was found in HIV-negative participants, and from 36.9% to
27.5% (chi-squared p = 0.023, relative drop = 25.4%) in HIV-positives. For the closed cohort
we observed a drop in CFA positivity from 20.9% to 19.4% (McNemar´s exact p = 0.117, rela-
tive drop = 7.3%) in 723 HIV-negatives and from 27.5% to 21.7% (McNemar´s exact p = 0.125,
relative drop = 21.1%) in 69 HIV-positive participants. The reason for this pronounced differ-
ence (7.3% vs. 21.1%) is a higher incidence of CFA positivity in the HIV negative participants
where 15 (2.6%) of the 572 initially CFA negative participants turned CFA-positive, whereas
none of the 50 HIV-positive participants who were initially CFA-negative turned CFA-positive
(chi-squared p = 0.246). The proportion of initially CFA positives who turned CFA negative
was very similar in HIV-negative (26/151 = 17.2%) and HIV-positive participants (4/
19 = 21.1%, chi-squared p = 0.679). When combining this information about change in LF sta-
tus in one outcome variable (-1 = turned CFA negative; 0 = no change in CFA status; 1 = turned
CFA positive) univariable linear regression modelling resulted in a coefficient β for the HIV
infected subgroup of -0.043 (95%CI = -0.102 to 0.016, p = 0.154).
Fig 4. Baseline CFA prevalence by age for HIV-positive and HIV-negative participants. Prevalence of CFA positivity in HIV-negative (blue) and HIV-
positive (red) participants. No HIV/LF co-infection was observed in participants below 10 years of age.
doi:10.1371/journal.pntd.0004618.g004
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Analysing the prevalence reduction in the closed cohort for adults> = 18 years only, a drop
from 42.7% to 40.3% (McNemar´s exact p = 0.248, relative drop = 5.6%) was noted for HIV-
negatives, and from 32.7% to 25.5% (McNemar´s exact p = 0.125, relative drop = 22.0%) in the
HIV-positive subgroup. Summarizing our results, we found more pronounced drops in preva-
lence among the HIV positive subgroup, compared with the HIV negative, no matter, whether
all participants or only adults are analysed and also with both possible ways of evaluating the
data (open cohort or closed cohort).
The measurement of CFA with the Trop Bio ELISA is semi-quantitative; with the OD of the
plasma samples reflecting the participant’s worm burden. Our findings for CFA intensities par-
allel those for CFA prevalence: geometric mean intensities before treatment were relatively
similar between HIV-positives (157 units) and HIV-negatives (179 units, Wilcoxon rank sum
p = 0.34), which is also true for the relative reduction of geometric mean intensity after treat-
ment, which was 26% and 30% respectively (Wilcoxon rank sum p = 0.50)
Discussion
In our study we found a significant decrease in LF-prevalence after only 2 years of MDA in an
area with high HIV co-infection in South-West Tanzania. This was in contrast to our expecta-
tions and previously published manuscripts [2, 6, 7, 16, 27]. Furthermore we did not find any
evidence that HIV co-infection impairs the effectiveness of antifilarial treatment. On the con-
trary, our data show a more pronounced decrease in prevalence and CFA intensity among
HIV-positive compared to HIV-negative participants. We tried to consider several factors
which could have affected our analysis. The age distribution of LF and HIV infection had to be
taken into account, but also the composition of the study population and potential changes
during follow-up. However, an almost three-fold relative drop in LF prevalence was seen for
HIV-positive compared to HIV-negative participants in the most stringent analysis which only
considered individuals for whom we have data both before and after treatment. We do not
want to overstate this result since the overall numbers of participants with HIV/LF-co-infec-
tion was low, despite an initially large cohort and accordingly the differences in cure and inci-
dence rate between HIV-infected and uninfected participants are not significant. Moreover, we
are unable to present an explanation for this finding. Reports about the LF prevalence in HIV-
negative and HIV-positive individuals have been rare and conflicting in the past. Nielsen et al.
Table 2. Uni- and Multivariable binomial log-link regression models showing associations of Age, Sex and HIV positivity with LF infection in 2092
individuals before antifilarial treatment commenced.
Univariable Multivariable
All: n LF pos (%) RR 95% CI P RR 95% CI P
2,092 24.8
HIV
neg 1,905 23.6 1 1.26 to 1.94 <0.001 1 0.85 to 1.27 0.689
pos 187 36.9 1.56 1.04
Sex:
female 1,067 23.2 1 0.99 to 1.32 0.064 1 1.11 to 1.44 <0.001
male 1,025 26.5 0.15 0.27
Age (years)
0-<18 1,124 9.6 1 1
18-<50 689 39.2 4.01 3.27 to 5.08 <0.001 4.10 3.29 to 5.10 <0.001
> = 50 279 50.5 5.26 4.20 to 6.58 <0.001 4.16 4.32 to 6.70 <0.001
doi:10.1371/journal.pntd.0004618.t002
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described a positive association of HIV and LF infection after adjusting for age and sex in a
cross-sectional study from Northern Tanzania [20], even though a further evaluation of this
group of individuals did not support an association between HIV and LF [19]. No difference
regarding CFA levels was found in other cross sectional studies from India [18] and Malawi
[28]. The latter findings are supported by the cross sectional analysis of our study participants
in 2009. To date, no other longitudinal study has compared the effectiveness of antifilarial
treatment in HIV-positive and negative subgroups.
One interesting finding is the higher pre-treatment CFA prevalence in the open compared
to the closed cohort which demonstrates that LF-positive individuals were more likely to be
lost to follow-up than LF-negative participants. This can at least partly be explained by the
higher prevalence of LF in adults, who are more likely than younger participants to relocate
(e.g. in search of a job), to harbour diseases that prevent them from further study participation
(e.g. HIV-infection) and to die.
Most other studies analyse the treatment effectiveness after 6, 8 or even more years of treat-
ment. Thus one limitation of our study is the short duration of follow-up, which is a conse-
quence of funding restrictions and does not allow for a conclusive analysis of MDA
effectiveness. Furthermore we are not able to identify individually who of our participants was
treated and who was not: the local district medical officer and Neglected Tropical Diseases
(NTD) coordinator, who supervised the drug distribution in Kyela district, reported coverages
of 60.8% in October 2009 and 68.2% in 2010 (Mrs. Masawe, personal communication). How-
ever, very few participants of the SOLF study were aware of the treatment program against LF,
when asked about their participation. Therefore, firm assumptions about efficacy, i.e. the effect
of antifilarial treatment on CFA prevalence and intensity under ideal conditions cannot be
made. Instead our data are better suited to describe the effectiveness of MDA under real-life
conditions. Furthermore, information on CD4 count and antiretroviral treatment status of
HIV infected individuals would have helped to refine our analysis, but this information was
not collected.
The Og4C3 antibody is supposed to specifically recogniseWuchereria bancrofti antigen
with no relevant cross-reaction to Onchocerca volvulus, Brugia spp.,Mansonella, Dracunculus
medinensis, Ascaris lumbricoides or Strongyloides stercoralis. In spite of this, cross reactivity
with Loamicrofilariae has been found in another test (Binax Now Filariasis Immunochromato-
graphic Test, Alere, Scarborough, ME, USA), which detects the same antigen as the Trop Bio
ELISA [29]. However, there is no significant reported disease burden of Loiasis in our study
area [30].
Conclusion
In an area with high prevalence of and no previous treatment against LF we investigated the
potential association of HIV and LF infection. When adjusting for age we found similar CFA
prevalence and intensities in HIV-positive and negative participants. After two rounds of treat-
ment a significant reduction in CFA prevalence and intensity was demonstrated, which was
more pronounced in the HIV-positive compared to HIV-negative participants. Hence, HIV
co-infection does not seem to negatively affect antifilarial treatment.
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Abstract
Background: With one quarter of the world population infected, the intestinal nematode Ascaris lumbricoides is one of the
most common infectious agents, especially in the tropics and sub-tropics. Infection is caused by oral intake of eggs and can
cause respiratory and gastrointestinal problems. To identify high risk areas for intervention, it is necessary to understand the
effects of climatic, environmental and socio-demographic conditions on A. lumbricoides infection.
Methodology: Cross-sectional survey data of 6,366 study participants in the Mbeya region of South-Western Tanzania were
used to analyze associations between remotely sensed environmental data and A. lumbricoides infection. Non-linear
associations were accounted for by using fractional polynomial regression, and socio-demographic and sanitary data were
included as potential confounders.
Principal Findings: The overall prevalence of A. lumbricoides infection was 6.8%. Our final multivariable model revealed a
significant non-linear association between rainfall and A. lumbricoides infection with peak prevalences at 1740 mm of mean
annual rainfall. Mean annual land surface temperature during the day was linearly modeled and negatively associated with
A. lumbricoides infection (odds ratio (OR) = 0.87, 95% confidence interval (CI) = 0.78–0.97). Furthermore, age, which also
showed a significant non-linear association (infection maximum at 7.7 years), socio-economic status (OR = 0.82, CI = 0.68–
0.97), and latrine coverage around the house (OR = 0.80, CI = 0.67–0.96) remained in the final model.
Conclusions: A. lumbricoides infection was associated with environmental, socio-demographic and sanitary factors both in
uni- and multivariable analysis. Non-linear analysis with fractional polynomials can improve model fit, resulting in a better
understanding of the relationship between environmental conditions and helminth infection, and more precise predictions
of high prevalence areas. However, socio-demographic determinants and sanitary conditions should also be considered,
especially when planning public health interventions on a smaller scale, such as the community level.
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Introduction
The intestinal nematode Ascaris lumbricoides is one of the most
common causes of infection among the soil-transmitted helminths
(STH). Common in the tropics and sub-tropics, it is estimated that
more than one quarter of the world population is infected with this
helminth [1–3].
The highest morbidity is found in children, especially in those
with a high worm burden. A. lumbricoides can lead to reduced
physical fitness, growth retardation, and respiratory and gastroin-
testinal problems [3–6]. Evidence if A. lumbricoides infection has a
negative impact on cognitive function and educational achieve-
ment in school children is controversially debated [7–10].
Infection occurs through the oral intake of eggs, usually
contained in soil or food. Adult worms live in the lumen of the
small intestine where the female lays unembryonated eggs which
are excreted with the feces. In the open, the eggs have to go
through three stages of development in order to become infectious;
a time during which they are exposed to environmental conditions
[5,11,12]. When embryonated eggs are swallowed by a human
host, the larvae hatch in the small intestine, have a short migratory
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phase (venous system, liver, lungs, trachea, esophagus) after which
they return to the small intestine where they mature and mate
[13,14].
Recently, remotely sensed environmental data have increasingly
been used to get a better understanding of the epidemiology and
spatial distribution of STH [15–22]. The use of environmental
data in combination with geographic information systems (GIS)
has become a powerful tool for mapping and predicting STH, with
the main purpose to identify high risk areas for intervention [23–
26].
However, there are still challenges in the statistical modeling of
environmental data. One problem is the consideration of non-
linear relationships between outcome and predictor variables.
Although non-linear relationships between environmental data
and STH infection are a recognized fact [16,22], this has rarely
been taken into account in multivariable analysis. A further
complication is the need to take care of potential confounders.
Especially risk factors linked to transmission, such as poor
sanitation facilities, crowding, and high population density
[2,6,12,14,27–32], need to be considered when associations
between environmental factors and STH infection are analyzed.
Therefore, the main objective of this study was to assess
associations between remotely sensed environmental data and A.
lumbricoides infection while considering potential non-linear rela-
tionships and confounders. A manuscript that examines associa-
tions of hookworm infection with environmental factors has
recently been accepted [33], and manuscripts regarding Trichuris
trichiura and schistosome infection are presently being prepared.
Methods
Ethics Statement
The study was approved by the ethics committee of the
Tanzanian National Institute for Medical Research and conducted
according to the principles expressed in the Declaration of
Helsinki. All participants provided written informed consent
before enrolment into the study; parents consented for their
children below 18 years of age. Specifically, children who were old
enough to understand the process were asked to participate in the
consenting procedure, and children who were 12 years old or
older were asked to sign/thumbprint the document in addition to
their parent’s signature/thumbprint.
Study Area and Epidemiological Data Collection
Data for this study were collected in nine study sites in the
Mbeya Region in south-western Tanzania (Figure 1) from June
2008 until June 2009 during the third annual survey of the EMINI
(Evaluating and monitoring the impact of new interventions)
cohort study. The region is predominantly rural and most income
generating activities are related to agriculture. During an initial
population census in the nine sites, more than 42,000 households
were identified and their geographical positions recorded, using
handheld geographical positioning system (GPS) devices (Spor-
Trak handheld GPS, Magellan Navigation Inc., Santa Clara, CA,
USA). Geographically stratified random selection was used to
choose 10% (4,283) of these households to participate in the main
EMINI cohort study. During each annual survey these households
were visited once to collect biological specimen and interview data.
All participants provided written informed consent before
inclusion into the study, with parents or care takers consenting
for their minors.
The collection of stool samples started in 2008. Due to logistic
constraints, households were randomized into two groups of equal
size of which only one was annually sampled for stool.
Interviews to characterize the socio-economic status (SES) of
each household were conducted with the household head and
included questions regarding infrastructure of the household,
ownership of livestock, the availability of certain household assets,
and materials that were used to build the house(s) in each
homestead. Data on socio-demographic status (sex, age, marital
status, religious denomination, education, occupation etc.), rele-
vant behavior, knowledge and practices regarding various diseases
were collected in interviews with each individual household
member or – for children below 12 years – with their caretaker.
All interviews and medical examinations were performed at the
household and conducted in Kiswahili language.
Before stool collection started in the third survey round,
intestinal nematodes were neither diagnosed nor treated as part
of this study, and to our knowledge no other treatment programs
had been conducted in the region. Stool samples were collected in
pre-labeled screw-top containers, refrigerated at 4 uC directly after
collection, using mobile refrigerators (WAECO CoolFreeze CF-
50, WAECO, Emsdetten, Germany) and kept cool until slide
preparation in the laboratory within two days of collection. The A.
lumbricoides infection status of participants was established by Kato-
Katz examination [34] of two sub-samples (41.7 mg each) from a
single stool specimen, which was thoroughly mixed before slide
preparation. Kato-Katz slides were examined for A. lumbricoides
eggs by experienced staff within two days after slide preparation.
A. lumbricoides infection was defined as the presence of at least one
A. lumbricoides egg in any of the two slides and infection intensity
was classified according to Montresor et al. [35]. To assure the
quality of our lab results all Kato-Katz slides were archived and a
sample of randomly selected slides were reexamined after at least
one month by different lab staff.
Helminth infected participants were offered treatment with
albendazole (for A. lumbricoides and other intestinal nematode
infections) and/or praziquantel (for schistosome infections),
according to their respective diagnosis.
Environmental Data
The following remotely sensed environmental data were
considered for this analysis: Elevation was obtained using the
NASA Shuttle Radar Topography Mission (SRTM) global digital
elevation model (DEM) version 2.1 [36]. These elevation data
were also used to calculate the slope. Mean annual rainfall and
ambient temperature were downloaded from the WorldClim –
Global Climate Data website [37]. Mean annual land surface
temperature during day and night (LST-day and LST-night) and
vegetation cover (Enhanced vegetation index (EVI)) which had
been collected during NASA’s Moderate-Resolution Imaging
Spectroradiometer (MODIS) Terra mission, were downloaded
from the Land Processes Distributed Active Archive Center (LP
DAAC) [38,39].
Household positions and inhabitant numbers from the initial
population census were used to calculate population density
around the household. Population density, ambient temperature,
elevation, rainfall, LST, EVI, and slope were averaged for a buffer
area within a 1,000 meter radius around each homestead in order
to characterize the environmental situation around the household.
This approach was preferred to using the respective spot values at
the homestead position because spot data are more prone to
random error than averages for a wider area. Latrine coverage in
the surroundings of each household was calculated as the inverse
distance weighted percentage of households with their own latrine
within one kilometer around the household.
Initial processing of remotely sensed data was done in Idrisi GIS
software v.32 (Clark Labs, Worcester, MA, USA). The GIS
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program Manifold System 8.0 Professional Edition (Manifold Net
Ltd, Carson City, NV) was used to combine household positions
and environmental data.
Socio-economic Status and Other Confounding Variables
Household income and expenditure data in developing
countries, especially in rural areas, are often unreliable because
many people do not have a regular cash income. To overcome this
problem we employed a modification of a method initially
proposed by Filmer and Pritchett (2001) that uses principal
component analysis to generate an SES score using proxy
variables [40–42]. The following proxy variables were used:
Household assets (clock or watch, radio, television, mobile
telephone, refrigerator, hand cart, bicycle, motor cycle, car,
savings account), construction materials for the house, and sources
of household fuels and drinking water. In addition to the above
described SES score, age, sex, population density, latrine coverage
around the household, and presence of a latrine in the household
were considered as potential confounders.
Statistical Analysis
All statistical analyses were performed using Stata/SE (Version
11.2, StataCorp LP, College Station, TX). Because our environ-
mental variables showed a high degree of correlation, multi-
collinearity was assessed using the variance inflation factor (VIF)
(VIFi~1=Ti) calculated with the tolerance (T) (Ti~1{R
2
i ). R
2
i is
the calculated variance of each covariate associated with the rest of
the other independent variables. A VIF higher than 10 indicates a
serious problem of multicollinearity [43–45].
After multicollinearity analysis we performed univariable linear
logistic regressions for each considered independent variable. All
variables with a univariable Wald’s p,0.2 were included in the
multivariable analysis.
In our study design individual observations were clustered in
households and these were clustered within study sites. Therefore,
household clustering was accounted for by calculation of robust
standard errors using Huber/White variance estimates [46–48]
and the nine study sites were taken into account as dummy
variables.
Multivariable logistic regression with the inclusion of fractional
polynomials which is a flexible parametric approach for modeling
continuous factors was applied to analyze non-linear associations
between A. lumbricoides infection and environmental variables [49].
The power transformations xp are found with a predefined set of
powers S = 22,21,20.5,0,0.5,1,2,3 where x0 is defined as ln x. A
fractional polynomial model with one degree (FP1) takes the
form0z1x
p  ln x, with two degrees (FP2)0z1xpz2xp
 ln x. The restriction of powers and the consideration of
polynomials with degree 1 and 2 provide enough flexibility for
statistical modeling [50,51].
Multivariable fractional polynomial (MFP) models, an extended
algorithm introduced by Royston and Sauerbrei, were used to
detect non-linear associations. The MFP algorithm contains a
Figure 1. Location and altitude of the EMINI study sites. The large altitude range results in very diverse environmental conditions regarding
temperature, vegetation, slope etc.
doi:10.1371/journal.pone.0092032.g001
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function selection procedure which compares null, linear, and FP1
sub models for each covariate with an FP2 model based on the
deviance [52]. A detailed description of the MFP algorithm is
found in Ambler and Royston (2001) and in Sauerbrei and
Royston (2008) [53,54]. For the function selection procedure a
lower p-value than 0.05 is recommended to avoid over fitting [50].
Therefore, a p-value of 0.01 was chosen as cut off when non-linear
sub models were compared.
Our final model was calculated by removing variables with a p-
value above 0.05. Changes of the Akaike Information Criterion
(AIC) [55] and the Bayesian Information Criterion (BIC) [56],
measuring the relative goodness of fit, were simultaneously
considered. In order to asses spatial autocorrelation in the raw
A. lumbricoides infection data and in the deviance residuals of our
final logistic model the Stata module ‘‘spatcorr’’ was used to
calculate Moran’s I [57].
Results
Descriptive Results
The overall prevalence of A. lumbricoides infection in the study
population was 6.8% (n = 433/6,366). Most infections were of low
intensity, moderate and high intensity infections were rare. The
highest prevalences were found in Kyela (25.2%) and Isongole
(16.9%). sites. Figure 2 demonstrates that A. lumbricoides infection
was clustered both between and within sites.
Men (47%) and women (53%) were almost equally represented
in the study and the mean age was 23.6 years. Thus the majority of
the study population were children and adolescents and the peak
of A. lumbricoides infection occurred before the age of ten years
(Figure 3). Nearly all households (97.5%) had their own latrine,
which was a pit latrine in most cases (Table 1). The prevalence of
A. lumbricoides infection was similar in female (6.57%) and male
(7.11%) participants.
Univariable Logistic Regression and Multicollinearity
Analysis
In univariable analysis, all considered environmental variables
were significantly associated with A. lumbricoides infection (Table 2).
Elevation, LST-day and slope showed an inverse association,
whereas all other environmental variables were positively associ-
ated. Therefore, all environmental variables apart from elevation
and ambient temperature were included in the multivariable
analysis. Sex, household size, and population density were
excluded because their p-values were above 0.2, the threshold
which was chosen for the inclusion in multivariable analysis.
Due to high multicollinearity of the variables elevation
(VIF = 116.65), ambient temperature (VIF = 71.05) and LST-
night (VIF = 17.19), elevation and ambient temperature were
excluded from multivariable analysis, since their VIFs by far
exceeded the threshold of 10. We decided to include LST-night
not only because of its lower VIF, but more importantly, because
soil temperature appears to be more directly linked to helminth
egg development than elevation or ambient temperature, as eggs
develop in the soil or at the soil surface.
Multivariable Logistic Regression with Fractional
Polynomials
In MFP analysis we found a non-linear relationship of rainfall
and age with A. lumbricoides infection. In the full and in the final
reduced model a fractional polynomial transformation with two
degrees (FP2) was implemented.
For the other variables the linear assumption was retained and
odds ratios (ORs) were calculated. The full and the final reduced
multivariable regression models are shown in Table 3. Rainfall
and LST-day were kept as significant environmental variables in
the final model. LST-day showed an inverse association with A.
lumbricoides infection. With every degree Celsius increase in LST-
day the odds of being infected with A. lumbricoides decreased by
about 13%.
The calculated beta coefficients for the non-linear functions of
rainfall and age are not directly interpretable as ORs. For rainfall,
the odds of A. lumbricoides infection are increasing until a rainfall
maximum of 1,740 mm and are decreasing again at higher values
(Figure 4). For age there is a steep increase until an infection
maximum at 7.7 years, after which the odds are decreasing (curve
not shown). This is in agreement with the unadjusted age
prevalence curve shown in figure 2.
Except for latrine ownership in the household, all included
confounding variables (age, SES score and latrine coverage) were
significantly negatively associated with A. lumbricoides infection and
therefore retained in the final multivariable model.
In order to check our final model for plausible interactions we
calculated interaction terms between each beta of rainfall and
LST-day and between SES and latrine coverage. However, none
of these interactions were significant (data not shown).
The raw A. lumbricoides infection data show strong positive
spatial autocorrelation within separation distances of up to 8 km
(Figure 5). The lower values for Moran’s I in the deviance residuals
of our final model indicate that the variables in the model account
for a large part of this autocorrelation.
Discussion
Our univariable results show that A. lumbricoides infection is
significantly associated with several environmental factors. Of
these, mean annual rainfall and mean annual LST-day remained
significant in the multivariable model. LST-day had a linear
negative association with A. lumbricoides infection, whereas the
association of rainfall and age was non-linear with maximum
infection odds at 1,740 mm of mean annual rainfall and at an age
of 7.7 years. SES and latrine coverage around the household
showed significant negative associations with A. lumbricoides
infection, both in univariable and multivariable analyses.
Our results concerning LST-day are in line with the published
literature [21,23–25]. Two studies from Cameroon and Southeast
Asia found that a higher LST was significantly associated with a
lower risk of A. lumbricoides infection because high soil temperatures
reduce humidity and thus lead to desiccation of Ascaris eggs
[23,24]. These studies considered mean, minimum and maximum
LST, not LST for day and night as in our analysis. However, in
both studies minimum LST was excluded from multivariable
analysis which is in parallel to the exclusion of our LST-night
variable. Maximum LST was significantly negatively associated
with infection which is in agreement with the significant LST-day
variable in our final model. One study from Uganda found that A.
lumbricoides prevalence is ,5% where maximum LST exceeds 36–
37uC [21] and a study conducted in 20 schools in the Chad
predicted no A. lumbricoides prevalence in areas where mean LST
exceeds 37 uC [25].
Denser vegetation, as indicated by a higher EVI, showed a
strong positive association with A. lumbricoides infection in
univariable analysis, which, however, turned non-significant when
including other variables in the multivariable model. Our
significant univariable result for EVI is in line with multivariable
results from former studies [23,24,58]. The non-significance of
EVI in multivariable analysis is likely due to differences in local
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conditions compared to the former studies where EVI showed a
significant association.
The non-linear relationship of rainfall with infection can be
explained based on the life cycle of A. lumbricoides. Rainfall is an
important determinant of larval development because humidity,
Figure 2. A. lumbricoides prevalence in the study sites. Color coding indicates household prevalence, labels indicate site name and site
prevalence. A. lumbricoides infection is strongly clustered both between and within sites.
doi:10.1371/journal.pone.0092032.g002
Figure 3. Lowess smoothed plot of unadjusted A. lumbricoides prevalence over age. The main prevalence peak in childhood is in
accordance with the age of maximum infection intensity mentioned in the literature [14,67]. The second rise above the age of 30 with a less
pronounced peak in older age seems less common.
doi:10.1371/journal.pone.0092032.g003
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soil moisture, and land surface temperature have a strong impact
on embryonation [22]. Laboratory studies showed that higher
humidity facilitates larval development [59,60]. A multiple
regression analysis of rainfall, number of wet days and ambient
temperature in Sri Lanka found a significant association between
increased number of wet days per month and higher rates of A.
lumbricoides infections [61]. These findings are in line with the first
part of our predicted non-linear curve showing higher infection
odds when rainfall increases. However, another laboratory study
showed that the development of eggs located on an extremely wet
soil surface was delayed due to evaporation and the resulting low
temperatures [59]. Since, in contrast to hookworm larvae, A.
lumbricoides eggs are non-motile [12], they are directly exposed to
rainfall and LST on the soil surface. Crompton states that eggs
may be washed away by rainfall, too [5]. Increased rainfall can
lead to a leaching effect and eggs are washed to deeper regions of
the soil [62]. All these findings indicate that up to a certain
amount, increasing rainfall supports larval development but that
too much rain can delay larval development and thus reduce
transmission.
Regarding the examined possible confounding variables, our
univariable and multivariable results indicate that low SES and
bad sanitary conditions in and around the household are risk
factors for A. lumbricoides infection which is in line with former
publications [12,14,27,28,30,32]. The non-linear association
between age and A. lumbricoides infection describing a higher risk
in children and an infection peak in later childhood, is in line with
former epidemiological studies [3–6]. Although none of these
variables substantially confounded the associations of A. lumbricoides
Table 1. Description of variables.
Variables N Mean or percentage a) Std. Dev. Min Max
Ascaris infected 6,366 6.8%
Ascaris infection intensity b):
No infection (0 EPG) 5,933 93.2%
Low intensity (1–1,999) 317 4.98%
Moderate intensity (2,000–3,999 EPG) 66 1.04%
Heavy intensity ($4,000 EPG) 50 0.97%
Elevation [m] 6,366 1455 486 479 2313
Mean annual ambient temperature [uC] 6,366 19.8 2.8 14.7 25.0
Mean annual rainfall [mm] 6,366 1437 378 1013 2342
Mean annual LST-day [uC] 6,366 32.4 2.5 22.5 38.6
Mean annual LST-night [uC] 6,366 14.5 3.4 9.2 21.4
Mean annual EVI 6,366 0.288 0.058 0.151 0.472
Slope [u] 6,366 3.03 2.21 0.35 13.64
Age [years] 6,366 23.6 19.2 0 97.7
Male gender 6,317 47.0%
Household size [persons] 6,363 6.5 3.6 1 30
Population density [persons/km2] 6,366 1875 3179 10 13133
SES 6,363 20.52 1.17 22.82 4.08
Households with latrine 6,363 97.5%
Latrine coverage in surroundings [%] c) 6,366 95.8 8.2 29.6 100
N = number of observations; Std. Dev. = standard deviation; EPG = eggs per gram of feces; LST = land surface temperature; EVI = enhanced vegetation index; SES =
socio-economic score.
a)Mean for continuous and % for categorical variables.
b)According to Montresor, 1998 [35].
c)Percentage of households with a latrine within one kilometer around the participant’s household.
doi:10.1371/journal.pone.0092032.t001
Table 2. Univariable association of environmental and socio-
demographic factors with A. lumbricoides infection a).
Variables OR (95% CI) p-value
Elevation, per 100 meters 0.88 (0.84 to 0.91) ,0.001
Mean annual ambient temperature, per 1uC 1.23 (1.14 to 1.32) ,0.001
Mean annual rainfall, per 1000 mm 7.93 (5.85 to 10.75) ,0.001
Mean annual LST-day, per 1uC 0.73 (0.70 to 0.76) ,0.001
Mean annual LST-night, per 1uC 1.20 (1.13 to 1.27) ,0.001
Mean annual EVI, per 0.1 units 5.91 (4.10 to 8.50) ,0.001
Slope, per 1 u 0.72 (0.63 to 0.83) ,0.001
Age, per 10 years 0.95 (0.90 to 1.00) 0.060
Sex 1.09 (0.90 to 1.32) 0.389
Household size 1.01 (0.96 to 1.07) 0.603
Population density, per 1000/km2 0.98 (0.94 to 1.03) 0.379
SES, per 1 unit 0.59 (0.48 to 0.73) ,0.001
Latrine in household (yes/no) 0.24 (0.13 to 0.46) ,0.001
Latrine coverage, per 10%b) 0.57 (0.50 to 0.65) ,0.001
OR = odds ratio; 95% CI = confidence interval; LST = land surface
temperature; EVI = enhanced vegetation index; SES = socio-economic score.
a)Results of logistic regression models adjusted for household clustering using
Huber/White variance estimates.
b)Percentage of households with a latrine within one kilometer around the
participant’s household.
doi:10.1371/journal.pone.0092032.t002
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infection with environmental variables, it is important to consider
such factors when planning interventions or further studies on a
smaller scale, e.g. the community level.
In the literature, non-linear associations between environmental
variables and STH infection have rarely been analyzed in a
multivariable context. Brooker et al. [21] predict the prevalence of
various STH infections with generalized additive models in a
spatial analysis in Uganda and found that the predicted prevalence
of A. lumbricoides infection showed non-linear relationships with
LST and rainfall. A case study in Cameroon observed non-linear
Table 3. Multivariable association of environmental and socio-demographic factors with A. lumbricoides infection using logistic
regression with fractional polynomials (n = 6,363).
Full Model a) Final Model after Backward Elimination a)
Covariables b/OR (95% CI) p b/OR (95% CI) p
Mean annual rainfall, per 1000 mm b1 = 1.92 (0.33 to 3.51) 0.018 b1 = 1.58 (0.14 to 3.02) 0.032
(FP2 polynomial transformationb)) b2 = 22.08 (23.63 to 20.52) 0.009 b2 = 21.78 (23.19 to 20.37) 0.013
Mean annual LST-day, per 1 uC OR = 0.82 (0.73 to 0.93) 0.002 OR = 0.87 (0.78 to 0.97) 0.012
Mean annual LST-night, per 1 uC OR = 1.24 (0.81 to 1.90) 0.315 . .
Mean annual EVI, per 0.1 units OR = 0.79 (0.42 to 1.50) 0.471 . .
Slope, per 1 u OR = 0.90 (0.72 to 1.12) 0.324 . .
Age, per 10 years b1 = 2.57 (1.38 to 3.76) ,0.001 b1 = 2.56 (1.38 to 3.74) ,0.001
(FP2 polynomial transformationc)) b2 = 1.13 (0.57 to 1.70) ,0.001 b2 = 1.13 (0.56 to 1.69) ,0.001
SES, per 1 unit OR = 0.84 (0.70 to 1.00) 0.052 OR = 0.82 (0.68 to 0.97) 0.024
Latrine in household (yes/no) OR = 0.68 (0.32 to 1.43) 0.310 . .
Latrine coverage, per 10%d) OR = 0.82 (0.68 to 0.99) 0.043 OR = 0.80 (0.67 to 0.96) 0.018
AIC 2178 2178
BIC 2313 2287
b= beta coefficient; OR = odds ratio; 95% CI = confidence interval; LST = land surface temperature; EVI = enhanced vegetation index; SES = socio economic score,
AIC = Akaike information criterion; BIC = Bayesian information criterion.
a)Adjusted for household clustering using Huber/White/Sandwich variance estimates and for study sites.
b)Fractional polynomial transformation with two degrees and powers p = 3: b1x
p+b2xp*ln x.
c)Fractional polynomial transformation with two degrees and powers p = 20.5: b1x
p+b2xp*ln x.
d)Percentage of households with a latrine within one kilometer around the participant’s household.
doi:10.1371/journal.pone.0092032.t003
Figure 4. Non-linear partial prediction of the log odds of A. lumbricoides infection by annual rainfall. The partial predicted curve is
adjusted for LST-day, slope, SES, age, latrine coverage and the nine study sites. The maximum is at 1740 mm of mean annual rainfall. Grey shadings
indicate 95% confidence band.
doi:10.1371/journal.pone.0092032.g004
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associations between environmental variables (LST, rainfall and
vegetation) and A. lumbricoides infection in scatterplots of prevalence
and environmental data [22]. Our results suggest that the MFP
procedure can be effectively used as a multivariable parametric
approach to detect non-linear associations between environmental
data and A. lumbricoides infection. Especially when a turning point
within a non-linear prediction is detected, such as for rainfall in
our study, the MFP procedure can provide new insights into the
relationship between environmental conditions and STH infec-
tion. A more precise understanding of such relationships could
play an important role in the future prediction of high prevalence
areas to be targeted for interventions.
However, non-linear analysis also has its limitations. Trans-
formed variables are not directly interpretable, and thus hard to
generalize and compare between studies. Moreover, fractional
polynomials are very sensitive to outliers and over fitting, and
transformations can often be due to extreme observations. To
avoid this, it is very important to analyze transformed variables for
outliers and define lower p-values for the function selection
procedure when non-linear models are compared. Besides that, it
is recommended to analyze non-linearity only if prior knowledge
for non-linear relationships exists [54].
One problem when assessing STH infection by Kato-Katz (and
most other microscopy based techniques) is the low sensitivity of
the method. This is best compensated by the examination of more
than one stool specimen, which was logistically impossible in our
study. Instead, we examined two separate Kato-Katz slides from
the same sample. Although this should have increased sensitivity,
we have inevitably missed some of the lighter infections. However,
the Kato-Katz examination of a single stool specimen shows a
better sensitivity for the detection of A. lumbricoides infection than
for other STH infections [63,64].
Another limitation of our study is the lack of information
concerning soil types in our study sites, which could be important
in the context of rainfall and the survival of Ascaris eggs. Beaver
states that A. lumbricoides infections were more common in regions
with clayey soils [65,66]. Sandy soils are more permeable and are
unable to keep moisture. Moreover, in sandy soils eggs are more
likely to be washed down to deeper soil strata. Furthermore we are
unable to account for seasonal aspects of rainfall or the intensity of
rainfall within a short time. Gunawardena et al. [61] found out
that the number of wet-days per month were more significantly
associated with A. lumbricoides infection than the total amount of
rainfall. In this context they state that heavy rains facilitate the
scattering of eggs both vertically and horizontally, whereas steady
rainfall helps to maintain soil moisture.
Although our final model was able to account for most of the
spatial autocorrelation in the raw A. lumbricoides infection data
(Figure 5), the figure also shows some remaining positive spatial
autocorrelation in the deviance residuals of our final model. This
might have influenced the variance estimates of the model and in
turn might have led to spuriously low p-values for some of our
environmental variables. Therefore, these p-values should be
interpreted with caution.
To conclude, A. lumbricoides infection was associated with several
environmental, socio-demographic and sanitary factors in univari-
able analyses. Of these, mean annual rainfall, mean annual LST-
day, age, SES and latrine coverage remained significant in
multivariable analysis. MFP models can be used as an effective
statistical tool to get a better understanding of the – often non-
linear - relationship between environmental factors and A.
lumbricoides infection. Future studies should therefore consider
potential non-linear relationships between environmental factors
and STH in a multivariable context to yield more precise
predictions. However, if data are available, socio-demographic
and sanitary conditions should also be considered, especially when
planning interventions.
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Figure 5. Spatial autocorrelation of A. lumbricoides infection within sites. Moran’s I for spatial autocorrelation of A. lumbricoides infection in
the raw data and in the deviance residuals of the final multivariable model. Values above 0 indicate positive, values below 0 negative spatial
autocorrelation. The figure only considers autocorrelation between households within the same sites.
doi:10.1371/journal.pone.0092032.g005
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Abstract
Background: Hookworm disease is one of the most common infections and cause of a high disease burden in the tropics
and subtropics. Remotely sensed ecological data and model-based geostatistics have been used recently to identify areas in
need for hookworm control.
Methodology: Cross-sectional interview data and stool samples from 6,375 participants from nine different sites in Mbeya
region, south-western Tanzania, were collected as part of a cohort study. Hookworm infection was assessed by microscopy
of duplicate Kato-Katz thick smears from one stool sample from each participant. A geographic information system was
used to obtain remotely sensed environmental data such as land surface temperature (LST), vegetation cover, rainfall, and
elevation, and combine them with hookworm infection data and with socio-demographic and behavioral data. Uni- and
multivariable logistic regression was performed on sites separately and on the pooled dataset.
Principal Findings: Univariable analyses yielded significant associations for all ecological variables. Five ecological variables
stayed significant in the final multivariable model: population density (odds ratio (OR) = 0.68; 95% confidence interval
(CI) = 0.63–0.73), mean annual vegetation density (OR = 0.11; 95% CI = 0.06–0.18), mean annual LST during the day
(OR = 0.81; 95% CI = 0.75–0.88), mean annual LST during the night (OR = 1.54; 95% CI = 1.44–1.64), and latrine coverage in
household surroundings (OR = 1.02; 95% CI = 1.01–1.04). Interaction terms revealed substantial differences in associations of
hookworm infection with population density, mean annual enhanced vegetation index, and latrine coverage between the
two sites with the highest prevalence of infection.
Conclusion/Significance: This study supports previous findings that remotely sensed data such as vegetation indices, LST,
and elevation are strongly associated with hookworm prevalence. However, the results indicate that the influence of
environmental conditions can differ substantially within a relatively small geographic area. The use of large-scale
associations as a predictive tool on smaller scales is therefore problematic and should be handled with care.
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Introduction
Hookworm disease caused by Ancylostoma duodenale and Necator
americanus is among the most common infections in sub-Saharan
Africa (SSA) and affects up to 198 million people in this region [1–
3]. It causes iron deficiency anemia and protein malnutrition, and
has been shown to potentially cause growth retardation as well as
intellectual and cognitive impairments in children [2–4]. Although
hookworm disease causes only limited mortality, it ranks 49th in
terms of years lost due to disability globally and between 30 and 49
in SSA countries [5]. The educational, economic, and public-
health importance of hookworm infection necessitates compre-
hensive control strategies. To assure the effectiveness of control
programs, financial as well as human resources have to be targeted
to areas of greatest need. This warrants reliable estimates of
hookworm distribution and of population numbers requiring
intervention [6]. As hookworms do not replicate inside the human
body and larvae become infective only under favorable conditions
once excreted, environmental factors are crucial to hookworm
development and therefore to possible transmission to humans. In
recent years, the use of remotely sensed data has helped to
enhance the understanding of the epidemiology and spatial
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distribution of hookworm infection [7,8]. Model-based geostatis-
tics have been used to map helminth infection prevalence and to
predict prevalence at unsampled locations at national, provincial,
and regional levels [6,9–11], however, under the assumption that
the estimated associations are the same at all levels and not
modified by regional characteristics.
This study aimed to investigate the relationship between
hookworm infection and remotely sensed ecological factors, such
as elevation, vegetation density, land surface temperature (LST),
and rainfall, at an individual level in a cross-sectional survey of the
‘‘Evaluating and Monitoring the Impact of New Interventions’’
(EMINI - http://www.mmrp.org/projects/cohort-studies/emini.
html) cohort in Mbeya region in south-western Tanzania.
Furthermore, we analyzed the influence of potential confounders,
such as age, sex and socio-economic status (SES), on these
associations. The main focus was on the investigation of site-
specific effects and their comparison to effects in the pooled data
set to ascertain if associations between ecological factors and
hookworm infection found on a larger scale can equally be applied
at smaller scales. Additional articles pointing to Ascaris lumbricoides,
Trichuris trichiura, Schistosoma mansoni, and Schistosoma haematobium
infection are in preparation.
Methods
Ethics Statement
The study was approved by the ethics committee of the
Tanzanian National Institute for Medical Research and conducted
according to the principles expressed in the Declaration of
Helsinki. All participants provided written informed consent
before enrolment into the study; parents consented for their
minor children.
Study Area and Data Collection
Mbeya region is situated in south-western Tanzania. The region
is predominantly rural and most income-generating activities are
related to agriculture. Data for this study were collected from June
2008 to June 2009 as part of the third annual survey of the EMINI
cohort study. In preparation for EMINI, a complete census was
undertaken in nine distinct sites of Mbeya region. Over 42,000
households were identified and their locations were georeferenced
using hand-held global positioning system (GPS) receivers
(SporTrak handheld GPS, Magellan Navigation Inc., Santa Clara,
CA, United States of America). A geographically stratified random
sample of approximately 10% of these households was selected to
participate in the cohort study. During the first two EMINI
surveys only blood (for HIV and Plasmodium falciparum malaria
testing), urine (for S. haematobium diagnosis), and sputum samples
(from participants with persistent cough for tuberculosis diagnosis)
were collected. Interventions during this time included HIV and
tuberculosis counseling and referral, treatment of malaria (with
artemether/lumefantrine) and S. haematobium infections (with
praziquantel).
Stool collection only started at the third annual survey, and only
included inhabitants of a 50% random sample of the EMINI
households. Before this survey, intestinal nematodes were neither
diagnosed nor treated as part of this study, and to our knowledge
no other treatment programs had been conducted in the region.
Stool samples were collected in pre-labeled screw-top containers,
refrigerated at 4uC directly after collection using mobile refriger-
ators (WAECO CoolFreeze CF-50, WAECO, Emsdetten, Ger-
many) and kept cool until examined in the laboratory within two
days of collection. The hookworm infection status of participants
was established by Kato-Katz examination of two sub-samples
(41.7 mg each) from a single stool specimen which was thoroughly
mixed before slide preparation. Kato-Katz slides were examined
for hookworm eggs by experienced staff within one hour and for
other helminth eggs within two days after slide preparation.
Hookworm infection was defined as the presence of at least one
hookworm egg in any of the two slides. Helminth-infected
participants were offered treatment with albendazole (for hook-
worm and other intestinal nematode infections) and/or prazi-
quantel (for schistosome infections), according to their respective
diagnoses.
Interviews were conducted to collect socio-demographic infor-
mation. Age, sex, latrine type, and previous worm treatment were
included as potential confounders to be adjusted for during
analyses. In order to adjust for possible socio-economic confound-
ing, we constructed an SES score using polychoric principal
component analysis (PCA) [12,13] to characterize the socio-
economic situation of each household. This score combines
information on the availability of certain items in the household
(radio, TV, mobile telephone, refrigerator, hand cart, bicycle,
motor cycle, car, savings account); sources of energy and drinking
water; quality of materials used to build the main house; and
number of persons per room in the household.
Ecological Data
Information on elevation was retrieved using the NASA Shuttle
Radar Topography Mission (SRTM) global digital elevation model
(DEM) version 2.1 with a nominal resolution of 90 m [14]. Rainfall
and ambient temperature interpolated surfaces with 1 km spatial
resolution [15] were downloaded from the WorldClim – Global
Climate Data website (http://www.worldclim.org/).
LST during the day (LSTday) and during the night (LST-night),
and vegetation density (EVI = enhanced vegetation index) were
retrieved from data collected during NASA’s Moderate-Resolution
Imaging Spectroradiometer (MODIS) mission and were acquired
from the Land Processes Distributed Active Archive Center (LP
DAAC), located at the U.S. Geological Survey (USGS) Earth
Resources Observation and Science (EROS) Center [16]. LST
data (version MOD11A2) have 8 days temporal and ,1 km
spatial resolution. Vegetation data (version MOD13Q1) have 16
days temporal and 250 m spatial resolution [17].
Author Summary
Hookworm disease, caused by the nematodes Ancylosto-
ma duodenale and Necator americanus, is an important
cause of maternal and child morbidity in the developing
countries of the tropics and subtropics. In children,
hookworm disease has been shown to potentially result
in growth retardation as well as intellectual and cognitive
impairments. In a cross-sectional survey in Mbeya region,
Tanzania, we assessed the effects of possible risk factors
for hookworm infection with a focus on remotely sensed
ecological factors such as elevation, vegetation density,
land surface temperature, and rainfall. We found that
several ecological variables were significantly associated
with hookworm infection. However, differing effects for
these factors were estimated when performing the
analyses separately for the two sites with the highest
hookworm prevalence. Our study shows that effects are
scale-dependent and that prediction at smaller scales
using large-scale data and vice versa should be handled
with caution, because regional variation can substantially
influence the presence of hookworm infection.
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Both, LST and vegetation data were processed in the following
way to produce long-term averages: data surfaces for every 8-day
period (LST) and every 16-day period (EVI) for the years 2003 to
2008 were imported into Idrisi GIS software v.32 (Clark Labs,
Worcester, MA, United States of America). In Idrisi, long-term
averages of day- and night-LST and EVI were calculated utilizing
only those pixels that were ‘‘good data’’ according to the quality
assessment layers that are distributed together with the actual data.
Then LST was converted to uC and EVI was converted back to its
native range between 21 and +1. Population and household
densities, ambient temperature, rainfall, LST, EVI, and elevation
variables were averaged for a buffer area within a 1000 m radius
around each household in order to characterize the ecological
situation around the household.
Statistical Analyses
Stata statistics software (version 11, StataCorp, College Station,
TX, United States of America) was used for all statistical analyses.
Some of the variables were transformed in order to yield
interpretable results. Reported odds ratios (OR) for continuous
variables correspond to an increase of 10 years for age, 100 m for
elevation, 10 mm for mean annual rainfall, 1,000 people/km2 for
population density, and 0.1 units for EVI.
Univariable logistic regression was performed with each
variable, adjusting for within-household clustering using Huber/
White/Sandwich variance estimates [18–20]. Variables that either
had a Wald’s p-value,0.2 or were considered to be causally linked
to hookworm infection were included in the following selection
process.
Figure 1. Location and altitude of the nine EMINI study sites (Mbeya region, Tanzania, 2008/2009). Elevation of the participating
households ranges from 480 to 2,300 m above sea-level, resulting in large ranges also for the other environmental parameters that were examined.
doi:10.1371/journal.pntd.0002408.g001
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This study mainly focused on ecological data which by their
nature are prone to be correlated. To avoid problems in effect
estimation such as variance inflation, all variables of interest were
tested for multicollinearity by calculating the variance inflation
factor (VIF) [18]. A VIF above 10 was considered as an indicator
for serious multicollinearity [19,20] and the respective variables
were removed from further analyses.
Subsequently, two separate logistic models were developed: the
first contained solely variables collected on an individual level, i.e.,
age, sex, and previous worm treatment variables; the second
model grouped together variables that were collected at the
household level. These included environmental variables as well as
the SES score, latrine coverage, and latrine type. Model selection
was based on a 5% significance level, i.e., removal of variables that
had p.0.05, and on the contribution to the goodness of model fit
according to the Bayesian information criterion (BIC). When the
removal of a variable whose effect estimate did not reach statistical
significance resulted in a major increase of the BIC, the variable
was not excluded from the model. Remaining variables from the
separate models were merged into a final model where variables
with p.0.05 were removed by hand. The resulting model was
then run on a reduced dataset restricted to the two sites with the
highest hookworm prevalence. To detect differences in effects on a
site level, a moderated multiple regression was performed by
introducing a site dummy variable as the moderator and
interactions of this moderator with each environmental variables.
Furthermore, the final model was applied to each of these two sites
separately and compared to the results of the moderated model.
Results
Descriptive Statistics
Of the 6,375 subjects (from 1,617 households) participating in this
study, 17% (1,080 participants) were tested positive for hookworm
infection. Most infected participants had low intensity infections
(1,061), whereas medium (14) and high intensity infections (5) were
rare [21]. The diverse environmental conditions in the study area
are indicated by large ranges for elevation (Figure 1) and other
environmental variables (Table 1). The study population included
slightly more female than male participants. The median age of 16.6
years indicates that the majority of study subjects were children and
adolescents. The prevalence of hookworm infection rose sharply
from birth to adolescence and reached a plateau in early adulthood,
after which it stayed relatively constant (Figure 2). Most households
had simple or improved ventilated pit latrines, whereas water flush
toilets were uncommon.
Site-specific hookworm prevalences ranged from less than 2% in
Iyunga to more than 50% in Itaka (Figure 3). With 931
participants, Kyela was the biggest site and Iyunga with 444
participants the smallest. Due to exceptionally high hookworm
prevalences, Itaka (53.1%) and Kyela (40.8%) were selected for the
site-specific analyses.
Figure 2. Lowess smoothed plot of hookworm prevalence over age in EMINI participants (Mbeya region, Tanzania 2008/2009).
Prevalence rises sharply from birth to adolescence and reaches a plateau in early adulthood after which it stays relatively stable.
doi:10.1371/journal.pntd.0002408.g002
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Univariable Logistic Regression and Multicollinearity
Analysis
In univariable logistic regression analyses of the complete
dataset which included all nine sites (Table 2) the estimates for all
considered variables had p-values below 0.2, which was chosen as
the cut-off for inclusion into further analyses. Population density,
elevation and slope were inversely associated with hookworm
infection, whereas the other ecological variables showed positive
associations. SES, previous anthelmintic treatment, and latrine
coverage were again inversely related to hookworm infection.
Multicollinearity analysis revealed a VIF above 10 for the variables
LST-night (VIF = 15.77), elevation (VIF = 75.18), and mean
ambient temperature (VIF = 46.84). Elevation and mean annual
ambient temperature were therefore excluded from subsequent
analyses, and LST-night included since soil temperature seems
more directly related to the development of hookworm larvae than
ambient temperature and elevation. Removal of these two
variables reduced the VIF for LST-night to 2.5.
Model Selection
In the multivariable regression model including only household-
level data (not shown), the p-values for mean annual rainfall, slope,
and latrine type exceeded the 5% threshold and were excluded
from the model. When including individual-level data into the
model, only sex yielded a p-value above 0.05 and was excluded,
whereas age and previous anthelmintic treatment remained
significantly associated with hookworm infection. Compared to
univariable regression results, the direction of the effect in the
multivariable models changed for several variables: the ORs for
EVI and LST-day switched from above to below unity; the
negative univariable association of latrine coverage changed to
positive in multivariable analysis.
In the multivariable model combining household-level and
individual-level variables (Table 3, ‘‘All sites’’) all included
variables yielded significant p-values. No qualitative changes in
the ORs compared to the separate models for household-level and
individual-level variables (data not shown) were observed. Equally,
Table 1. Characteristics of the study participants and environmental conditions at their places of residence.
Variable N
Median or
proportion (%)* IQR Min Max
Hookworm infection binary 6,375 16.9%
Hookworm infection intensity
Median EPG (infected only) 1,080 132 228 12 6,187
Grouped{:
No infection (0 EPG) 5,295 83.1%
Low intensity (1–1,999 EPG) 1,061 16.6%
Moderate intensity (2,000–3,999 EPG) 14 0.2%
Heavy intensity ($4,000 EPG) 5 0.1%
Ecological variables
Elevation [m] 6,375 1,574 510 479 2,313
Mean annual EVI 6,375 0.287 0.071 0.151 0.472
Mean annual LST-day [uC] 6,375 33.2 3.4 22.5 38.6
Mean annual LST-night [uC] 6,375 14.0 4.2 9.2 21.4
Mean annual ambient temperature [uC] 6,375 19.5 3.7 14.7 25.0
Mean annual rainfall [mm] 6,375 1,254 444 1,013 2,342
Slope [u] 6,375 2.34 2.76 0.35 13.64
Population density [persons/km2] 6,375 415 1,745 10 13,133
Adjustment variables
Age [years] 6,375 16.6 26.5 0 97.7
Sex [0 = female/1 = male] 6,326 47.0%
SES score 6,372 20.092 1.202 21.892 3.997
Anthelmintic treatment in past year [0 = n/1 = y] 5,829 7.1%
Latrine coverage in surroundings [%] 6,375 99.3 5.7 36.15 100
Latrine type in household 6,372
None 160 2.5%
Pit latrine simple 5,860 92.0%
Ventilated improved pit latrine 230 3.6%
Water flush toilet 122 1.9%
EPG = eggs per gram of feces; EVI = enhanced vegetation index; IQR = inter-quartile range; LST = land surface temperature; N = number of observations; SES = socio-
economic status.
*Median for continuous and proportion in percent for binary variables; IQR, minimum and maximum values only shown for continuous variables.
{According to Montresor, 1998 [21].
doi:10.1371/journal.pntd.0002408.t001
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the magnitude of effects in the combined model is comparable to
those of the separate models, indicating that the effects of both sets
of variables are independent of each other.
Running a model with the same variables on data from Kyela
(Table 3, ‘‘Kyela site’’) only yielded statistically significant ORs for
LST-day (OR = 1.38; p = 0.005), SES score (OR = 0.68;
p = 0.015), and age (OR = 1.12; p = 0.002). While the magnitude
of ORs for SES score and age differed only marginally from the
all-sites model, a qualitative difference was observed for LST-day
where the association with hookworm infection switched from
negative in the all sites model to positive in the Kyela site model.
Site-specific analysis for Itaka (Table 3, ‘‘Itaka site’’) resulted in
significant ORs for population density (OR = 0.08; p = 0.008),
LST-night (OR = 1.56; p = 0.010), latrine coverage (OR = 0.94;
p = 0.022), age (OR = 1.16; p = 0.001), and prior anthelmintic
treatment (OR = 0.42; p = 0.042), of which only latrine coverage
differed qualitatively from the all-sites model.
To test the presence of site-specific effects, we introduced site-
interaction terms for environmental variables. In the moderated
model, which was estimated on a data set restricted to observations
from Itaka and Kyela sites, only the interaction term for
population density yielded a significant p-value (p = 0.008). The
p-values for the interaction terms for EVI and latrine coverage
slightly exceeded the 5% threshold (p = 0.052 and 0.086,
respectively) and were therefore also considered as relevant. The
main effects of the moderated model represent the effects in Itaka,
i.e., site = 0, whereas the effects for Kyela (site = 1) can be
calculated by multiplying the main effect with the respective effect
of the interaction term.
Keeping all variables at their average value, infection odds did
not vary significantly between Kyela and Itaka (OR = 3.26;
p = 0.592). However, the effect of population density, EVI and
latrine coverage on infection odds was strongly dependent on the
site. The data in Table 4 summarize the conditions in Kyela and
Itaka, and the site-specific predictions of hookworm infection
probability in Figure 4 demonstrate that a qualitative difference
between the two sites was present for the association of population
density and EVI with hookworm infection, whereas the association
of latrine coverage differed only quantitatively between Itaka and
Kyela sites.
Discussion
Our results demonstrate that hookworm infection in the study
population is strongly associated with ecological factors. The
univariable analyses further show that infection is favored when
these factors entail more tropical conditions. This is in agreement
with the literature, where similar associations of infection with
elevation, temperature, rainfall, and vegetation (as an indicator of
soil humidity and shade) are reported [22–24]. It also concurs with
laboratory studies which show that hookworm larvae require
warm and moist conditions in order to survive [25,26], a fact that
Figure 3. Hookworm prevalence in the EMINI study sites (Mbeya region, Tanzania, 2008/2009). Color shading of Voronoi polygons
drawn around each household indicates household prevalence, labels indicate site name and site prevalence.
doi:10.1371/journal.pntd.0002408.g003
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is also demonstrated by the absence of hookworm infection in
more temperate climates world-wide [27] and very low preva-
lences in the high-altitude sites within our study area.
However, our data also show that some of these associations
switch direction in multivariable analysis. The associations of EVI
and LSTday with hookworm infection change from positive in
univariable analysis to negative in the all-sites multivariable model,
whereas the association of latrine coverage changes from negative
to positive. These switches in direction are mainly due to the
inclusion of LST-night, which appears to be the best predictor of
hookworm infection among the environmental variables. When
excluding LST-night from the all-sites multivariable model shown
in Table 3, both EVI and LST-day maintain the significant
positive association with infection (data not shown) that they have
in univariable analysis (Table 2) and latrine coverage maintains its
negative association, although this is no longer significant. For
LST-day this makes sense in an area including high altitude sites
with rather low temperatures. In this setting, the minimum
temperature (for which LST-night is a better proxy than LST-day)
is the main limiting factor for the survival of hookworm larvae.
Therefore, in the complete model that includes both LST-night
and LST-day, LST-night explains most of the variation that is due
to unsuitably low minimum temperatures, whereas the role of
LST-day in this model is limited to explain the variation that is
due to unsuitably high maximum temperatures. In our study area,
LST-day ranges from 22 to 39uC. Thus our finding corresponds
with experimental study results suggesting that development of
hookworm larvae reaches its peak between 20 and 30uC and
ceases at around 40uC [25]. The switches in direction of the
associations of EVI and latrine coverage with hookworm infection
in multivariable analysis are harder to explain but are most likely
based on similar effects. Contrary to the above described
differences between univariable and multivariable models, popu-
lation density, SES, age, and previous deworming show similar
associations with hookworm infection in uni- and multivariable
analyses. The negative associations of SES and deworming with
infection are highly plausible and have also been reported in other
studies [1,28]. This also applies to the positive association of age
with infection [29,30].
Regarding the relationship of population density with infection,
the interpretation is more complicated. While higher population
densities increase the chance of hookworm larvae to find a host
and could thus favor transmission, in our study area, they are also
an indicator of more urban and thus more developed conditions,
which would reduce transmission. Thus, the negative association
with hookworm infection found in this study is also plausible, and
accordingly both negative and positive associations have been
reported in the literature [10,24].
Another interesting phenomenon are the differences in associ-
ation of several factors, when comparing the two site specific
multivariable models for Kyela and Itaka (columns ‘‘Kyela site’’
and ‘‘Itaka site’’ in Table 3) with each other and when comparing
each of them with the all-sites model (‘‘All sites’’ in Table 3). When
comparing Tables 1 and 4, it is obvious that ecological variables in
the all-sites model cover a much wider range of conditions than in
each site-specific model, which is a plausible reason for the
differences of the site-specific models versus the all-sites model.
Figure 4 demonstrates that the above reasoning may also apply
to the contradictory results when comparing the two site-specific
models with each other: population density and latrine coverage
show far more variation in Kyela than in Itaka, and the EVI
ranges for both sites do not show any overlap, with much lower
vegetation cover in Itaka. Thus, the different conditions in the two
sites are a likely explanation for the different associations of these
factors in the two sites. However, it is also possible that these
differences in association are a consequence of one or more
unobserved factors that our analysis is unable to account for.
Strengths of this study include the large number of participants
of all age groups and the detailed information that we have for
each individual, including the place of residence. This allows for a
detailed assessment of individual exposure to environmental
factors. In contrast, most other studies into the spatial epidemi-
ology of hookworm and other soil-transmitted helminth infections
are school-based [9–11,24,31–33]. Thus, they do not examine
hookworm infection in adults and rely on the geographical
position of the school to quantify participant’s exposure to
environmental factors [34].
However, our study also has some limitations. The use of only
one stool specimen for the determination of hookworm infection
status is known to lack sensitivity due to the intra-specimen and
day-to-day variation in hookworm egg output [35,36]. Although
we prepared two Kato-Katz thick smears from each stool
specimen to increase sensitivity, it is likely that we missed some
of the lighter infections. Unfortunately the Kato-Katz examination
of stool is unable to differentiate between N. americanus and A.
duodenale. However, previous studies indicate that N. americanus is
the predominant species in East Africa [32], and stool-PCR data
Table 2. Univariable associations of considered variables with
hookworm infection*.
Variable OR 95% CI p-value
Ecological variables
Elevation [per 100 m] 0.87 0.85–0.89 ,0.001
Mean annual EVI [per 0.1 units] 1.37 1.11–1.69 0.003
Mean annual LST-day [per 1uC] 1.19 1.14–1.24 ,0.001
Mean annual LST-night [per 1uC] 1.24 1.21–1.27 ,0.001
Mean annual ambient temperature
[per 1uC]
1.37 1.32–1.41 ,0.001
Mean annual rainfall [per 10 mm] 1.005 1.001–1.008 0.005
Slope [per 1u] 0.86 0.82–0.91 ,0.001
Population density [per 1,000
persons/km2]
0.76 0.71–0.82 ,0.001
Adjustment variables
Age [per 10 years] 1.08 1.05–1.12 ,0.001
Sex [0 = female/1 = male] 1.11 0.97–1.26 0.131
SES score [per 1 unit] 0.63 0.56–0.71 ,0.001
Anthelmintic treatment in past year
No 1.00
Yes 0.44 0.30–0.64 ,0.001
Missing 1.47 1.05–2.04 0.025
Latrine coverage [per 1%] 0.97 0.96–0.98 ,0.001
Latrine type in household
None 1
Pit latrine simple 0.57 0.36–0.92 0.020
Ventilated improved pit latrine 0.15 0.05–0.44 0.001
Water flush toilet 0.12 0.03–0.48 0.003
CI = confidence interval; EVI = enhanced vegetation index; LST = land surface
temperature; OR = odds ratio; SES = socio-economic status.
*From separate logistic regression models which only include one covariate,
adjusted for household clustering using robust variance estimates.
doi:10.1371/journal.pntd.0002408.t002
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from our own ongoing WHIS study, where we only find N.
americanus infections, seem to indicate that this is also the case for
our study area. Thus it is likely that most or all of the hookworm
infections in our study population were caused by N. americanus,
although we cannot completely exclude that A. duodenale is also
present.
Unfortunately, we are also lacking information about soil
composition in the study area which has been shown to strongly
influence hookworm infection [24,31]. Motility of the hookworm
larvae is crucial to avoid adverse environmental conditions and is
thus important for their survival. The porosity of sandy soils
facilitates larval movement deeper into the soil to escape
desiccation and upwards movement to avoid rising water levels
after heavy rainfall. Soils with high clay content are less porous
and thus inhibit larval motility [23,37–39].
Furthermore, apart from previous worm treatment which was
assessed by interview, our study does not account for behavioral
factors which also can strongly influence hookworm transmission
and prevalence. However, although soil composition and behavior
are both important determinants of hookworm infection which
would likely have improved our models if included, data on these
factors are rarely available in tropical developing countries where
hookworm is most prevalent. Thus, their potential to predict
infection in order to plan helminth control is limited, especially in
those regions where control is urgently needed.
This study and many others have shown that remotely sensed
data such as vegetation indices, LST, and elevation are strongly
associated with hookworm prevalence [2,8]. However, our study
also shows that these associations are scale-dependent and that
predictions using these data should be handled with care. On a
large scale, they can provide powerful tools to identify regions that
warrant control and intervention programs, their big advantage
being public availability and global coverage.
Nevertheless, when making predictions of hookworm infection
on a smaller scale, regional characteristics, such as seasonal
flooding, dry spells, etc., have to be taken into account. As our
study has shown, even within a relatively small geographic area the
effects of environmental conditions can differ to a large extent.
Thus, large-scale findings cannot necessarily be used for prediction
on smaller scales and vice versa.
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Table 3. Multivariable associations of selected ecological and adjustment variables with hookworm infection status*.
All sites{ Kyela site Itaka site Moderated model`
N = 6,372 N = 931 N = 846 N = 1,777
Variables OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Mean annual EVI [per 0.1 units] 0.11 0.06–0.18 ,0.001 2.10 0.84–5.26 0.114 0.21 0.02–1.74 0.147 0.21 0.03–1.73 0.147
Mean annual LST-day [per 1uC] 0.81 0.75–0.88 ,0.001 1.38 1.10–1.73 0.005 1.19 0.61–2.33 0.611 1.18 0.61–2.28 0.633
Mean annual LST-night [per 1uC] 1.54 1.44–1.64 ,0.001 0.57 0.15–2.16 0.408 1.56 1.11–2.19 0.010 1.54 1.10–2.16 0.012
Population density [per 1,000 persons/km2] 0.68 0.63–0.73 ,0.001 1.08 0.78–1.50 0.627 0.08 0.01–0.51 0.008 0.08 0.01–0.53 0.008
Age [per 10 years] 1.10 1.06–1.14 ,0.001 1.12 1.04–1.20 0.002 1.16 1.06–1.28 0.001 1.14 1.07–1.20 0.000
SES score [per 1 unit] 0.82 0.73–0.93 0.002 0.68 0.50–0.93 0.015 0.79 0.58–1.09 0.158 0.79 0.57–1.08 0.143
Anthelmintic treatment [0 = n/1 = y]1 0.45 0.30–0.69 ,0.001 0.73 0.36–1.46 0.376 0.42 0.18–0.97 0.042 0.52 0.29–0.94 0.030
Latrine coverage [per 1%] 1.02 1.01–1.04 0.002 0.99 0.96–1.02 0.484 0.94 0.89–0.99 0.022 0.94 0.89–0.99 0.022
Site [0 = Itaka/1 = Kyela] 3.26 0.04–243 0.592
EVI* Site 9.82 0.98–98.5 0.052
LST-day* Site 1.17 0.58–2.36 0.655
LST-night* Site 0.35 0.09–1.41 0.140
Population density* Site 12.79 1.97–83.2 0.008
SES score* Site 0.87 0.56–1.36 0.542
Latrine coverage* Site 1.05 0.99–1.12 0.086
CI = confidence interval; EVI = enhanced vegetation index; LST = land surface temperature; OR = odds ratio; SES = socio-economic status.
*Results of logistic regression adjusted for within-household clustering with robust variance estimates with each model containing only those variables for which data
are shown in the Table.
{Performed on pooled dataset combining all nine sites.
`Moderated model for Kyela and Itaka sites with site-interaction terms for environmental variables.
1Missing stratum not shown.
doi:10.1371/journal.pntd.0002408.t003
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Figure 4. Linear predictions of hookworm infection probabilities for population density, EVI, and latrine coverage. According to the
site-specific models for Kyela and Itaka, adjusted for all variables shown in the site-specific models in Table 3.
doi:10.1371/journal.pntd.0002408.g004
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Abstract
Objective: To evaluate the diagnostic performance of two rapid detection tests (RDTs) for HIV 1/2 in plasma and in whole
blood samples.
Methods: More than 15,000 study subjects above the age of two years participated in two rounds of a cohort study to
determine the prevalence of HIV. HIV testing was performed using the Determine HIV 1/2 test (Abbott) in the first (2006/
2007) and the HIV 1/2 STAT-PAK Dipstick Assay (Chembio) in the second round (2007/2008) of the survey. Positive results
were classified into faint and strong bands depending on the visual appearance of the test strip and confirmed by ELISA and
Western blot.
Results: The sensitivity and specificity of the Determine RDT were 100% (95% confidence interval = 86.8 to 100%) and
96.8% (95.9 to 97.6%) in whole blood and 100% (99.7 to 100%) and 97.9% (97.6 to 98.1%) in plasma respectively. Specificity
was highly dependent on the tested sample type: when using whole blood, 67.1% of positive results were false positive, as
opposed to 17.4% in plasma. Test strips with only faint positive bands were more often false positive than strips showing
strong bands and were more common in whole blood than in plasma. Evaluation of the STAT-PAK RDT in plasma during the
second year resulted in a sensitivity of 99.7% (99.1 to 99.9%) and a specificity of 99.3% (99.1 to 99.4%) with 6.9% of the
positive results being false.
Conclusions: Our study shows that the Determine HIV 1/2 strip test with its high sensitivity is an excellent tool to screen for
HIV infection, but that – at least in our setting – it can not be recommended as a confirmatory test in VCT campaigns where
whole blood is used.
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Introduction
The World Health Organisation (WHO) Global Programme on
AIDS first recommended the use of simple rapid detection tests
(RDTs) for HIV in 1992 [1]. Since then RDTs have been widely
used throughout Africa and the developing world for blood safety
screening, surveillance and in prenatal or voluntary counselling
and testing (VCT) centres [2]. Until recently the National
guidelines for VCT in Tanzania recommended using the SD
Bioline HIV 1/2 3.0 (Standard Diagnostics, Kyonggi-do, Korea)
as a screening test, with initial reactive samples re-tested using the
Determine HIV 1/2 test (Abbott Laboratories, Abbott Park, IL).
The Uni-GoldTM HIV-1/2 (Trinity Biotech, Bray Ireland) is used
as a final test if results are discrepant [3]. A fourth HIV rapid test,
HIV 1/2 STAT-PAK (Chembio Diagnostics Systems, Medford,
NY, USA) is used in neighbouring countries mainly as a
confirmatory test. All four RDTs are less expensive than ELISA
or Western Blot tests, require little or no equipment, can be stored
at room temperature and are easy to use and to read. Because they
allow for real-time, point-of-care HIV testing, individuals can
receive their test result during a single clinic visit which is likely to
increase the uptake of VCT [4,5], especially in Sub Saharan
Africa, where in some settings more than two weeks may be
needed for laboratory results to become available [6]. However, it
seems that the diagnosis of HIV by RDT is challenged by
confounding regional factors. Especially the Determine HIV 1/2
test received very diverse reports regarding its specificity which
ranged from 91.7% to above 99% [7,8,9,10,11,12].
Here we evaluate the diagnostic test performance for HIV
testing of the Determine HIV 1/2 and the HIV 1/2 STAT-PAK
(Chembio Diagnostics Systems, Medford, NY, USA) RDTs in a
general population cohort in South West Tanzania where, in
contrast to previous studies, children and adults of both genders
were included. The two tests are referred to below as the
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‘‘Determine’’ RDT and the ‘‘STAT-PAK’’ RDT, in order to
improve the readability of this article. The manufacturer’s
information applies to the time of the study; today both tests are
manufactured and sold by Alere, formerly named Inverness
Medical Professional Diagnostics, Princeton, NJ.
Methods
Ethical Considerations
The study was approved by the National Ethical Committee/
Medical Research Coordinating Committee of the National
Institute for Medical Research, Tanzania. All adult participants
provided written informed consent prior to enrolment into the
study. Parents gave the permission for their children, if they were
below 18 years of age. In addition children above the age of 12
years signed their own consent form together with their parents.
The study, including the consent forms for adults and children,
was additionally approved by the Mbeya Medical Research and
Ethics Committee.
Data Collection
Data for this study were collected between May 2006 and June
2008 in the Mbeya Region in Tanzania. The EMINI project
(Establishment of the infrastructure to Evaluate and Monitor the
Impact of New Interventions), a population based cohort study,
investigated the prevalence and incidence of HIV in 9 selected
communities with a total population of ,171,000 people. The
urban, semi-urban and rural study sites were carefully chosen in
order to reflect the geographic diversity of the Region, from
altitudes of about 475 meters above sea level near Lake Nyassa, to
over 2300 meters. Subsequently, 10% of all households in the
study sites were randomly selected, which resulted in a cohort of
approximately 18,000 individuals of all age groups and both sexes.
Study participants were visited annually for specimen and data
collection, including an HIV rapid test. Collected data further
included socio-economic characteristics of the study participants,
previous and current medical history, as well as individual
knowledge regarding different diseases.
During the first survey (2006/2007) the Determine RDT was
used to screen for HIV-1 infection. 2.7 ml of blood were collected
by venae puncture from participants above the age of 6 years.
However, venae puncture was not possible in all participants, and
especially problematic in younger children. In these cases, 300 ml
of blood were collected after finger prick, using microvettes
(Sarstedt, Nürnbrecht, Germany). In most cases this smaller
amount of blood did not supply sufficient plasma, so that HIV
testing in children below 6 years was mostly done using whole
blood. During the second and third annual survey round, where
the STAT-PAK RDT was used for HIV screening, we collected
2.7 ml of blood from all participants above 2 years of age, thus all
our STAT-PAK RDT results were obtained from plasma samples.
Results of the third survey are not reported here, they were only
used when needed to verify results from the two previous surveys.
For both RDTs our results only include data from participants
above the age of 2 years in order to exclude false test-positivity due
to the presence of maternal antibodies.
According to the manufacturer’s instructions for both assays,
any test result with visible lines in both test control areas,
regardless of intensity, were considered reactive [13,14]. How-
ever, we recorded variations of intensity of the strip test. Any
assay with an apparent positive band which was noticeably
lighter than the control band on the test card was regarded as
‘‘faint’’.
Additional testing to verify the initial RDT results was only done
if.
i. the RDT result was the first HIV positive result obtained from
this participant (true for positive results from survey 1 and
newly positive results from survey 2), or if
ii. the RDT result differed from the result of the previous or the
following survey.
In these cases the sample was retested using an ELISA HIV test
(Enzygnost Anti HIV 1/2 Plus, DADE-Behring, Marburg,
Germany) (Figures 1 and 2). Samples where the RDT and the
ELISA had discordant results were tested again, using a second
ELISA (rLAV, Biorad Laboratories, Redmond WA, USA). If both
ELISAs were in agreement, the ELISA result was used as the
reference-standard. Samples with discordant ELISA results were
retested by Western Blot (MPD HIV Blot 2.2, MP Biomedicals, and
Geneva, Switzerland) to determine the HIV status. If the Western
Blot result was indeterminate, the results for this sample were
excluded from statistical analysis. In addition, samples with
discordant results were repeat-tested with the respective RDT to
reconfirm the initial RDT results and to exclude a technical error.
Retesting of whole blood results was not possible due to lack of
stored plasma. Instead we regarded these results as true positive if the
result in the next survey was also positive and as false positive if the
participant had a negative test result in the subsequent survey, which
was confirmed using the above reference algorithm. Whole blood
results from participants not participating in at least one of the two
following surveys were excluded from our analysis because their true
HIV status could not be determined.
Negative RDTs from the first or second annual surveys which
were confirmed by another negative RDT in the following survey
and were not in conflict with earlier positive results, were regarded
as confirmed and not further tested. For all HIV incident cases,
which were found newly positive in surveys 2 or 3, the negative
result of the previous round was confirmed by the above described
testing reference algorithm.
All participants from the nine different study sites were visited at
their home. The collected specimens were brought to the central
laboratory in Mbeya, where the RDTs were performed in order to
ascertain comparable test quality across sites and field teams. In
addition to HIV other concomitant infections and influences were
examined. Plasmodium falciparum infection was assessed using Rapid
Malaria Tests (ICT Diagnostics, Cape Town, South Africa) and
Schistosoma haematobium infection was assessed by urine microscopy
for S. haematobium eggs.
Information on elevation was retrieved using data from the NASA
Shuttle Radar Topography Mission (SRTM) global digital elevation
model (DEM) version 2.1 with a nominal resolution of 90 meters.
Annual ambient temperature interpolated surfaces with 1 km spatial
resolution were downloaded from the WorldClim – Global Climate
Data website (http://www.worldclim.org/) [15,16]. These data and
the participant household’s positions which had been collected using
handheld GPS receivers were combined in a geographic information
system in order to calculate elevation and mean annual ambient
temperature at the household position.
Statistical Analysis
All statistical analyses were performed using Stata version 10
(Stata Corp., College Station, TX). Diagnostic test performance
(sensitivity, specificity, predictive values and diagnostic likelihood
ratios) was calculated only for participants where a definitive HIV
diagnosis (reference-standard) was available, using the ‘‘diagt’’
Stata component. Because predictive values are affected by the
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prevalence of disease in the tested population, we also report the
positive and negative diagnostic likelihood ratios (DLRs), which
are less affected by prevalence [17]. DLRs incorporate both the
sensitivity and specificity of a test and provide a direct estimate of
how much a test result will change the odds of having or not
having a disease. DLR calculation uses the following formulae:
positive DLR~sensitivity= 1{specificityð Þ
negative DLR~ 1{sensitivityð Þ=specificity:
Positive DLRs can thus range from unity to infinity, negative
DLRs from unity to 0 with better tests having DLRs further away
from unity.
Uni-variable and multi-variable binomial regression with a log
link adjusted for within household clustering was used to calculate
risk ratios for possible associations of false positive RDT results
with participant age, sex, P. falciparum and S. haematobium infection
status, and elevation and annual mean ambient temperature at the
participant’s residence.
Results
During the first survey we obtained Determine RDT results
from 8,747 female and 7,590 male participants between 2 and
97 years of age with a median age of 19.8 years (inter-quartile-
range [IQR] = 10.2 to 35.3) and 16.8 years (IQR = 9.2 to
34.1) respectively. Of these RDT results 1,889 were obtained
using whole blood samples (median age = 4.1 years, range 2 to
87, IQR = 2.9 to 5.3 years) and 14,448 using plasma (median
age = 21.1 years, range 2 to 97, IQR = 12.1 to 36.9). Samples
that could not be verified according to the above reference
algorithm were excluded. Therefore, the below analysis was
done with 1,696 and 12,916 Determine RDT results, obtained
from testing whole blood and plasma samples respectively
(Figure 1).
During the second survey the STAT-PAK RDT was used
instead of the Determine RDT and we collected 2.7 ml of blood
by venae puncture from all participants above the age of 2 years,
so that testing with whole blood was no longer necessary. We
obtained STAT-PAK RDT results from 8,574 female and 7,383
male participants with a median age of 19.1 (range = 2 to 98,
IQR = 9.9 to 35.6) and 16.1 (range = 2 to 96, IQR = 8.8 to 34.0)
Figure 1. HIV-Testing Algorithm and Exclusion criteria Survey 1. In Survey 1 we tested 1,889 whole blood specimen and 14,448 plasma
specimen with the Determine HIV1/2 RDT. The confirmation algorithm included two different ELISAs and one Western Blot. If both ELISAs were in
agreement their result was used as the reference standard result. Samples with discordant ELISA results were retested by Western Blot and the
Western Blot result used. Samples with indeterminate Western Blot results were excluded from analysis. Negative RDT results were not directly
confirmed, but regarded as true negative if the result of the following survey was also negative. Whole blood results where confirmation by ELISA
testing was impossible due to lack of plasma, were regarded as true positive if the result in the next survey was confirmed positive and as false
positive if a negative test result in the next survey was confirmed using the above reference algorithm. Results where the true HIV status could not be
verified according to the reference algorithm were excluded from this analysis.
doi:10.1371/journal.pone.0039529.g001
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years respectively. Again we excluded all samples where verifica-
tion of the result was not possible which resulted in performing the
analysis with 13,139 STAT-PAK RDT results, all derived from
plasma samples (Figure 2).
Determine RDT
The sensitivity and specificity of the Determine RDT were 100%
and 96.8% in whole blood and 100% and 97.9% in plasma
respectively. We did not encounter any false negative results with
this test (tables 1 and 2). However, the positive predictive value was
low in plasma (82.6%) and very low in whole blood (32.9%), meaning
that 67.1% of the positive results were incorrect in whole blood and
17.4% in plasma. This high proportion of false positive tests was
mainly due to the appearance of faint bands. Only 2% of whole blood
samples with faint bands were truly HIV-1 positive according to the
reference-standard. In plasma the proportion of true positive faint
bands was 7.6%. For those whole blood and plasma samples where
strong bands were recorded the concordance with the reference-
standard was 86.2% and 96.4% respectively.
STAT-PAK RDT
The sensitivity and specificity of the STAT-PAK RDT were
99.7% and 99.3% respectively; the positive and negative predictive
values were 93.1% and 99.97%. Of the 11,886 samples with a
negative STAT-PAK RDT result, four were positive according to
ELISA and Western Blot testing. All four tests had a positive result
in the previous and the following survey but were repeatedly
negative when retested using the STAT-PAK RDT. Of the 1,253
positive STAT-PAK RDT results 9.7% showed a faint band, and
again the proportion of true positives was lower in faint-banded
(45.5%) than in strong-banded tests (98.1%). Of the positive RDT
results, 1166 (93.1%) were confirmed with the reference algorithm.
Figure 2. HIV-Testing Algorithm and Exclusion criteria Survey 2. In Survey 2 we tested only plasma samples from 15,957 participants
using the STAT-PAK-HIV1/2 RDT. The confirmation algorithm was essentially the same as in Survey 1.It included two different ELISAs and one
Western Blot for RDT positive samples. Participants, who’s positive RDT result had been confirmed in Survey 1 already were not re-tested. 319
negative RDT results were directly confirmed by Behring ELISA, 11563 were regarded as true negative because the result of the following survey
was also negative.
doi:10.1371/journal.pone.0039529.g002
Table 1. Diagnostic Test performance of Determine and
STAT-PAK RDT numbers of positive and negative results.
HIV RDT: Determine STAT-PAK
tested sample: whole blood plasma plasma
N included 1696 12916 13139
Reference standard positives 26 1184 1170
Reference standard negatives 1670 11732 11969
True positives, all 26 1184 1166
True positives, faint bands 1 17 55
True positives, strong band 25 1167 1111
False positives, all 53 250 87
False positives, faint band 49 207 66
False positives, strong band 4 43 21
True negatives 1617 11482 11882
False negatives 0 0 4
doi:10.1371/journal.pone.0039529.t001
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Comparison of Determine and STAT-PAK Performance
The 250 false positive plasma samples from survey 1 were
retested with the Determine RDT in order to exclude technical
errors. The Determine RDT was repeatedly false positive in all
samples. To compare the performance of the two RDTs in false
positive samples, we later re-tested 25 (10%) of these false positive
plasma samples from survey 1 with the STAT-PAK RDT. None
of these samples was positive using the STAT-PAK RDT. The
250 participants with false positive plasma samples in Survey 1
were followed closely in the consecutive surveys. Thirty-six did not
join the surveillance in survey 2, of the remaining 214 participants
only 2 had a false positive test result again using the STAT-PAK
RDT. However, in other survey 2 participants the STAT PAK
RDT was actually false positive, demonstrating a different pattern
of false positivity for both tests. In order to investigate whether
false-positivity might be a transient problem or a feature associated
with the Determine RDT, samples of 19 participants who had a
false positive result in survey 1 were re-tested in survey 2 both with
the STAT PAK and the Determine RDT. It appeared that the
false positive result of the Determine RDT was not transient, but
persisted in 10 out of 19 cases (52.6%) whereas STAT-PAK RDTs
performed on the same samples were negative in all these cases.
Comparing the Determine RDT results which were obtained in
plasma, with those of the STAT-PAK RDT, we found a higher
positive predictive value and a higher specificity of the STAT-
PAK RDT. Four false negative results however lead to a lower
sensitivity of the latter test. Comparing the overall performance of
both tests we found a positive DLR of 46.9 for the Determine
RDT and of 137.1 for the STAT-PAK RDT, when using plasma
for both tests. This means that in our study population the initial
likelihood to be HIV-infected increases 46.9 times with a positive
Determine RDT and 137.1 times after receiving a positive result
with the STAT-PAK RDT when these tests are done with plasma
samples.
Possible Influence of Concomitant Infections
We hypothesized that false positive results for both RDTs might
be related to exposure to infectious agents other than HIV.
Therefore we examined the associations of co-infection with S.
haematobium (urinary schistosomiasis) and P. falciparum (malaria
tropica), participant age, sex, altitude and ambient temperature at
the site of the participant’s home with false positivity (coded as 0 =
RDT true negative; 1 = RDT false positive) as the binary
outcome, using only results obtained in plasma samples. The
binomial regression models (tables 3 and 4) showed significant
associations of false-positivity with age, both for the Determine
RDT (probability ratio (PR) per 10 years increase in age = 1.09;
95% confidence interval (95%CI) = 1.03 to 1.15) and for the
STAT-PAK RDT (PR = 1.10; 95%CI = 1.00 to 1.21), indicating
that the probability of a false positive result in both tests increases
by about 10% with a 10 years increase in age. Furthermore, false
positive results of the Determine RDT were associated with low
altitude (PR per 100 m increase = 0.78; 95%CI = 0.66 to 0.93).
Associations of Determine RDT false positivity with ambient
temperature and P. falciparum co-infection, which were significant
in uni-variable regression, both became non-significant in the
multi-variable analysis when altitude of residence was included
into the model.
As opposed to the Determine RDT, false positive STAT PAK
results were also associated with participant sex, with males having
a significantly lower proportion of false positive results than
females (PR = 0.63, 95%CI = 0.42 to 0.98).
Discussion
An essential requirement of all HIV testing is the accuracy of
the test results. HIV RDTs are usually designed to be used as
screening tests with a positive result being confirmed by more
specific methods. Therefore they are geared towards high
sensitivity. This is reflected in the results of both RDTs that we
evaluated: when read according to manufacturer’s instructions, the
Determine RDT was 100% sensitive and the sensitivity of the
STAT-PAK RDT was very close to this optimum. However, both
tests had problems regarding specificity, which – for the
Determine RDT – was worse when using whole blood instead
of plasma for testing.
According to a WHO publication from 2002, the sensitivity and
specificity of the Determine RDT in whole blood was 100% and
99.7% respectively [18]. Studies from the Ivory Coast [10], the
Central African Republic [11], Cameroon [19], Tanzania [20,21]
and the Netherlands [12] reported slightly lower sensitivities, but
similar specificity when using plasma [10,11,12] or whole blood
[19,20,21]. However, two recent publications from Uganda
demonstrated lower than expected specificities of 94% [7] and
91.7% [8] for the Determine RDT.
Table 2. Diagnostic Test performance of Determine and STAT-PAK RDT sensitivity, specificity, predictive values and likelihood
ratios.
Determine RDT in whole blood Determine RDT in blood plasma STAT-PAK RDT in blood plasma
Result 95%CI Result 95%CI Result 95%CI
HIV prevalence according to reference
standarda (%)
1.53 1.00 to 2.24 9.17 8.67 to 9.68 8.90 8.42 to 9.40
Sensitivity (%) 100.00 86.77 to 100.00 100.00 99.69 to 100.00 99.66 99.13 to 99.91
Specificity (%) 96.83 95.87 to 97.61 97.87 97.59 to 98.12 99.27 99.10 to 99.42
Positive predictive value (%) 32.91 22.75 to 44.40 82.57 80.50 to 84.50 93.06 91.51 to 94.40
Negative predictive value (%) 100.00 99.77 to 100.00 100.00 99.97 to 100.00 99.97 99.91 to 99.99
ROC area 0.984 0.980 to 0.988 0.989 0.988 to 0.991 0.995 0.993 to 0.996
Positive likelihood ratio 31.51 24.18 to 41.07 46.93 41.51 to 53.05 137.10 111.20 to 169.04
Negative likelihood ratiob 0.00 – to – 0.00 – to – ,0.01 0.00 to 0.01
aPrevalences differ from total population prevalence due to exclusion of participants.
bNo confidence interval can be calculated if sensitivity = 100%.
doi:10.1371/journal.pone.0039529.t002
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One possible reason for these diverse reports could be the
subjective interpretation of test results [22]. A recent study from
Uganda suggests that the difference in reported specificity of the
Determine RDT could be caused by different interpretation of
faint positive bands [7]. The authors found a specificity of 94.1%
for the Determine RDT in plasma, which improved to 99.6% after
exclusion of faint positive bands. Our data confirm these findings
in a much larger population and show that the problem is
aggravated when using whole blood instead of plasma. The
interpretation of faint positive bands as negative might thus be one
reason for the differences in sensitivity and specificity of the
Determine RDT that are reported in some of the previous studies.
Most studies that examine the diagnostic performance of HIV
RDTs use plasma or serum for testing. However, another study
from Uganda that used whole blood found a specificity of the
Determine RDT of only 96.2% which is very similar to our results
[23].
Because the STAT-PAK RDT results were exclusively derived
from plasma samples we can only compare them to the plasma
results of the Determine RDT. The STAT-PAK RDT was
considerably more specific than the Determine RDT. However,
still 6.9% of all positive test results were false and again the
proportion of true positives was lower in faint-banded (45.5%)
than in strong-banded tests (98.1%).
It is noteworthy that half of our participants with false positive
Determine RDT results were still false positive when re-tested with
the Determine RDT one year later. This shows that for these
participants the cause of the false positive result remains present
over at least 12 month. It has been suggested that the laboratory
diagnosis of HIV might be confounded by regional factors, for
example cross reaction with antibodies against other diseases such
as schistosomiasis [24]. We demonstrated that in our study area
with an altitude range from 475 to over 2300 meters, false positive
results of the Determine RDT, but not the STAT-PAK RDT, are
more common in the lower parts with higher ambient tempera-
tures that favour co-infections with various infective agents
[25,26]. In contrast to the published data regarding the Murex
HIV Ag/Ab Combination EIA [24] we did not find an association
with concurrent schistosomiasis infection for any of the rapid tests.
Results in the uni-variable analyses show an association of
Determine RDT false positivity with P. falciparum infection with
nearly twice as many false positive Determine results in
participants who were co-infected with P. falciparum. However, in
multi-variable analysis, which included altitude of residence as an
independent variable, this association became non-significant,
suggesting that the cause of the false positive result was not P.
falciparum infection. Similarly ambient temperature became non-
significant when adjusted for altitude. It might be that in low
altitude regions of our study area, where several other infections
are common [27], humoral immune responses against concom-
itant infections interfere with the Determine RDT result. These
potential cross-reactions could explain some of the differences
between previous reports regarding the diagnostic performance of
the Determine and other RDTs.
Interestingly we found no such association for temperature,
altitude or co-infection with P. falciparum for the Stat-Pak RDT
false positivity. The gender difference showing less false positive
STAT PAK results in men than in women was not reported
previously. This might be due to the fact that most studies focus on
either women (microbicide trials) or men (circumcision trials). But
we presently do not have an explanation for this finding.
Table 3. Association of various factors with false positive
Determine RDT results in plasma; uni- and multi-variable log-
link binomial regression results adjusted for clustering within
household (N = 11732).
uni-variable multi-variable*
Covariate
stratum PR 95%CI P PR 95%CI P
Age
per 10 years 1.10 (1.04 to 1.16) 0.001 1.09 (1.03 to 1.15) 0.002
Elevation
per 100 meters 0.88 (0.86 to 0.90) ,0.001 0.78 (0.66 to 0.93) 0.006
Ambient temperature
per oC 1.26 (1.20 to 1.32) ,0.001 0.81 (0.59 to 1.10) 0.180
P. falciparum infection
negative 1 - - 1 - -
positive 1.93 (1.07 to 3.47) 0.028 1.47 (0.81 to 2.68) 0.210
Gender
female 1 - -
male 1.00 (0.79 to 1.27) 0.992
S. haematobium infection
negative 1 - -
positive 0.99 (0.58 to 1.69) 0.980
PR = probability ratio for a false positive result; p = p-value; 95% CI = 95%
confidence interval.
*covariates were only included in multi-variable model if uni-variable p-value
,0.2.
doi:10.1371/journal.pone.0039529.t003
Table 4. Association of various factors with false positive
STAT-PAK RDT results in plasma; uni- and multi-variable log-
link binomial regression results adjusted for clustering within
household (N = 11969).
uni-variable multi-variable*
Covariate
stratum PR 95%CI P PR 95%CI p
Age
per 10 years 1.11 (1.01 to 1.21) 0.035 1.10 (1.00 to 1.21) 0.045
Gender
female 1 - - 1 - -
male 0.63 (0.41 to 0.96) 0.031 0.64 (0.42 to 0.98) 0.038
Elevation
per 100 meters 1.02 (0.97 to 1.06) 0.444
Ambient temperature
per oC 0.99 (0.92 to 1.07) 0.808
S. haematobium infection
negative 1 - -
positive 0.62 (0.15 to 2.52) 0.502
PR = probability ratio for a false positive result; p = p-value; 95% CI = 95%
confidence interval.
P. falciparum infection not included due to empty cells (no false positive results
in P. falciparum infected participants because of low P. falciparum prevalence in
survey 2).
*variables were only retained in multi-variable model if uni-variable p-value
,0.2.
doi:10.1371/journal.pone.0039529.t004
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Since age is a proxy for lifetime exposure to different diseases,
cross reactions with persisting antibodies to other diseases should
occur more frequently in older people, which is compatible with
the rise of false positivity with age which is apparent in our data.
The relatively high number of false positive results that we
found for both tests may not be a problem in settings where every
positive screening result is confirmed by more specific, reliable and
expensive methods. It is however problematic in resource
constrained VCT settings, where testing is done on whole blood
and where positive RDT screening results are usually confirmed
only by additional RDTs, which might be susceptible to the same
characteristics that caused the initial false positive result.
Since most of our false positive results showed faint bands, it is
an important question how to deal with these. Interpreting them as
negative is problematic as it would decrease sensitivity (e.g. from
100% to 98.6% for Determine RDT testing of plasma in our
study) and classify some HIV-infected patients as uninfected with
all the negative consequences this would have for transmission and
the management of their infection. Interpreting them as positive
would also be problematic as it would further decrease specificity
of the test and cause unnecessary anxiety in some patients. We
therefore believe that the best option in a screening setting is to
record the strength of the band when testing and to consider this
information once the standard testing reference algorithm for a
positive sample is finalised. Positive results with faint bands should
therefore be considered for additional testing in one of the Care
and Treatment Centres, which have access to more specific
methods, such as ELISA, Western Blot or PCR testing.
To avoid too many questionable results it would be best to chose
a testing strategy which leaves as few open questions as possible.
Thus it seems more sensible to use the Determine RDT with its
high sensitivity but low specificity during initial screening and not
as a confirmatory test as it was practiced until recently. For
confirmation, a more specific test such as the Stat-Pak RDT
should be used.
A strength of this study is its huge sample size and the fact that it
includes male and female participants of all age groups, apart from
infants. To our knowledge it is the first study to date to confirm the
findings from Uganda showing that faint bands pose a problem
when using the Determine RDT with plasma [7]. It is the only
study which shows that this problem also occurs when using the
STAT-PAK RDT and is aggravated when using whole blood. The
two main limitations of this study concern the lack of direct
confirmation (i.e. retesting of the same sample by other means) of
negative results in whole blood and in plasma and of positive
results obtained with whole blood. As mentioned above, RDT-
negative samples were only retested if the RDT-result of the
previous or the next survey was in disagreement ( = positive) and
regarded as reference-standard-negative if the result in the
following survey was also negative. This could have led us to
overestimate the sensitivity of both tests because we can not
exclude that both the Determine and the STAT-PAK RDT are
repeatedly false-negative in the same person. However, we believe
that this would occur only very rarely, if at all. This is supported by
the fact that none of the Determine-negative plasma samples that
needed to be retested due to a positive RDT result in the next
survey were regarded as positive according to our testing reference
algorithm.
Because retesting of positive Determine RDT results obtained
from whole blood samples was impossible due to lack of plasma,
these were regarded as true positive if the result of the following
survey was confirmed positive, as false positive if the result of the
following survey was confirmed negative and excluded from this
analysis if no HIV results from later surveys were available. This
could have increased our specificity estimates for the Determine
RDT in whole blood if initially HIV negative participants with a
false positive Determine RDT result got HIV infected before the
following survey. Equally it could have decreased our specificity
estimates if an initial positive Determine RDT result was due to
technical error. Although both is possible, it is again unlikely that
this has happened in more than a few cases which would only
marginally change the numbers presented here. Furthermore the
specificity of the Determine RDT in whole blood is so low that a
slight change in this diagnostic parameter would not make any
difference in practice.
To summarize the above: Due to small shortcomings in our
reference standard we can not completely exclude that the true
sensitivities for both tests are slightly lower than reported in this
article and that the true specificity of the Determine in whole
blood may slightly deviate from the result reported here. However,
both is unlikely, and with the large number of tests that were done,
the very few cases where the reference standard might be incorrect
would not substantially change the presented results.
Conclusion
The Determine RDT strip test can not be recommended as a
confirmatory test for prevalence studies and in VCT settings, due
to its low specificity and low positive predictive value. The
specificity of the test is even lower when using whole blood instead
of plasma. However, with its optimal sensitivity of 100%, the
Determine RDT is an excellent screening test, if another more
specific RDT is used for confirmation of positive test results. Since
our study did not apply the HIV-testing algorithm as stipulated in
the National guidelines for voluntary counselling and testing in
Tanzania, we are unable to judge the diagnostic performance of
this algorithm. Nevertheless, the practice of using the Determine
RDT as confirmatory assay in voluntary counselling and testing
settings, where whole blood is used, should be reconsidered. The
HIV 1/2 STAT-PAK RDT performed much better regarding
specificity and was only slightly less sensitive. However, the
problem of faint positive bands with their low positive predictive
value could also be demonstrated for the STAT-PAK RDT,
although to a far lesser extent.
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BACKGROUND
Acute human immunodeficiency virus type 1 (HIV-1) infection is a major contributor 
to transmission of HIV-1. An understanding of acute HIV-1 infection may be impor-
tant in the development of treatment strategies to eradicate HIV-1 or achieve a func-
tional cure.
METHODS
We performed twice-weekly qualitative plasma HIV-1 RNA nucleic acid testing in 2276 
volunteers who were at high risk for HIV-1 infection. For participants in whom acute 
HIV-1 infection was detected, clinical observations, quantitative measurements of 
plasma HIV-1 RNA levels (to assess viremia) and HIV antibodies, and results of im-
munophenotyping of lymphocytes were obtained twice weekly.
RESULTS
Fifty of 112 volunteers with acute HIV-1 infection had two or more blood samples col-
lected before HIV-1 antibodies were detected. The median peak viremia (6.7 log10 copies 
per milliliter) occurred 13 days after the first sample showed reactivity on nucleic acid 
testing. Reactivity on an enzyme immunoassay occurred at a median of 14 days. The 
nadir of viremia (4.3 log10 copies per milliliter) occurred at a median of 31 days and 
was nearly equivalent to the viral-load set point, the steady-state viremia that persists 
durably after resolution of acute viremia (median plasma HIV-1 RNA level, 4.4 log10 
copies per milliliter). The peak viremia and downslope were correlated with the viral-
load set point. Clinical manifestations of acute HIV-1 infection were most common 
just before and at the time of peak viremia. A median of one symptom of acute HIV-1 
infection was recorded at a median of two study visits, and a median of one sign of 
acute HIV-1 infection was recorded at a median of three visits.
CONCLUSIONS
The viral-load set point occurred at a median of 31 days after the first detection of 
plasma viremia and correlated with peak viremia. Few symptoms and signs were ob-
served during acute HIV-1 infection, and they were most common before peak viremia. 
(Funded by the Department of Defense and the National Institute of Allergy and Infec-
tious Diseases.)
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Events during acute human immuno-deficiency type 1 (HIV-1) infection may modulate the long-term course of HIV-1 
disease.1-4 Acute and early HIV-1 infection is a ma-
jor contributor to the epidemic spread of HIV-1,5-7 
and limiting this spread through “test and treat” 
strategies may require treatment of persons dur-
ing the acute phase of infection.8-10 The HIV-1 
reservoir, which confounds efforts to cure infec-
tion,11 may be more responsive to antiviral ther-
apy during acute HIV-1 infection than during 
chronic infection.12-14 Intervention during this 
stage of infection could dramatically reduce epi-
demic spread,15 reduce the size of the HIV-1 
reservoir, and potentially achieve long-term con-
trol of plasma viremia without the use of long-
term antiviral treatment.16
Studies of the clinical presentation and kinetics 
of viremia in persons with acute HIV-1 infection 
and of the role of these factors in predicting long-
term outcomes show conflicting results. Initial 
descriptions of acute HIV-1 infection were based 
on cohorts of persons who were identified on 
the basis of symptoms that were often character-
ized as those of seronegative mononucleosis.1,17-21 
The use of pooled nucleic acid testing has per-
mitted broader identification of acute HIV-1 infec-
tion, and classification systems for the staging 
of acute HIV-1 infection have been developed on 
the basis of the sequential reactivity of nucleic 
acid testing, the presence of the p24 antigen in 
plasma, and results of antibody testing.22,23
We performed a study involving volunteers 
who were at high risk for HIV-1 infection. Plasma 
nucleic acid testing was performed twice weekly, 
and a systematic analysis of the clinical, viro-
logic, and immunologic characteristics of the 
earliest stage of HIV-1 infection was conducted.
Me thods
Study Design and Population
RV 217 is a prospective natural-history study 
conducted at the Makerere University Walter Reed 
Project, Kampala, Uganda; the Walter Reed Proj-
ect, Kericho, Kenya; the Mbeya Medical Research 
Centre, Mbeya, Tanzania; and the Armed Forces 
Research Institute of Medical Sciences, Bangkok, 
Thailand. The protocol (available with the full 
text of this article at NEJM.org) was approved by 
the local ethics review boards and the Walter Reed 
Army Institute of Research. Written informed 
consent was obtained from all participants.
Participants were recruited from bars, clubs, 
and other locations associated with transactional 
sex. Men and women, 18 to 50 years of age, who 
were at high risk for HIV-1 infection were identi-
fied with the use of an audio computer-assisted 
self-interview. To be eligible for study entry, par-
ticipants had to meet at least one of the following 
four criteria within the previous 3 months: had 
exchanged goods for sex, had unprotected sex 
with a known HIV-positive partner, had unpro-
tected sex with three or more partners, and had 
symptoms of a sexually transmitted infection. In 
the first part of the study, which involved sur-
veillance of participants who were not infected, 
volunteers who had at least one of these high-
risk criteria underwent small-volume blood collec-
tions by fingerstick measurement twice weekly 
and large-volume blood collections of 26 to 67 ml 
every 6 months. Small-volume blood samples 
were tested for HIV-1 RNA within 24 to 48 hours 
after collection.
Volunteers in whom tests for HIV-1 RNA were 
reactive entered the second part of the surveillance 
phase, during which large-volume blood samples 
were obtained and a structured medical evalu-
ation was performed twice weekly for 4 weeks. 
Volunteers with confirmed HIV-1 infection were 
enrolled in the long-term follow-up phase. Full 
details of the study design and statistical analy-
sis plan are provided in the protocol.
Medical Management
Volunteers with HIV-1 infection were referred to 
a local care provider for treatment, including 
antiretroviral therapy. Counseling regarding HIV 
risk reduction was provided every 3 months and 
informally during small-volume blood collec-
tions. Condoms and lubricants were provided to 
participants at the study sites. The study team 
encouraged care providers to initiate treatment 
promptly if the volunteers had clinically signifi-
cant symptoms of acute retroviral syndrome, were 
pregnant, or met national guidelines for the 
initiation of antiretroviral therapy.
Nucleic Acid Testing
Approximately 600 μl of whole blood measured 
with a fingerstick device was collected into a BD 
Microtainer (Becton Dickinson) containing EDTA. 
Whole blood was centrifuged at 9000 ×g for 
3 minutes and plasma was separated into aliquots 
for same-day or next-day testing. Plasma was 
diluted (in a 1:5 ratio) in phosphate-buffered 
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saline (pH, 7.0 to 7.5) and tested for HIV-1 RNA 
with the use of the Aptima HIV-1 RNA Qualita-
tive Assay (Hologic).
HIV Serologic Testing, Measurement of Viral 
RNA, and Flow Cytometry
HIV serologic testing with the use of standard 
diagnostic methods was performed at screening, 
every 6 months, and during the second part of 
the surveillance phase (see the Supplementary 
Appendix, available at NEJM.org). Plasma HIV-1 
RNA levels were measured in batches with the use 
of the RealTime HIV-1 Assay (m2000 RealTime 
System, Abbott Molecular). EDTA-anticoagulated 
samples of whole blood were analyzed with the 
use of the BD Multitest on an FACSCalibur flow 
cytometer (Becton Dickinson). HIV-1 subtyping 
was performed as described previously (see the 
Supplementary Methods section in the Supple-
mentary Appendix).
Data Analysis
Day 0 was defined as the day on which the first 
blood sample was reactive for HIV-1 RNA. Viral 
RNA levels below the lower limit of quantitation 
were imputed by dividing the limit of quantita-
tion by two. The viral upslope was calculated 
from the date of the last negative sample to the 
peak viral load, excluding data from participants 
for whom the period between the last negative 
sample and the first sample that was positive for 
HIV-1 RNA was more than 10 days. The early 
nadir in the HIV-1 RNA viral load was defined 
as the lowest viral load after the peak viral load 
through day 42. Viral downslope was calculated 
from the peak viral load to the early nadir viral 
load. The viral-load set point was defined as the 
average viral load of all samples collected before 
antiretroviral therapy was administered between 
days 42 and 365 among participants in whom at 
least two viral-load values were measured during 
this period.
Results of physical examinations and reported 
clinical symptoms are described according to 
the study visit and per patient. Data on partici-
pants were censored at the initiation of anti-
retroviral therapy.
Statistical Analysis
We performed an exploratory analysis of viral-
load dynamics in acute HIV-1 infection without 
prespecified hypotheses. Correlations between 
viral load and immune factors were assessed with 
the use of Spearman’s rank-correlation coeffi-
cients (rho). Regional differences in viral loads 
in East Africa and Thailand were evaluated with 
the use of Wilcoxon rank-sum tests. We used 
Wilcoxon signed-rank test to assess changes 
from baseline. Log-transformed viral RNA dy-
namics during the first year were assessed with 
the use of regression splines with participant-
specific intercepts and slopes. Lymphocyte data 
were assessed with the use of repeated-measures 
models with adjustment for region and study 
visit. (Details of the statistical analysis are pro-
vided in the Supplementary Methods section in 
the Supplementary Appendix.)
Clinical signs (abnormal physical findings on 
examination) and symptoms were described pri-
marily with comparisons between geographic 
regions for individual findings with the use of 
Fisher’s exact test. All analyses were performed 
with the use of SAS software, version 9.3 (SAS 
Institute) and GraphPad Prism, version 6.0a 
(GraphPad Software).
R esult s
Study Participants
From June 2009 through June 2015, a total of 
3954 volunteers were screened (Fig. 1) and 2276 
of 3676 high-risk participants (61.9%) with 
negative results on an enzyme immunoassay for 
HIV antibodies entered the surveillance phase. 
Figure 1 (facing page). Enrollment and Outcomes.
Single false reactive results on qualitative nucleic acid 
testing were common, but acute HIV infection was 
confirmed in all participants who had two consecutive 
plasma samples that were reactive for HIV-1 RNA on 
qualitative nucleic acid testing. Among 112 participants 
with acute infection, peak viremia could be accurately 
defined in 54 participants who had at least two sam-
ples in which testing for HIV-1 RNA was reactive and 
enzyme immunoassay was nonreactive. Four of these 
participants were excluded from virologic and immu-
nologic analyses because they received early antiretro-
viral therapy (ART). Most infections were of the sub-
type HIV-1 CRF01_AE in Thailand and of the HIV-1 
subtype A and recombinant form of the A, C, and D 
strains in East Africa. Fiebig stages range from I through 
VI, with higher stages indicating a more mature stage 
of antibody response to HIV. CI denotes confidence 
 interval, EIA enzyme immunoassay, and NAT nucleic 
acid test.
The New England Journal of Medicine 
Downloaded from nejm.org on December 21, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 374;22 nejm.org June 2, 2016 2123
HIV-1 Infection in Adults in Africa and Thailand
3676 (93%) Qualified as high-risk
67% Reported >1 risk criterion
3954 Participants were screened for
high-risk behavior (HIV prevalence, 28.4%)
278 Did not meet high-risk
criteria
20 Were HIV-positive
258 Were HIV-negative
1219 Were excluded
872 Were HIV-positive and were not enrolled
347 Exited study before enrollment
149 Returned to surveillance phase
4 Started ART during early acute
HIV-1 infection
3 Had physician recommendation
1 Was pregnant
181 HIV-positive participants had
small-volume blood collections to
minimize risk of stigmatization
of excluded HIV-infected volunteers
2276 HIV-negative participants had
small-volume blood collections
261 Had initial reactive nucleic acid results
112 Had acute HIV confirmed
(mean age, 24 yr [range, 18–48])
28 Were in Kenya
21 Were in Tanzania
50 Were in Thailand
13 Were in Uganda
60 Were female
52 Were male 
54 Had 2 or more EIA-negative/HIV-1 
NAT–reactive samples and a sample
before HIV-1 infection
50 Were included in virologic and
 immunologic analysis
16 Were in Kenya
8 Were in Tanzania
17 Were in Thailand
9 Were in Uganda
45 Had 2 or more samples after 
day 42 (set point)
6 Had only a single EIA-negative/
HIV-1 NAT–reactive sample
10 Had no preinfection EIA-negative/
NAT-negative sample
29 Did not have a single EIA-negative/ 
HIV-1 NAT–reactive sample or were 
lost to follow-up
13 in Thailand had at least one
Fiebig I–III sample in treatment phase
50 Were included in the primary analysis
74 Had subtyping performed
Incidence rate (95% CI)
Overall, 3.4 (2.7–4.0)
Kenya, 2.6 (1.7–3.6)
Tanzania, 3.1 (1.8–4.4)
Thailand, 5.1 (3.7–6.5)
Uganda, 2.0 (0.9–3.1)
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 >174,950 Nucleic acid tests performed
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The majority of participants reported receiving 
goods for sex (64%), having symptoms of a sexu-
ally transmitted infection (61%), or both (Table 
S1 in the Supplementary Appendix). Most par-
ticipants with acute HIV-1 infection in the three 
African sites were heterosexual women, where-
as most participants with acute infection from 
Thailand were homosexual men or transgender 
women.
To accurately define peak viremia, we restrict-
ed the analysis to the 50 participants in whom 
at least two large-volume blood samples showed 
detectable HIV-1 RNA and a nonreactive enzyme 
immunoassay, who had had at least one study 
visit before detection of viral RNA, and who had 
quantitative HIV-1 RNA data. Analysis of the 
viral-load set point in 45 participants who had 
not received antiretroviral treatment required 
two blood samples obtained after day 42. In 
these participants, a median of 4 days (range, 2 to 
162 days) occurred between the last negative 
sample and the first sample that was reactive for 
HIV-1 RNA.
 HIV-1 Viral Dynamics
Figure 2 shows HIV-1 viremia during the first 
100 days of HIV-1 infection, including the median 
days to the peak viral load, enzyme immuno-
assay reactivity, and early nadir viral load. The 
median initial viral RNA level was 4.0 log10 copies 
per milliliter (range, 1.3 to 7.3), and a median 
peak of 6.7 log10 copies per milliliter (range, 4.5 to 
8.5) was reached 13 days (range, 6 to 18) after 
the first sample showed reactivity for RNA on 
nucleic acid testing. A third-generation enzyme 
immunoassay was reactive at a median of 14 days 
(range, 8 to 48). The median early nadir viral 
RNA level, 4.3 log10 copies per milliliter (range, 
1.7 to 6.3), occurred at a median of 31 days 
(range, 18 to 42). The median viral-load RNA set 
point was 4.4 log10 copies per milliliter (range, 
2.5 to 6.0) (Tables S3 and S4 in the Supplemen-
tary Appendix).
The spline models showed a significant inter-
action between viremia and geographic region 
and indicated differences in viral RNA dynamics 
among regions. The models also showed that 
the viral-load set point was established at the 
conclusion of acute viremia and remained stable 
subsequently (Fig. S1 in the Supplementary Ap-
pendix). Peak viremia was positively correlated 
Figure 3 (facing page). Viral-Load Associations.
Spearman’s correlations of peak (Panel A) and nadir 
(Panel B) viremia with the viral-load set point in partic-
ipants from Thailand (black dots) and East Africa (red 
dots) are shown. Five participants were excluded be-
cause of missing viral-load data or the initiation of anti-
retroviral therapy. The early viremic nadir and viral-load 
set point were highly correlated (Panel B) and did not 
differ significantly (Panel C). A significant positive 
Spearman’s correlation of viral-load downslope with 
the viral-load set point was observed in 44 participants 
with acute HIV-1 infection (Panel D). Viral-load upslope 
did not show significant Spearman’s correlation with 
the viral-load set point in the overall sample (Panel E). 
Seven of 45 participants were excluded from the upslope 
analysis because the interval between the last test that 
was negative for HIV-1 RNA and the first test that was 
reactive for HIV-1 RNA was longer than 10 days. Com-
parisons with the use of a Wilcoxon rank-sum test did 
not show regional differences between East Africa and 
Thailand with respect to peak viral load (Panel F); how-
ever, the viral-load set point was higher in participants 
in Thailand, with a narrower range of values (Panel G). 
Sex, race or ethnic group, and HIV-1 subtypes also dif-
fered between the two groups.
Figure 2. Viral Loads over the First 100 Days of HIV-1 Infection in 50 Participants.
Longitudinal viral-load values are plotted against the number of days since 
the first blood sample was reactive for HIV-1 RNA in 33 participants from 
East Africa and 17 from Thailand who had two or more blood samples that 
were nonreactive on enzyme immunoassay (EIA) and were reactive on nu-
cleic acid testing. Day 0 is the day of the first positive nucleic acid test. The 
box-and-whisker plots show the median, interquartile range, and range for 
each variable. The vertical box plots show peak and nadir viral loads, and 
the horizontal box plots show the number of days from the first reactive re-
sult on nucleic acid testing to the peak viral load, to reactivity on the EIA, 
and to the nadir viral load. Median values are shown for each variable.
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with the viral-load RNA set point in the total 
cohort (rho = 0.49, P<0.001) (Fig. 3A) and inde-
pendently in each geographic region (Fig. S2A in 
the Supplementary Appendix). There was a strong 
correlation between an early viral RNA nadir at 
the end of acute HIV-1 infection and the viral-
load set point (rho = 0.81, P<0.001) (Fig. 3B); this 
correlation remained significant within each re-
gion (Fig. S2B in the Supplementary Appendix). 
The values of the early nadir and set point did 
not differ significantly (Fig. 3C); this shows 
that the viral-load RNA set point was estab-
lished within the first 42 days after viremia 
was detectable.
The downslope of viral RNA was correlated 
with the viral-load RNA set point (rho = 0.33, 
P = 0.03) (Fig. 3D). The upslope of viral RNA was 
not correlated with the viral-load set point in the 
overall cohort (Fig. 3E); it was strongly correlat-
ed in Thailand only (rho = 0.66, P = 0.004) (Fig. 
Figure 4. Immune-Cell Counts over 510 Days of Follow-up in 50 Participants.
The absolute counts of CD4+ T cells (Panel A), CD8+ T cells (Panel B), natural killer cells (Panel C), and B cells (Panel D) are plotted 
against the mean visit day. The red dots indicate 33 participants from East Africa, and the black dots 17 participants from Thailand. The 
blue dotted line indicates the mean viral load. Wilcoxon signed-rank tests were performed on available paired data before the initiation 
of antiretroviral treatment. A significant decrease in absolute CD4+ counts and a significant increase in absolute CD8+ counts at day 17 
roughly coincided with the timing of the peak viral load in 44 participants with data that could be evaluated. By day 510, absolute CD4+ 
and CD8+ counts had not returned to initial levels in 26 participants. Absolute natural-killer-cell counts decreased at day 17 in 42 partici-
pants; however, these counts returned to original levels by day 510 in 24 participants. There was a significant decrease in absolute B-cell 
counts (P<0.001) at day 17 in 42 participants; however, these counts recovered by day 510 in 24 participants.
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S2D in the Supplementary Appendix). Although 
the peak viral RNA level was nearly the same in 
Thailand and East Africa (Fig. 3F), the viral-load 
set point differed significantly between the two 
regions (Fig. 3G).
 Immunophenotype
Immunophenotyping of lymphocytes showed no 
change or a minimal variation from normal val-
ues at the first study visit after the onset of 
plasma viremia (Fig. 4A through 4D, and Fig. S3 
in the Supplementary Appendix). Subsequently, 
levels of both B cells and CD4+ T cells decreased 
sharply at the time of peak viremia, while levels 
of CD8+ T cells increased significantly. Changes 
in levels of natural killer cells during acute in-
fection were variable. After peak viremia, levels 
of CD4+ T cells increased and levels of CD8+ T 
cells decreased, but these levels never returned 
to a normal range.
Levels of CD4+ T cells and B cells were in-
versely correlated with contemporaneous viral 
RNA levels, whereas the increase in the number 
of CD8+ T cells was correlated directly with 
contemporaneous viral RNA levels in a model 
adjusted for geographic region and study visit. 
After adjustment for other cell counts, region, 
and visit, a 100-cell increase in the CD4+ T-cell 
count was associated with an average decrease 
of 0.1 in log10 viral RNA across visits. The nadir 
CD4+ T-cell count was correlated with the CD4+ 
T-cell count at 12 months (rho = 0.59, P<0.001).
 Clinical Presentation
A structured history was obtained and a physical 
examination was performed at study entry, every 
6 months, and every 3 or 4 days throughout the 
period of acute infection. Symptoms and signs 
were identified at least once during observation 
in 94% of the participants with acute HIV-1 in-
fection (88% reported at least one symptom and 
78% reported at least one sign). However, during 
the period of acute infection, in 367 of 518 visits 
in which participants underwent a physical ex-
amination (71%), participants reported no symp-
toms, and 50% of these participants had neither 
symptoms nor signs.
Fever, headache, and malaise were the most 
common symptoms, and tachycardia, lymphade-
nopathy, and other head and neck findings were 
the most common signs (Table S5 in the Supple-
mentary Appendix). The greatest number of 
symptoms was reported at the study visit before 
the peak viral RNA level (median, 1; range, 0 to 
15) and was reported at a median of two visits 
(Fig. 5A). Observed signs on physical examina-
tion peaked at the visit before the peak viremia 
(median, 1; range, 0 to 3) and were recorded for 
a median duration of three visits (Fig. 5B). Heat 
maps enumerating each volunteer’s symptoms 
or signs at each visit show that most findings 
Figure 5. Medical Symptoms and Signs before and after Diagnosis of HIV 
Infection in 50 Participants.
The symptoms reported from the medical history (Panel A) and the number 
of abnormal physical findings (signs) on examination (Panel B) are shown 
at study visits before, after, and at the time of peak viremia. The dashed 
lines indicate individual participants.
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occurred before and at the time of peak viremia 
but waned quickly thereafter (Fig. S4A and S4B 
in the Supplementary Appendix). Although fever 
was the most common reported symptom, only 
six volunteers were found to be febrile on physi-
cal examination.
Lymphadenopathy was more common among 
participants in Thailand than among those in 
East Africa (P<0.001) (Table S5 in the Supplemen-
tary Appendix). The magnitude of the lymph-
node enlargement was minimal; the maximal 
lymph-node diameter was greater than 2 cm in 
only five volunteers.
Disease Progression
The CD4+ T-cell count at 12 months after the 
diagnosis of HIV-1 infection and the last avail-
able CD4+ T-cell count were used to evaluate the 
disease course. The start of antiretroviral ther-
apy was not used as an end point because it was 
most frequently initiated because of pregnancy.
After exclusion of five participants without a 
CD4+ T-cell count within 120 days before or 
after the 12-month time point, the CD4+ T-cell 
count was inversely correlated with the viral-load 
RNA set point (rho =  −0.65, P<0.001). Similarly, 
the last available CD4+ T-cell count was highly 
and inversely correlated with the viral-load RNA 
set point (rho = −0.50, P = 0.004).
A surrogate clinical end point was the num-
ber of days to two consecutive visits during 
which a CD4+ T-cell count of less than 350 cells 
per cubic millimeter was recorded. After exclusion 
of volunteers who were pregnant or who had 
started to receive antiretroviral therapy for reasons 
other than a CD4 T-cell count below 350 cells 
per cubic millimeter, 15 of 50 participants reached 
this surrogate clinical end point in a median of 
306 days (range, 7 to 1083).
There was no difference in follow-up time 
between participants who reached the end point 
and those who did not (P = 0.68). The peak viral 
RNA level did not differ significantly between 
participants who reached the end point and 
those who did not; however, the viral-load RNA 
set point was significantly higher among those 
who reached the end point than among those 
who did not (median, 4.83 log10 copies per milli-
liter vs. 4.02 log10 copies per milliliter, P = 0.002), 
absolute CD4+ T-cell counts at 1 year were lower 
(median, 356 cells per cubic millimeter vs. 639.5 
cells per cubic millimeter, P = 0.002), and CD8+ 
T-cell peaks were higher (median, 1661 cells per 
cubic millimeter vs. 1202 cells per cubic milli-
meter, P = 0.06).
Discussion
In contrast to previous studies of acute HIV-1 
infection in which volunteers were evaluated less 
often, we evaluated high-risk volunteers twice 
weekly in order to systematically describe both 
the clinical disease and host–virus interactions, 
with precise determination of the onset and dy-
namics of acute plasma viremia. The upslope, 
peak, and downslope of viremia in acute infec-
tion were defined with precision and at a high 
frequency among observed cases of HIV-1 infec-
tion. These variables were significantly associ-
ated with the viral-load set point; this association 
underscored the crucial role of the very earliest 
interactions between the host and virus in deter-
mining the long-term course of the disease. Our 
study showed that the viral-load RNA set point 
was established within 42 days after detectable 
viremia, was steady over the period of observa-
tion, and was associated with the early clinical 
outcome as measured by the CD4+ T-cell count 
12 months after infection and a CD4+ T-cell 
count below 350 cells per cubic millimeter.
The peak viremia reported here was of a 
higher magnitude (median, log10 6.7; range, log10 
4.5 to 8.5) than that which is commonly re-
ported,24-28 probably because of the frequency of 
assessment. Although the peak viremia was near-
ly equivalent in East Africa and Thailand, there 
was a significant difference of 0.8 log10 copies 
per milliliter in the viral-load RNA set point. 
Differences in viral-load RNA set points accord-
ing to sex have been reported; set points in men 
are generally approximately three times as high 
as set points in women who have infections of 
the same viral subtype.29 Because of multiple 
confounding variables, including host genetic 
factors, viral subtype, endemic disease, and risk 
characteristics, a mechanistic explanation for this 
regional variation in the viral set point remains 
undefined.
This study showed the alterations in cell phe-
notype before and during peak viremia. At the 
onset of plasma viremia, immunophenotypes were 
largely normal, but subsequently, CD4+ T-cell 
counts decreased and CD8+ T-cell counts in-
creased around the time of the peak viral RNA 
level, were highly correlated with the viral RNA 
level during acute HIV-1 infection, and did not 
The New England Journal of Medicine 
Downloaded from nejm.org on December 21, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 374;22 nejm.org June 2, 2016 2129
HIV-1 Infection in Adults in Africa and Thailand
fully recover as the viral RNA level decreased to 
the set point. Ndhlovu et al. recently described 
an association between the timing and magni-
tude of CD8+ T-cell activation and the viral-load 
set point in 11 cases of acute infection.30 The 
observed, dramatic loss of B cells has been re-
ported in simian immunodeficiency virus,31-33 
but data on the role of this loss in acute HIV-1 
infection in humans are lacking.34
In many studies of HIV-1, patients had symp-
toms before an evaluation for the diagnosis of 
acute infection was initiated.35,36 As in other 
studies of acute HIV-1 infection, most persons 
in our study (94%) had clinical manifestations 
sometime during acute infection. However, non-
specific symptoms and signs were most common, 
severe manifestations were not observed, volun-
teers reported symptoms in only 29% of visits, 
and on any given visit day the likelihood of ob-
serving a symptom or sign was only 50%. The 
frequency of clinical manifestations of disease 
clustered before the peak viremia and at the time 
of peak viremia and resolved quickly, but the 
median number of symptoms and signs was 
only 1.
Since the study scheduled visits throughout 
the period of acute HIV-1 infection, the propor-
tion of participants who would have sought 
medical care is unknown. Sullivan et al. reported 
symptoms and signs of acute infection among 
discordant couples who were prospectively fol-
lowed every 3 months and found that a majority 
of patients with incident HIV-1 infection could 
not recall an illness and did not pursue medical 
care.21 Thus, systematic identification of acute 
HIV-1 infection may be challenging and will 
probably require nucleic acid testing with a rapid 
turnaround and frequent evaluation of high-risk 
groups rather than clinical presentation in a 
health care setting.
The contribution of acute HIV-1 infection to 
HIV-1 transmission may be substantial.5-7,37,38 Pre-
sumably, a high viral load plays a part, but the 
biologic characteristics of transmitted founder 
viruses, the homogeneity of viral sequence dur-
ing acute HIV-1 infection, and the incomplete or 
immature host immune response may create a 
transmission diathesis. HIV-1 may evolve to main-
tain efficient replication in the host and lose 
characteristics that are favorable for transmis-
sion. Recent data show that transmitting viruses 
are qualitatively distinct from those emerging 
under host immune pressure.39 Viral RNA is a 
dominant factor in the risk of transmission in 
various patient groups (e.g., among infants who 
may become infected through perinatal trans-
mission and among heterosexuals), and if a high 
level of viral RNA in acute HIV-1 infection is the 
primary variable contributing to increased infec-
tiousness in early and acute HIV-1 infection, the 
duration of this risk appears to be brief because 
the viral-load RNA set point is achieved within a 
few weeks after peak viremia. This observation 
may have important consequences and may 
limit the effect of test-and-treat strategies on 
overall rates of transmission.
The data reported here emphasize the impor-
tance of acute infection to our understanding of 
the pathogenesis of HIV-1. They also provide 
evidence that during the acute phase, identifica-
tion of cases of HIV-1 on the basis of clinical 
criteria may prove to be difficult.
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Additional Study Details: RV 217 “HIV-1 Prevalence, Incidence, Cohort Retention, 
and Host Genetics and Viral Diversity in Cohorts in East Africa and Thailand” 
 
Design Details: 
Phase Ia: Non-randomized, cohort, prospective, 24-month observational study to be 
conducted in two parts. The study conducted a screening visit and initial follow-up in all 
enrolled volunteers. This included both HIV negative and HIV prevalent cases.  
Prevalence was estimated to be high in these populations and as many as 1000-1500 
volunteers will be enrolled and evaluated in the first two visits with an enrollment target 
of 500 HIV negative, high-risk volunteers per site. Subsequently, only HIV negative 
volunteers were followed for a period of 24 months, except for a small number of HIV 
positive individuals for masking to minimize risk of stigmatization. After the initial two 
visits, volunteers were seen at the research clinic approximately every 3 months. In 
addition, at the research clinic or other locations that were convenient to the volunteers, 
small blood volume samples were collected using microvettes twice weekly.  These 
samples were analyzed and results returned to the site within 48 hours to permit new HIV 
positive participants to be identified while they remain antibody negative, HIV nucleic 
acid test positive. Any participant with a reactive nucleic acid test was entered into phase 
Ib. 
Phase Ib: Participants had repeat medical encounters twice weekly for a total of 9 visits to 
include HIV-1 nucleic acid testing, HIV antibody testing and larger blood collections to 
characterize host immune responses and a structured history and physical. The purpose of 
this intensive analysis was to establish HIV diagnosis and characterize the viral-host 
interaction during acute HIV infection.  All newly infected participants were referred to 
phase II of the study. 
Phase II: study of HIV incident cases arising within phase I. HIV incident volunteers 
were asked to consent to participate in phase II to intensively characterize viral dynamics, 
host immune response and potential impact of host genetics over a period of at least 50 
months from the time of entering the AHI phase..  
Participants 
The study population will include men and women, aged 18-50 years old, who may be 
members of the following high risk groups: female and male sex workers (SWs), 
barworkers (BWs), sexually transmitted infection clinic attendees (STIAs), motorcycle 
passenger transporters (Boda-Boda), transgenders (TG), and men who have sex with men 
(MSM).  Although these populations are known to be among “Most at-Risk Populations” 
or MARPs, not all members of these occupational groups engage in equivalent risk 
behavior.  Enrollment will therefore engage members of these populations whose 
behavior places them at higher risk as documented through an Audio-Computer Assisted 
Self-Interview.  Only participants identifying at least one of four risk factors were 
enrolled (see table S1). 
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Supplementary methods: 
	  
Informed Consent:  Written informed consent was obtained in the native language of 
the participant. Standard procedures for enrolling illiterate volunteers were observed. 
 
HIV serological diagnostics: 
HIV serology was performed at screening, every 6 months and during phase IB using the 
Genetic Systems HIV-1/HIV-2 Plus O EIA (Bio-Rad Laboratories, Inc; Redmond, WA).  
Reactive samples were repeated in duplicate then confirmed by the Genetic Systems 
HIV-1 Western Blot (Bio-Rad Laboratories).   
 
HIV subtyping: HIV-1 near full-length genomes or two overlapping half genomes were 
sequenced from plasma RNA using a single genome amplification strategy.1 The PCR 
amplification and sequencing methods were as described.2 HIV-1 subtype was assigned 
using the HIV-1 Genotyping Tool at the National Center for Biotechnology Information 
and confirmed by Maximum Likelihood phylogenetic analysis and jumping profile 
hidden Markov model (jpHMM).3,4  
	  
Spline	  statistical	  methods:	  
The	  spine	  was	  defined	  using	  the	  truncated	  power	  function	  basis	  with	  degree	  2.	  The	  
number	  of	  spline	  knots	  were	  selected	  by	  minimizing	  the	  Akaike	  information	  criteria	  
(AIC).	  Region-­‐specific	  spline	  effects	  were	  were	  added	  to	  the	  base	  model	  after	  being	  
tested	  for	  significance	  using	  the	  AIC.	  Subject-­‐specific	  splines	  were	  also	  considered	  
but	  did	  not	  improve	  model	  fit	  or	  the	  AIC.	  Splines	  models	  were	  fit	  in	  PROC	  GLIMMIX.	  	  	  	  
	  
Flow	  Cytometry	  Analysis:	  
Lymphocyte	  analysis	  focused	  on	  visits	  where	  more	  than	  30	  observations	  were	  
available.	  	  Models	  were	  fit	  using	  restricted	  maximum	  likelihood	  estimation	  
accounting	  for	  within	  subject	  covariance	  using	  unstructured	  covariance	  matrices	  for	  
univariable	  and	  multivariable	  models.	  All	  models	  were	  adjusted	  for	  region	  and	  visit.	  
	  	  
	  
Study Conduct and Analysis: The study was designed by Merlin Robb, Leigh Anne 
Eller, Sheila Peel, Robert O’Connell, Mark deSouza, and Nelson Michael. Data were 
gathered by Hannah Kibuuka, Kathleen Rono, Lucas Maganga, Sorachai Nitayaphan, 
Eugene Kroon, Somchai Sriplienchan, Samuel Sinei, Fred Sawe, Linda Jagodzinski, 
Mark Manak, Sodsai Tovanabutra, and Mike Eller.  Data analysis was performed by 
Merlin Robb, Leigh Anne Eller, Andrew Lewandowski, Hao Wu, and Peter Dawson. 
Merlin Robb, Leigh Anne Eller, Mark Millazo, and Peter Dawson vouch for the data. The 
paper was written by Merlin Robb, Leigh Anne Eller, Peter Dawson, Jerome Kim and 
Nelson Michael. The decision to publish the paper was made by Merlin Robb and Nelson 
Michael. 
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Table S1: Description of screening, surveillance and acute infection cohorts 
All Sites Kenya Tanzania Uganda  overall 
Uganda-
Female 
Uganda 
MSM 
Thailand 
Overall 
Thailand  
FSW 
Thailand  
MSM 
Thailand 
TG 
SCREENING POPULATION           
Volunteers screened 3954 1046 1010 870 681 187 1028 165 444 418 
HIV prevalence at screening (%) 28.4 23.0 40.3 32.2 37.0 14.2 19.5 1.3 28.2 17.7 
Entry risk criteria for high risk pop   
   Received goods for sex (%) 64 80 18 68 70 61 87 88 87 88 
   Unprot. Sex w/ known HIV+ (%) 17 4 29 14 11 22 19 9 24 18 
   Unprot Sec w/ 3 or more (%) 50 50 34 66 61 88 51 27 58 53 
   Reported STI symptoms (%) 61 36 86 69 71 58 54 76 51 49 
Lost to follow up once in SBV (%) 30.0 28.4 34.0 29.5 35.1 14.1 29.2 30.5 28.6 30.3 
SBV compliance (%) 86.8 95.4 84.7 89.7 90.2 87.9 77.2 81.8 77.6 74.1 
ACUTE INFECTIONS   
Total # acute cases 112 28 21 13 9 4 50 2 32 16 
Incidence rate 
 (95% CI) 
3.3 
 (2.7-3.95) 
2.6  
(1.7-3.6) 
3.1  
(1.8-4.4) 
2.0  
(0.9-3.1) 
1.7 
(0.6-2.8) 
3.6 
(0.7-7.1) 
5.1  
(3.7-6.5) 
0.8 
(0.3-2.0) 
8.4 
(5.5-11.3) 
4.5 
(2.3-6.7) 
Person-Years Follow Up 3362 1060 684 640.3 529 111 977.7 239.8 380.2 357.7 
Median age incident cases 
(range) 
23  
(18-48) 
24  
(18-34) 
23  
(18-34) 
24 
(18-33) 
26  
(18-33) 
21 
(18-24) 
23  
(18-48) 
40  
(32-48) 
23  
(18-35) 
22  
(18-29) 
Entry high risk criteria    
   Received goods for sex (%) 77 89 24 85 78 100 90 100 94 81 
   Unprot. Sex w/ known HIV+ (%) 21 4 29 8 11 0 30 50 31 25 
   Unprot Sec w/ 3 or more (%) 54 61 43 85 78 100 46 50 47 44 
   Reported STI symptoms (%) 58 46 91 46 67 0 54 50 59 44 	  
1Participants were enrolled if they reported one of the following: 1) vaginal or anal intercourse in exchange for money, goods or services 2) unprotected vaginal or anal intercourse with one 
or more known HIV-positive partners 3) unprotected vaginal or anal intercourse with three or more partners of known or unknown HIV status 4) new sexually transmitted disease.  
STI=Sexually Transmitted Infection; SBV=Small blood volume (twice weekly collections) 
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Table S2: Acute cohort: Analysis and excluded cohorts 
	  
All#cases#(112)# n=50#included#in#primary#
analysis#
n=62#excluded#from#primary#
analysis#
p#value#
##Gender#(%)# Male:#52##(46)#
Female:#60#(54)#
Male:#19(38)#
Female:#31(62)#
Male:#33(53.2)#
Female:#29(46.8)#
0.13#
Median#Age#(IQR)# 23(20K27)# 24(20K25)# 23(20K27)# 0.72#
##per#site#(%)# Kenya:#28#(25)#
Uganda:#13#(11.6)#
Tanzania:#21#(18.8)#
Thailand:#50#(44.6)#
Kenya:#16(32)#
Uganda:##9(18)#
Tanzania:#8(16)#
Thailand:#17(34)#
Kenya:#12(19.4)#
Uganda:##4(6.5)#
Tanzania:#13(21)#
Thailand:#33(53.2)#
0.057#
Entry#high#risk#criteria#(%)# Received#goods#for#sex:#77#
Unprot.#Sex#w/#known#HIV+:#21#
Unprot#Sec#w/#3#or#more:#54#
Reported#STI#symptoms:#58#
Received#goods#for#sex:#80#
Unprot.#Sex#w/#known#HIV+:#12#
Unprot#Sec#w/#3#or#more:#58#
Reported#STI#symptoms:#50#
Received#goods#for#sex:#74#
Unprot.#Sex#w/#known#HIV+:#27#
Unprot#Sec#w/#3#or#more:#50#
Reported#STI#symptoms:#65#
0.51#
0.060#
0.45#
0.13#
Median#Viral#Load#set#point#
(log10#copies/ml)#
4.31#(3.80K4.87),#n=78! 4.35#(3.70K4.83),#n=45# 4.31#(4.09K4.92),#n=33# 0.73#
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Table S3: Summary quantitative viral RNA statistics  
Mean, Median (IQR) 
All Africa Thailand 
Peak VL (n=50) 6.75, 6.74 (6.24, 7.50) 6.76, 6.76 (6.12, 7.53) 6.73, 6.66 (6.26, 6.91) 
Peak Day (n=50) 12.5, 13 (10, 14) 12.2, 13 (10, 14) 13.1, 14 (11, 15) 
Nadir VL(n=47)1 4.24, 4.33 (3.55, 4.79) 4.03, 4.22 (3.43, 4.71) 4.65, 4.70 (4.14, 5.44) 
Nadir Day(n=47) 1 32.7, 31 (28, 41) 32.1, 31 (27, 38) 33.9, 33 (28, 42) 
Set-Point VL (n=45) 2 4.26, 4.35 (3.7, 4.83) 4.00, 3.99 (3.39,4.50) 4.69, 4.77 (4.41, 5.22) 
EIA Reactive Day (n=43) 3 15.4, 14 (13,18) 15.1, 14 (13-18) 15.4, 14 (13,18) 
Up Slope (n=43) 4 0.40, 0.39 (0.35, 0.43) 0.41, 0.40 (0.36, 0.44) 0.38, 0.38 (0.34, 0.41) 
Down Slope (n=49)5 -0.14, -0.13 (-0.16, -0.09) -0.15, -0.14 (-0.18, -0.10) -0.11, -0.10 (-0.13, -0.08) 
 
12	  cases	  not	  included	  due	  to	  start	  of	  ART	  and	  1	  case	  not	  included	  due	  to	  missing	  visits	  
25	  cases	  not	  included	  due	  to	  start	  of	  ART	  
37	  cases	  not	  included	  due	  to	  missing	  data	  
47	  cases	  not	  included	  due	  to	  interval	  >10	  days	  between	  last	  negative	  and	  first	  positive	  
51	  case	  not	  included	  due	  to	  missing	  visit
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Figure S1: Viral Load Regional Spline Models 
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Figure S1: Regression splines with subject-specific slopes and intercepts were fit using the first year of viral load data for each region (panel B and C).  Day 0 is 
defined as the first reactive APTIMA RNA test. The spline was defined using the truncated power function basis with degree 2. The number of spline knots were 
selected by minimizing the Akaike information criteria (AIC). Region-specific spline effects were added to the base model after being tested for significance 
using the AIC. Subject-specific splines were also considered, but did not improve model fit or the AIC. Splines models were fit in PROC GLIMMIX of SAS 
version 9.3.   
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Table S4: Individual Viral Load Data  
	  
Region
peak 
day 
peak vl 
log10 
copies/ml
nadir day 
log10 
copies/ml
nadir vl 
log10 
copies/ml
set point vl 
log10 
copies/ml
Day of 
last 
negative 
VL Downslope 
(Rate of Change 
Peak to Nadir)
VL Upslope (Rate of 
Change Last Negative 
to Peak)
Last known 
Absolute CD4 
count (cells/ul) 
Absolute CD4 
Count 1 year 
(cells/ul)
Africa 11 7.51 34 4.29 3.97 -21 -0.14 556 771
Africa 12 5.57 42 2.88 3.89 -28 -0.09 594 594
Africa 18 5.49 39 3.43 3.69 -4 -0.10 0.25 618 1035
Africa 10 6.92 35 4.01 4.08 -5 -0.12 0.46 290 514
Africa 14 6.74 42 3.55 3.52 -14 -0.11 746 746
Africa 13 6.62 27 4.59 4.13 -14 -0.15 625 554
Africa 6 6.32 30 4.22 4.35 -162 -0.09 453
Africa 14 7.63 31 4.94 -4 -0.16 0.42 442
Africa 14 7.94 32 4.71 5.20 -4 -0.18 0.44 323 323
Africa 9 7.99 36 5.12 4.28 -4 -0.11 0.61 1543 1412
Africa 8 6.25 28 3.57 2.66 -32 -0.13 376 579
Africa 11 8.2 31 4.55 2.52 -4 -0.18 0.55 814 873
Africa 13 6.68 29 3.54 3.70 -4 -0.20 0.39 345 347
Africa 14 7.64 25 4.79 5.35 -4 -0.26 0.42 495 265
Africa 11 6.02 27 3.21 3.01 -5 -0.18 0.38 368 760
Africa 13 6.12 25 3.56 -4 -0.21 0.36 676
Africa 11 6.54 36 2.72 3.57 -4 -0.15 0.44 788
Africa 13 6.95 39 4.33 4.87 -4 -0.10 0.41 186 186
Africa 15 8.2 31 4.31 4.02 -4 -0.24 0.43 725 890
Africa 14 6.93 41 2.76 3.04 -4 -0.15 0.39 534 661
Africa 14 6.73 22 4.61 4.54 -4 -0.27 0.37 249 257
Africa 9 5.68 23 2.06 2.90 -21 -0.26 465
Africa 9 4.47 29 2.84 3.25 -4 -0.08 0.34 669 1041
Africa 17 5.45 38 3.78 -7 -0.08 0.23 935 935
Africa 12 7.57 -3 0.50 509
Africa 18 7.5 28 3.93 4.38 -3 -0.36 0.36 427 618
Africa 14 6.76 32 5.75 4.83 -3 -0.06 0.40 382 454
Africa 11 7.34 36 6.26 5.96 -10 -0.04 0.35 474 474
Africa 10 4.85 41 1.7 3.16 -3 -0.10 0.37 393 685
Africa 7 6.05 18 4.52 3.77 -10 -0.14 0.36 259 463
Africa 14 7.53 42 4.81 4.85 -4 -0.10 0.42 379 379
Africa 7 7.83 27 5.56 4.46 -7 -0.11 0.56 1018 1021
Africa 18 6.96 -3 0.33 583
Thailand 15 7.31 42 5.61 5.35 -3 -0.06 0.41 360 421
Thailand 14 5.79 28 3.55 3.78 -3 -0.16 0.34 307
Thailand 16 6.4 41 4 4.64 -7 -0.10 0.28 180 627
Thailand 10 8.46 31 5.71 5.22 -7 -0.13 0.50 180 180
Thailand 14 6.24 42 3.76 4.47 -5 -0.09 0.33 249 868
Thailand 11 6.66 42 5.38 5.28 -6 -0.04 0.39 283 464
Thailand 13 6.5 29 4.36 4.02 -4 -0.13 0.38 695
Thailand 14 6.67 35 4.79 4.83 -5 -0.09 0.35 491 462
Thailand 10 7.35 28 5.49 5.39 -3 -0.10 0.57 189 264
Thailand 12 6.49 26 4.62 4.83 -2 -0.13 0.46 343 358
Thailand 17 5.81 42 3.26 3.60 -4 -0.10 0.28 490 433
Thailand 14 6.86 24 4.28 4.77 -5 -0.26 0.36 225 391
Thailand 18 6.09 42 4.78 4.41 -2 -0.05 0.30 257 603
Thailand 10 6.91 4.30 -7 0.41 781 971
Thailand 7 6.26 21 4.45 4.45 -9 -0.13 0.39 431 525
Thailand 15 6.82 41 4.77 5.07 -4 -0.08 0.36 154 356
Thailand 12 7.77 29 5.57 5.35 -7 -0.13 0.41 81 344
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Figure S2: Regional viral load correlations  
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Figure	  S2:	  Peak	  vial	  load	  correlated	  to	  set	  point	  viral	  load	  in	  East	  Africa	  (EA)	  and	  Thailand	  (TH)	  (Panel	  A).	  	  	  Nadir	  and	  set	  point	  viral	  load	  were	  strongly	  
correlated	  in	  both	  regions	  (Panel	  B).	  	  Although	  downslope	  correlated	  to	  set	  point	  in	  the	  combined	  group	  (Figure	  3D,	  main	  paper),	  when separated by region, the 
correlation was not present in East Africa (EA) or Thailand (Panel C).  The correlation of viral load upslope to set point viral load was only significant in Thailand (Panel 
D).	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Figure S3:  Immune cell counts over 510 days of follow up by region  
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Figure S3: The absolute counts for CD4 (Panel A,B), CD8 (Panel C,D), NK cell (Panel E,F) and B cell (Panel G,H) 
for 50 subjects were plotted by the mean visit day on the x-axis. African participants (n=32) are shown on the left and 
Thailand participants (n=18) on the right.  The mean viral load at each time point is plotted in blue on the right Y-
axis.  Wilcoxon Signed-Rank tests were performed on available paired data prior to start of ARV treatment. 
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Table S5: Frequency of clinical symptoms and signs overall and by region 
	  
	  
Africa (n=31) Thailand (n=17) All (n=48) 
Symptom: N(%) N(%) N(%) 
   Fever 18 (55%) 7 (41%) 25 (50%) 
   Headache 17 (52%) 6 (35%) 23 (46%) 
   Feeling of Illness 14 (42%) 5 (29%) 19 (38%) 
   Coughing 10 (30%) 9 (53%) 19 (38%) 
Abnormality: 
   HEENT**  6 (18%) 16 (94%) 22 (44%) 
   Lymph* 3 (9%) 16 (94%) 19 (38%) 
   Tachycardia 11 (33%) 5 (29%) 16 (32%) 
*Fisher’s Exact p-value < 0.001 
**Fisher’s Exact p-value <0.001 
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Figure S4A: Heat map-Symptoms reported in medical history 
	  
Region Pre)
Infection
Visit0500000
Pre)Peak
Visit040000Pre)
Peak
Visit030000Pre)
Peak
Visit020000Pre)
Peak
Visit010000Pre)
Peak
Peak Visit010After0
Peak
Visit020After0
Peak
Visit030After0
Peak
Visit040After0
Peak
Visit050After0
Peak
Total00#0Visits0
Post)infection0
w/0Symptoms
Total0Reported0
Symptoms0Post)
infection
Africa 0 . . 0 0 0 0 0 0 0 0 0 0 0
Africa 0 . 0 0 0 0 0 0 . 0 0 0 0 0
Africa 0 . . . 0 0 0 0 0 0 0 0 0 0
Africa 0 . . . 0 0 0 0 0 0 0 0 0 0
Africa 0 . . 0 0 0 0 0 0 0 0 0 0 0
Thailand 0 . 0 0 0 0 0 0 0 0 0 0 0 0
Africa 0 . . . 6 . 0 0 0 0 0 0 1 6
Africa 0 . . . . 3 0 0 0 0 0 0 1 3
Africa 0 . . 0 0 . 0 0 0 0 0 4 1 4
Africa 0 . . 0 3 0 0 0 0 0 0 0 1 3
Africa 0 . . 0 3 0 0 0 0 0 0 0 1 3
Africa 0 . . 0 1 0 0 . 0 0 0 0 1 1
Africa 0 . . . 0 1 0 0 0 0 0 0 1 1
Africa 0 . 0 4 0 0 0 0 0 0 0 0 1 4
Africa 0 . . . . 0 0 0 0 4 0 0 1 4
Thailand 0 . . . . 2 0 0 0 0 0 0 1 2
Africa 0 . . 0 6 1 0 0 . 0 0 0 2 7
Africa 0 . . . 1 0 2 0 0 0 0 . 2 3
Africa 1 . . . 1 1 0 0 0 0 0 0 2 2
Africa 3 . . . 9 0 0 0 0 0 0 1 2 10
Africa 0 . . . 0 9 1 0 0 0 0 0 2 10
Africa 0 . . 0 0 11 3 0 0 0 0 0 2 14
Africa 0 1 0 1 0 0 0 0 0 0 . 0 2 2
Africa 0 . . . . 5 8 . . 0 0 0 2 13
Africa 0 . 4 . 2 0 0 . . . . . 2 6
Thailand 0 . 0 0 0 1 1 0 0 0 0 0 2 2
Thailand 2 . . . 0 1 2 0 0 0 0 0 2 3
Thailand 0 . . 0 0 0 3 1 0 0 0 0 2 4
Thailand 6 . . . 0 7 3 0 0 . 0 0 2 10
Thailand 0 . . 0 0 0 1 1 0 0 0 0 2 2
Africa 0 . . . 0 2 17 0 1 0 0 0 3 20
Africa 0 . . 0 2 1 5 . . . . . 3 8
Africa 0 . . 0 1 4 0 0 0 0 0 7 3 12
Thailand 0 . . . 1 3 5 . . . . . 3 9
Africa 0 . . . 5 0 0 0 3 0 1 0 3 9
Africa 0 . . 2 0 1 2 2 0 0 0 0 4 7
Africa 3 . . 0 0 15 2 0 2 0 1 0 4 20
Africa 1 . . . 2 1 4 0 1 0 0 0 4 8
Thailand 1 . 2 0 0 4 1 0 0 1 0 0 4 8
Thailand 0 3 2 1 0 0 0 2 0 0 0 0 4 8
Thailand 0 . 0 0 0 6 3 2 0 2 0 0 4 13
Thailand 0 . . 0 4 2 1 1 1 0 0 0 5 9
Thailand 0 1 0 0 2 3 1 0 1 0 0 0 5 8
Africa 0 . . . . 5 10 1 0 2 0 1 5 19
Africa 0 . . . 5 2 3 1 1 0 2 0 6 14
Africa 0 . . . 0 1 2 1 1 0 1 1 6 7
Thailand 0 . 1 1 0 1 1 1 1 0 1 0 7 7
Thailand 0 . 1 0 4 2 1 0 1 1 1 0 7 11
Thailand 0 . 2 2 3 1 0 0 1 2 1 1 8 13
Thailand 0 . . 0 1 7 1 4 1 1 1 1 8 17
Average0#0
Symptoms0
per0Visit
0.34 1.7 0.92 0.39 1.4 2.1 1.7 0.38 0.34 0.28 0.2 0.35
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Figure S4B: Heat map-Physical Exam findings 
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Africa 0 . . 0 0 0 0 0 0 0 0 0 0 0
Africa 0 . 0 0 0 0 0 0 . 0 0 0 0 0
Africa 0 . . . 0 0 0 0 0 0 0 . 0 0
Africa 0 . . . 0 0 0 0 0 0 0 0 0 0
Africa 0 . . . . 0 0 0 0 0 0 0 0 0
Africa 0 . . 0 0 . 0 0 0 0 0 0 0 0
Africa 0 . . . 0 0 0 0 0 0 0 0 0 0
Africa 0 . . . . 0 0 0 0 0 0 0 0 0
Africa 0 . . 0 0 0 0 0 0 0 0 0 0 0
Africa 0 . . . . 0 0 . . 0 0 0 0 0
Africa 0 . 0 . 0 0 0 . . . . . 0 0
Africa 0 . . 0 1 0 0 0 . 0 0 0 1 1
Africa 0 . . . 1 . 0 0 0 0 0 0 1 1
Africa 0 . . . 0 0 0 1 0 0 0 0 1 1
Africa 0 . . . 0 0 0 0 1 0 0 0 1 1
Africa 1 . 0 3 0 0 0 0 0 0 0 0 1 3
Africa 0 . . 0 0 1 0 0 0 0 0 0 1 1
Thailand 0 . 0 0 1 0 0 0 0 0 0 0 1 1
Africa 0 . . 0 0 0 1 1 0 0 0 0 2 2
Africa 0 . . 1 1 0 0 0 0 0 0 0 2 2
Africa 0 . . 1 0 2 0 0 0 0 0 0 2 3
Africa 0 . . 0 0 1 1 . . . . . 2 2
Africa 0 0 0 1 0 0 0 0 0 0 . 1 2 2
Africa 0 . . . 0 0 0 0 1 0 1 0 2 2
Africa 1 . . . . 1 2 0 0 1 0 0 3 4
Africa 0 . . . 1 1 0 1 0 0 0 0 3 3
Africa 1 . . . 0 2 1 1 0 0 0 0 3 4
Thailand 1 . . . 2 3 3 . . . . . 3 8
Africa 0 . . 0 1 0 0 0 1 1 0 0 3 3
Africa 0 . . . 2 0 2 1 1 0 0 0 4 6
Thailand 0 . 1 0 0 1 1 0 1 0 0 0 4 4
Thailand 0 . 1 0 0 2 2 0 0 0 0 1 4 6
Thailand 0 1 0 0 2 1 0 0 0 1 0 0 4 5
Africa 0 . . 0 0 3 1 2 1 0 1 0 5 8
Thailand 0 . 1 0 0 1 2 2 1 0 0 1 6 8
Thailand 1 . . . 1 1 2 1 1 . 1 0 6 7
Africa 1 . . . 3 2 0 0 3 2 1 1 6 12
Africa 0 . . . 2 1 2 1 3 1 0 0 6 10
Africa 0 . . . 2 0 2 1 1 1 1 2 7 10
Thailand 0 . . . 2 1 2 1 1 1 0 1 7 9
Thailand 1 . . . . 1 1 1 1 1 1 1 7 7
Africa 0 . . 1 1 2 1 2 2 0 2 2 8 13
Thailand 0 . 0 0 1 2 2 1 2 2 2 1 8 13
Thailand 0 . 0 2 0 2 2 2 1 1 2 1 8 13
Thailand 1 . . 1 2 1 2 2 2 1 1 1 9 13
Thailand 0 . . 1 1 1 1 1 1 1 1 1 9 9
Thailand 1 . . 1 2 2 2 2 1 1 1 2 9 14
Thailand 0 . . 1 1 1 1 1 1 2 1 1 9 10
Thailand 2 . 1 3 2 2 1 1 1 2 2 2 10 17
Thailand 0 2 2 2 1 1 1 2 2 1 1 1 11 16
Average0#0of0
Abnormalities0
per0visit
0.22 1 0.46 0.64 0.73 0.81 0.76 0.61 0.68 0.43 0.41 0.43
	  
	  
	  
Figure S4A and S4B: The number of symptoms reported in the medical history (Figure S4A) and 
physical findings on exam (Figure S4B) at each visit is shown for each participant. The visit for each 
participant where peak viral load occurred is shown at the center of the table and the visits preceding peak 
viral load are to the left and visits subsequent to peak viral load are on the right.  The Pre column 
indicates the number of reported symptoms for each participant at a pre-infection visit.  The total number 
of findings and visits with findings are shown on the right for each participant.  
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ABSTRACT We evaluated the diagnostic performance of two tests based on the release of
lipoarabinomannan (LAM) into the urine, the MTB-LAM-ELISA assay and the Determine TB-LAM-strip
assay, in children with suspected tuberculosis (TB) in a high TB/HIV-prevalence setting.
In a prospective study, 132 children with suspected active TB were assigned to diagnostic subgroups.
Urine samples were subjected to testing by both assays to ascertain sensitivity and specificity. Host factors
associated with positive LAM results were investigated and LAM excretion monitored after antituberculous
treatment initiation.
18 (13.6%) children had culture-confirmed pulmonary TB. The assays’ sensitivity was higher in HIV-
positive versus HIV-negative children: 70% (95% confidence interval 35–93%) versus 13% (0–53%) for
MTB-LAM-ELISA and 50% (19–81%) versus 0% (0–37%) for Determine TB-LAM. In 35 (27%) children
with excluded active TB, both assays showed a specificity of 97.1% (85–100%). Proteinuria and low body
mass index were independently associated with LAM positivity. In most patients, LAM excretion declined
to zero during or at conclusion of antituberculous treatment.
HIV/TB co-infected children might benefit from LAM-based tests to aid early TB diagnosis and
subsequent positive impact on morbidity and mortality. Using LAM as a rule-in and treatment-monitoring
tool may also show further potential.
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ORIGINAL ARTICLE
TUBERCULOSIS
Introduction
The diagnosis of tuberculosis (TB) is usually established by detecting mycobacteria, either through smear
microscopy or culturing methods, which is considered the current gold standard. However, due to the
paucibacillary nature of TB in children, the microbiological diagnosis is extremely difficult. Smear
microscopy is positive in <15% [1–3] and mycobacterial culture is positive in 20–80% of children with
presumed TB [1, 2, 4]. Paediatric TB diagnosis is therefore mainly based on clinical assessments, scoring
systems and radiological findings, which can be erroneous. In an autopsy study from Zambia, TB
accounted for 18% of deaths in HIV co-infected and 26% of deaths in HIV-negative children with
respiratory illnesses [5]. In contrast, during a recent review of the global burden of disease in children [6,
7], TB was not listed among the most common causes of paediatric deaths, demonstrating the low number
of microbiologically confirmed cases.
For TB cases in clinical settings, the inconsistency between pathological and epidemiological data
highlights the need for new and more accurate methods to diagnose TB in children, using non-invasive
clinical samples. Lipoarabinomannan (LAM) detection in urine for TB diagnosis was first investigated in
the late 1990s [8–10]. LAM is a 19 kD (±8.5 kD) lipopolysaccharide, specific to the cell wall of members of
the Mycobacterium genus and is released from metabolically active or degrading bacterial cells [11, 12]. It
can subsequently be detected in urine and other body fluids. Advantages of urine LAM diagnosis include
the ease of specimen collection, short bench-time, low cost and relatively low training and set up
requirements [13, 14]. Ideally the LAM-strip assay can be even performed as a point-of-care test in remote
settings. The reported sensitivity of the different LAM diagnostic tests in adults ranges between 13% [15]
and 67% [16], with best performance in patients with advanced HIV disease [15–18]. Data on children are
scarce with only one study published previously on performance of LAM diagnostic tests in children [19].
The two diagnostic assays evaluated here, the MTB-LAM-ELISA (Chemogen, Portland, OR, USA) and the
Determine TB-LAM (Alere, Waltham, MA, USA), have been studied recently in South African children,
for whom they performed poorly [19]. We evaluated the diagnostic performance of both assays in
Tanzanian children with presumed TB and a high HIV co-infection rate. We also investigated host factors
that might be related to LAM performance, as well as the change in LAM excretion during the course of
anti-TB treatment.
Methods
Study design and setting
We undertook a prospective observational study in children presenting with suspected TB at the
outpatient department of the Mbeya Zonal Referral Hospital (Mbeya, Tanzania). The study was
coordinated by the National Institute for Medical Research (NIMR) Mbeya Medical Research Centre
(MMRC), in close collaboration with the Mbeya Zonal Referral Hospital. The study was approved by the
ethics committee of the Tanzania National Institute for Medical Research and the local Mbeya Medical
Research and Ethics Committee. Written informed consent for all children was obtained from an
accompanying parent or a legal guardian. In addition, children aged ⩾9 years signed an assent form.
Clinical study procedures
From May 2008 till November 2010, we approached all children with suspected TB attending the outpatient
clinic and invited them to take part in the study. Inclusion criteria were 6 weeks to 14 years of age, and at
least one of the following symptoms: persistent unremitting cough for >21 days; repeated episodes of fever
within the last 21 days; weight loss or failure to thrive within the previous 3 months. Children who had
received antituberculous treatment within the last 3 months were excluded from the study. Recruitment
procedures, baseline diagnostics, physical assessment and clinical treatment of this cohort have previously
been described [20]. Follow-up visits were scheduled at 1, 3, 6 and 12 months after enrolment or after
antituberculous treatment initiation. For this evaluation, children were retrospectively assigned to distinct
diagnostic subgroups, based on the recently proposed classification by GRAHAM et al. [21] (fig. 1).
A decision on antituberculous treatment initiation was made in liaison with the paediatric department of
the Mbeya Zonal Referral Hospital and the District TB and Leprosy Coordinators and was based on
microbiological and clinical findings (including tuberculin skin test and chest radiography), and previous
medical history. Antituberculous treatment was administered following Tanzanian National Guidelines and
patients diagnosed with HIV infection were referred for further staging and treatment to the relevant HIV
Care and Treatment Centres.
Sample collection and laboratory procedures
Up to three induced sputum samples were collected from each child at baseline and processed for smear
microscopy and Mycobacterium tuberculosis (MTB) culture [20]. Additionally, the Xpert MTB/rifampicin
762 DOI: 10.1183/09031936.00003315
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(RIF) assay (Cepheid, Sunnyvale, CA, USA) was performed on stored, frozen sputum samples as reported
previously [20]. The results were not included in the diagnostic algorithm as all children were enrolled before
Xpert endorsement by the World Health Organization (WHO). At each study visit, a urine sample was
collected for LAM testing, either midstream urine when possible or with a collection bag in younger children.
Within 8 h of collection, all urine was boiled at 95–100°C for 30 min, centrifuged and the supernatants frozen
at −20°C. For the execution of the MTB-LAM-ELISA assay, the thawed urine was processed in duplicate,
according to the manufacturer’s instructions as described previously [18]. For the Determine TB-LAM assay,
60 µL of pre-treated urine was applied onto the sample pad of the LAM strip. After 25 min, the test band
colour intensity was compared to the colour intensity of a series of bands on a paper reference card supplied
by the manufacturer. Grade 1 colour intensity and above were defined as positive results, consistent with the
manufacturer’s instructions at the time of the study [22]. According to the manufacturer (personal
communication) and our own data, results for the Determine TB-LAM assay do not differ between
pre-treated (boiled and centrifuged) or native urine samples. All lab staff performing LAM tests was blinded
to culture results and clinical data. Furthermore, all urine samples underwent testing with urine dipsticks
(Combur-Test; Roche, Basel, Switzerland) for detection of protein, glucose, leukocytes and erythrocytes.
All participants were screened for HIV, using the HIV1/2 STAT-PAK RDT (Chembio Diagnostics Systems,
Medford, NY, USA) and following the manufacturer’s instructions. RDT results were confirmed with a
third generation ELISA (Biorad Laboratories, Redmond WA, USA) and, in case of discordance, retested by
Western Blot (MPD HIV Blot 2.2, MP Biomedicals, Geneva, Switzerland). For children below the age of
2 years a PCR (Roche Amplicor) was performed instead of ELISA. In HIV-positive participants CD4
count and HIV viral load were determined by flow cytometry and PCR (Amplicor; Roche). HIV-positive
children were classified according to the WHO classification of HIV-associated immunodeficiency in
infants and children (see the online supplementary data) [23].
Statistical analysis
In contrast to the classification in the original study, all children were re-classified into five different
diagnostic groups in order to comply with the recently published proposed consensus of paediatric clinical
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not TB
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Microbiological
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FIGURE 1 Algorithm for diagnostic classification. Diagnostic classification for children presenting with suspected
pulmonary/intrathoracic tuberculosis (TB). In total, 379 sputum samples were analysed, 122 children gave three sputa,
six children only two and three children only one sputum sample. One child classified as “No TB”, gave no sputum
sample. In five children with signs of extrapulmonary TB, one pleural fluid sample, one ascites sample and three lymph
node aspirates were analysed. Mycobacterium tuberculosis was confirmed in the pleural fluid and in one lymph node
aspirate. Both children were additionally diagnosed with sputum culture confirmed TB. All 132 children received chest
radiography examination which was assessed by a radiologist and two clinical study investigators who were blinded to
clinical and microbiological data. In case of discrepant readings a consensus radiography diagnosis was made after
discussion among the investigators. Clinical follow-up of all analysed children allowed assessment of treatment response
in those who received antituberculous treatment.
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case definition by GRAHAM et al. [21]. Statistical analyses were performed using Stata statistics software
(version 12; Stata Corp., College Station, TX, USA). The sensitivity, specificity and their respective
confidence intervals were calculated using the “diagt” command in Stata. Pearson’s Chi-squared test was
used to compare binominal variables between groups (confirmed TB versus no-TB or HIV-positive versus
HIV-negative) and the non-parametric Wilcoxon rank sum test was used to compare selected baseline
characteristics of continuous variables, since none of the continuous variables was normally distributed.
The correlation of optical density values and grading of MTB-LAM ELISA and Determine TB-LAM assays
were compared by Spearman rank correlation. Univariable and multivariable log link binomial regression
analyses, using robust variance estimates, were performed to examine the influence of potentially
important factors on LAM positivity.
Results
Between May 2008 and November 2010, 180 children with presumed intrathoracic TB were enrolled into
the study. Due to an incomplete data set, 48 study subjects were excluded from this analysis. In the
majority of excluded children, 37 (77%) out of 48, no urine sample was collected at baseline. As depicted
in figure 2, all diagnostic groups were equally affected by this exclusion criterion. The remaining 132
children were assigned to one of five distinct diagnostic classification groups in line with the definitions by
GRAHAM et al. [21] (figs. 1 and 2). Antituberculous treatment was offered to all children with confirmed
and probable TB and to more than half of the children with possible TB, depending on their clinical and
radiological presentation. Five children initially received antituberculous treatment, but a different
diagnosis was later established. 14 (10.5%) children who demonstrated immunological evidence of TB at
baseline, but improved without antituberculous treatment, were classified with MTB infection. Overall, a
decision for antituberculous treatment was made for 80 (61%) of the 132 children. 69 of all recruited
Confirmed TB
18
ELISA + 8 (44%)
Strip + 5 (28%)
132 children with LAM result and clinical
classification for analysis
Probable TB
36
ELISA + 6 (17%)
Strip + 2 (6%)
Possible TB
43
ELISA + 0
Strip + 1 (2%)
180 enrolled children with suspected tuberculosis
48 children were excluded
37 children without urine sample (10 of them died)
 7 (19%) with "confirmed TB"
 5 (14%) with "probable TB"
 10 (27%) with "possible TB"
 2 (5%) with Mycobacterium tuberculosis infection
 4 (11%) with "no TB"
 9 (24%) not classifiable
9 children not classifiable
 1 died early in the study, 8 were lost
2 children withdrew from study
no TB
21
ELISA + 0
Strip + 0
Mycobacterium  
  tuberculosis infection
14 ("latent")
ELISA + 1 (7%)
Strip + 1 (7%)
FIGURE 2 Study flow chart with diagnostic classification of participants. The number of Mycobacterium
tuberculosis-lipoarabinomannan (LAM)-ELISA positive urines (ELISA +) and the number of Determine TB LAM-Strip
positive urines (STRIP +) is given for each clinical diagnostic group. Confirmed TB: 18 children had microbiological
confirmation of M. tuberculosis infection. Probable TB: tuberculosis could not be microbiologically confirmed, but was
highly probable in 36 children and antituberculous treatment was offered to all of them. Possible TB: tuberculosis could
not be reliably excluded in 43 children, but they did not fulfil criteria for any other group 24 (56%) of the children with
possible tuberculosis received tuberculosis treatment. MTB-infection: 14 children demonstrated immunologic evidence of
TB, but improved without antituberculous treatment. None of them died. No TB: In 21 children, tuberculosis was
retrospectively reliably excluded. Five children initially received antituberculous treatment, but subsequently an alternative
diagnosis was established. The tuberculin skin test was non-reactive in all children, all recovered during the follow-up.
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children were hospitalised at or during enrolment, 42 of whom were included in this analysis.
Demographical, radiological and clinical data of all children and differences in parameters per group at the
time of enrolment are displayed in table 1. Apart from the clinical and radiological data presented in table
1, no further data on extra-thoracic TB disease spectrum were systematically collected.
Out of the group of culture-confirmed TB, eight TB-cases were identified by the MTB-LAM-ELISA and five
by the Determine TB-LAM-strip assay, resulting in a sensitivity of 44% (95% CI 22–69%) and 28% (95% CI
10–54%), respectively (table 2). Among the children with a strong clinical suspicion of TB, six and two
(additional) children were flagged by the MTB-LAM-ELISA and the Determine TB-LAM-strip assay,
respectively. In a combined approach, including children of both groups, the sensitivity was 26% (95% CI 15–
40%) and 13% (95% CI 5–25%), respectively. Concerning specificity, none of the LAM-assays was positive in
the group of children where TB was reliably excluded, resulting in a specificity of 100% (95% CI 84–100%) at
baseline evaluation. One child with MTB infection had positive LAM diagnostic tests. If this diagnostic group
is included in the calculation, the overall specificity was 97.1% (95% CI 85–100%) for both tests. In the direct
comparison of both LAM-assays, the MTB-LAM-ELISA detected 14 of the 54 children with confirmed or
probable TB, whereas the Determine TB-LAM-strip assay only identified 7 of those children.
The overall HIV prevalence in our study cohort was 51%. In children with confirmed TB, the sensitivity of
both LAM diagnostic tests was significantly higher in HIV-positive compared with HIV-negative children:
70% (95% CI 35–93%) versus 13% (95% CI 0–53%) were detected by the MTB-LAM-ELISA and 50%
(95% CI 19–81%) versus 0% (95% CI 0–37%) by the Determine TB-LAM assay (table 2). The comparison
of the performance of both LAM-assays in children with advanced or severe immunosuppression versus
those with mild or no immunosuppression does however not suggest a higher sensitivity of LAM
diagnostics in those with advanced HIV infection.
Employing binominal regression analysis, we found an independent and strong association between
proteinuria and LAM positivity for the MTB-LAM-ELISA (table 3). No other urine-associated factors such
as haematuria, leukocyturia, specific weight or glycosuria could be linked with a positive LAM result (data
not shown). Testing the influence of additional host factors, we found that a positive MTB-LAM-ELISA was
independently associated with a low body mass index (BMI) for age and with higher mortality (table 3).
Similarly, a significant association of the Determine TB-LAM with low BMI was found. Trends for increased
risk were demonstrated for concomitant HIV infection and proteinuria, but did not reach significance
(table 4). No significant influence of age or sex on test positivity could be demonstrated for either assay.
In the per-sample analysis of the 16 urine samples identified as positive by one of the assays at baseline,
the quantitative readouts of the Determine TB-LAM (grade 1–5) and the LAM ELISA optical density
measurements showed a good correlation, reflected by a Spearman rank correlation of rho=0.79, p=0.0003
(data not shown). Seven out of eight positive Determine TB-LAM tests were graded 2 or above, the
remaining test was grade 1, which was a positive result at the time of testing.
In 13 out of 14 children with confirmed or probable TB and a positive LAM result at baseline, both LAM
assays were performed at follow up visits. Figure 3 shows the general decline of signal positivity for the
MTB-LAM-ELISA at different time points after starting antituberculous treatment. Overall, signal intensity
reached zero after 3 months of antituberculous treatment in six participants with MTB-LAM-ELISA-positive
urine samples at baseline. Only one child excreted measurable LAM more than 7 month after
antituberculous treatment started. Clinically, all children responded well to treatment and were considered
cured after 6 months of therapy. The same trend towards a major decline of signal positivity during
antituberculous treatment was seen for the Determine TB LAM assay (data not shown).
In the HIV-infected subgroup with confirmed TB diagnosis, both LAM-diagnostic tests demonstrated a better
sensitivity than smear microscopy, which detected only 30% of all HIV-positive confirmed TB-cases (fig. 4).
The combination of smear microscopy and Determine TB LAM strip led to a combined sensitivity of 60%
(fig. 4) and smear microscopy plus MTB-LAM-ELISA amounted to a sensitivity of 80%. Combining the
Xpert MTB/RIF assay and any of the LAM assays led to an overall sensitivity of 90% amongst these children,
as both LAM-tests detected one confirmed TB case which was negative in the Xpert MTB/RIF-assay (fig. 4).
Discussion
We evaluated the diagnostic performance of the MTB-LAM-ELISA and the new and easier-to-use Determine
TB-LAM strip test in a paediatric cohort from a resource limited setting in Tanzania with high TB and HIV
burden. In line with studies on adults [15, 16, 18, 24], both assays showed a poor sensitivity when compared
to MTB culture, which increased significantly in children with HIV co-infection. However, contrary to reports
on adults [15, 16, 25], a positive correlation between advanced immunosuppression and increased sensitivity
of the LAM-tests could not be confirmed by our paediatric data. Interestingly, LAWN et al. [26] reported that
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TABLE 1 Baseline characteristics of children in different diagnostic classes
Included children Excluded children# Confirmed TB Probable TB Possible TB MTB infection No TB p-value¶
Subjects n 132 45 18 36 43 14 21
Sex male+ 70 (53) 22 (50) 7 (39) 19 (53) 22 (51) 8 (57) 14 (67) 0.083
Age years 6.8 (3.9–9.5) 2.1 (0.7–5.5) 7.3 (4.8–11.5) 6.8 (3.9–9.4) 7.2 (3.9–10.0) 5.2 (2.6–8–8) 5.9 (3.9–10.1) 0.383
BMI for age z-score −0.44 (−1.5–0.4) −1.35 (−3.1–0.1) −1.21 (−2.6–0.1) −0.11 (−1.2–0.6) −0.96 (−2.0–0.2) 0.56 (−0.3–1.1) −0.49 (−1.2–0.4) 0.105
TST reactive 44 (36) 11 (31) 10 (59) 18 (55) 5 (12) 11 (92) 0 <0.001
Proteinuria >30 mg§ 13 (10) 3 (20) 4 (22) 4 (11) 4 (10) 0 1 (5) 0.104
Mortality 11 (8) 11 (24) 0 3 (8) 8 (19) 0 0
Days to treatment 21 (7–58) 15 (5–40) 9 (6–25) 18 (7–44) 31 (13–76) N/A 40 (6–61) 0.307
HIV-positive 67 (51) 19 (53) 10 (56) 18 (50) 22 (51) 4 (29) 13 (62) 0.688
In HIV-positive children:
ART at baseline 17 (25) 3 (16) 1 (10) 5 (28) 7 (32) 0 4 (31) 0.231
No significant immunosuppressionƒ 18 (27) 1 (6) 1 (10) 5 (28) 5 (24) 1 (25) 6 (46) 0.062
Mild immunosuppressionƒ 5 (8) 1 (6) 2 (20) 0 2 (10) 0 1 (8) 0.385
Advanced immunosuppressionƒ 8 (12) 0 3 (30) 2 (11) 1 (5%) 1 (25) 1 (8) 0.162
Severe immunosuppressionƒ 35 (53) 15 (88) 4 (40) 11 (61) 13 (62) 2 (50) 5 (38) 0.940
Data are presented as n (%) or median (interquartile range), unless otherwise stated. Site of tuberculosis for children with confirmed tuberculosis (TB): two perihilar infiltrate, nine hilar
lymphadenopathy, three tuberculous bronchopneumonia, four tuberculous pleural effusion. Site of tuberculosis for children with probable TB: nine perihilar infiltrate, nine hilar
lymphadenopathy, seven tuberculous bronchopneumonia, three tuberculous pleural effusion, three military TB, one cavitating pulmonary TB. MTB: Mycobacterium tuberculosis; BMI: body
mass index; TST, tuberculin skin test; ART: antiretroviral therapy. #: for three of the 48 excluded children no further clinical data were available; ¶: p-value for comparison between
children with confirmed TB and no TB using Pearson’s Chi-squared test for binary and the Wilcoxon rank-sum test for continuous variables; +: for one (excluded) child no sex information
was available; §: for two included children no urine dipstick result was available; ƒ: for one included child no CD4 count was measured and the level of immunosuppression could not be
calculated.
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TABLE 2 Diagnostic performance of both lipoarabinomannan (LAM) assays
Sensitivity# Specificity¶
Confirmed TB Probable TB Combined TB diagnosis TB excluded Combined TB excluded and TB infection
All children
ELISA 8/18 (44) 6/36 (17) 14/54 (26) 21/21 (100) 34/35 (97)
Determine strip 5/18 (28) 2/36 (6) 7/54 (13) 21/21 (100) 34/35 (97)
HIV-negative children
ELISA 1/8 (13) 2/18 (11) 3/26 (12) 8/8 (100) 18/18 (100)
Determine strip 0/8 (0) 1/18 (6) 1/26 (4) 8/8 (100) 18/18 (100)
HIV-positive children
ELISA 7/10 (70) 4/18 (22) 11/28 (39) 13/13 (100) 16/17 (94)
Determine strip 5/10 (50) 1/18 (6) 6/28 (21) 13/13 (100) 16/17 (94)
Immunosuppression
Mild or not significant
ELISA 3/3 (100) 2/5 (40) 5/8 (63) 7/7 (100) 8/8 (100)
Determine strip 2/3 (67) 1/5 (20) 3/8 (38) 7/7 (100) 8/8 (100)
Advanced or severe
ELISA 4/7 (57) 2/13 (15) 6/20 (30) 6/6 (100) 8/9 (89)
Determine strip 3/7 (43) 0/13 (0) 3/20 (15) 6/6 (100) 8/9 (89)
The diagnostic performance of both LAM assays is shown for HIV-negative and HIV-positive children. For HIV-positive children, two subgroups
were analysed. The children with no significant or mild immune suppression were compared with thechildren with advanced or severe immune
suppression. The Pearson’s Chi-squared test was used to compare LAM positivity between HIV-positive versus HIV-negative children. The
difference of MTB-LAM positivity in confirmed and probable TB HIV-negative versus HIV-positive was p=0.020. The difference of Determine TB
LAM strip positivity in confirmed and probable TB HIV-negative versus HIV-positive was p=0.055. #: data presented as test positive/total n children
in diagnostic class (%); ¶: data presented as test negative/total n TB negative children (%)
TABLE 3 Association of host factors with MTB-LAM-ELISA positivity in confirmed and probable
TB cases
Subjects LAM RR (95% CI) p-value
Age 54 14 (26) 1.07 (0.93–1.22) 0.371
Sex
Female 28 8 (29) 1
Male 26 6 (23) 0.81 (0.32–2.03) 0.650
HIV status
Negative 26 3 (12) 1
Positive 28 11 (39) 3.40 (1.06–11.0) 0.040
Immunosuppression
None or mild 8 5 (63) 1
Advanced or severe 20 6 (30) 0.48 (0.20–1.15) 0.100
Proteinuria
No 39 7 (18) 1
Yes 14 7 (50) 2.79 (1.18–6.58) 0.019
BMI for age
Z score 54 14 (26) 0.76 (0.60–0.96) 0.020
Died
No 51 12 (24) 1
Yes 3 2 (67) 2.83 (1.09–7.32) 0.032
TB classification
Confirmed TB 18 8 (44) 1
Probable TB 36 6 (17) 0.38 (0.15–0.93) 0.033
Data are presented as n or n (%), unless otherwise specified. Results from separate univariable binomial
log link regression models for each of the above variables. A significantly increased risk for a positive
Mycobacterium tuberculosis (MTB)- lipoarabinomannan (LAM)-ELISA result was found in participants with
confirmed tuberculosis (TB) diagnosis, concomitant HIV infection, proteinuria, low body mass index (BMI)
and participants who died during the course of the trial. In a multivariable model, which only included HIV,
BMI and proteinuria, the risk ratios (RRs) and p-values remained similar, demonstrating an independent
association of these variables with LAM-positivity.
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especially those (adult) individuals with advanced disease and poor outcome were detected by urine-based TB
diagnostic assays such as the LAM-test. The fact that, in our study, LAM positivity was positively and
independently associated with culture-confirmed TB, a low BMI-z-score and death might further support
these findings. Furthermore, and equally to findings from adult studies [18], we found a correlation between
TABLE 4 Association of host factors with Determine TB LAM positivity in confirmed and
probable TB cases
Subjects LAM RR (95% CI) p-value
Age 54 7 (13) 1.23 (0.96–1.58) 0.100
Sex
Female 28 5 (18) 1
Male 26 2 (8) 0.43 (0.09–2.06) 0.292
HIV status
Negative 26 1 (4) 1
Positive 28 6 (21) 5.57 (0.70–44.1) 0.104
Immunosuppression
None or mild 8 3 (38) 1
Advanced or severe 20 3 (15) 0.40 (0.09–1.62) 0.199
Proteinuria
No 39 4 (10) 1
Yes 14 3 (21) 2.09 (0.53–8.30) 0.295
BMI for age
Z score 54 7 (13) 0.67 (0.48–0.92) 0.012
Died
No 51 6 (12) 1
Yes 3 1 (33) 2.83 (0.48–16.9) 0.253
TB classification
Confirmed TB 18 5 (28) 1
Probable TB 36 2 (6) 0.20 (0.04–0.95) 0.042
Data are presented as n or n (%), unless otherwise stated. Results from separate univariable binomial log
link regression models for each of the above variables. A significantly increased risk for a positive
Determine TB LAM was demonstrated for confirmed tuberculosis (TB) diagnosis and low body mass index
(BMI) for age, similar to the association demonstrated for the Mycobacterium tuberculosis (MTB)-
lipoarabinomannan (LAM)-ELISA. Trends for increased risk were demonstrated for concomitant HIV
infection and proteinuria, but did not reach significance level.
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FIGURE 3 Signal intensity of Mycobacterium tuberculosis (MTB)- lipoarabinomannan (LAM)-ELISA at different time points
after initiation of tuberculosis (TB) treatment. A drop of signal intensity of the MTB-LAM-ELISA for children with confirmed
and probable TB during the course of antituberculous treatment was observed. Optical density (OD) results for HIV-positive
participants are shown in red solid lines, results for HIV-negative participants as black dashed lines. The median OD at
baseline was higher for HIV-positive children compared with HIV-negative children (0.221 versus 0.118, respectively). The
signal intensity reached 0 after 3 month of treatment in six participants. One child excreted measurable LAM more than
7 months after TB therapy started. Y-axis shows logarithmic scale for mean OD. Neg.: negative.
768 DOI: 10.1183/09031936.00003315
TUBERCULOSIS | I. KROIDL ET AL.
proteinuria and LAM-positivity, indicating that the excretion of LAM might also depend on the condition of
the kidney membrane. This and other risk factors for LAM-positivity require further investigation in order to
better define the potential paediatric target group for LAM-based diagnostics in the future.
Our data regarding the overall sensitivity of the Determine TB-LAM strip test, were comparable with those
previously published for a paediatric cohort from Cape Town [19]. However, the Cape Town study was
unable to demonstrate an improved LAM sensitivity in TB/HIV co-infected children. Unfortunately, an
in-depth comparison of our findings with those of NICOL et al. [19] is hampered by the extremely low
sensitivity of both LAM tests, as well as the poor correlation between the MTB-LAM-ELISA and the
Determine TB-LAM strip test in that study.
Contrary to our previously published data from the same setting in Tanzania [18, 27] and the data
published by NICOL et al. [19], the specificity of both LAM assays was high in our cohort. Depending on
the hygienic standards and the procedures during sample collection, false-positive LAM results had been
observed previously, most likely due to contamination of the sample with environmental mycobacteria or
other bacteria [27]. In this study, we collected urine samples with great precautions, including washing
instructions and the use of clean containers, in order to avoid false positive results. However, especially in
HIV-positive children response to antituberculous treatment should be closely monitored as LAM-based
urine tests cross react with other pathogenic mycobacteria (e.g. Mycobacterium avium complex) and might
influence results. Although the sensitivity of both LAM assays was unsatisfactory, and the requirements for
correct sample collection are high, our data indicate that the use of urine LAM-based tests as rule-in test
could still be advantageous for children in certain settings where sophisticated TB diagnostics are not
available but strict urine collection criteria can be adhered to.
Furthermore, the fact that a decline of LAM-excretion could be measured during treatment may open up a
possibility to monitor antituberculous treatment success in LAM positive children. Although LAM-based
TB diagnosis has the disadvantage that it does not include information on drug resistance, it could be
hypothesised that ongoing excretion of urine LAM during treatment might provide information on
insufficiently treated drug resistant TB. Larger studies with a long clinical follow up are needed to further
scrutinise this hypothesis.
One weakness of our study is the relatively low number of 18 confirmed TB cases, which prevented a
definite conclusion of the performance of LAM assays in certain subgroups, such as HIV-negative children
or in children with HIV co-infection and different levels of immunosuppression. Furthermore, the
exclusion of 37 children from the analysis because no urine sample or LAM result was available at
baseline, may have introduced a selection bias. Urine collection was more cumbersome especially in
younger and sicker children as it requires both the child’s and the caregiver’s cooperation and may be
affected by medical causes such as dehydration. However, gathering a urine specimen was not a priority
when the main study was designed, and we are confident that the proportion of children with an available
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FIGURE 4 Sensitivity of single and combined tuberculosis (TB) diagnostic tests in HIV-infected children. This graph shows
the sensitivity of each diagnostic test alone and the additional gain when combining lipoarabinomannan (LAM) diagnostic
tests with either smear microscopy or Xpert MTB/RIF-assay in HIV-postive individuals with confirmed TB. LAM-Strip:
Determine-TB-LAM; LAM ELISA: MTB LAM-ELISA; Xpert: GeneXpert.
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sample would be higher if staff could be trained accordingly. We hypothesise that the exclusion of young
children with advanced disease might have led rather to an underestimation of LAM-sensitivity, as data
from our analysis indicate.
In conclusion, both LAM tests demonstrated a reasonable sensitivity in HIV-positive TB-infected children,
whereas for HIV-negative children the sensitivity was extremely poor. The combination of LAM tests with
other rapid TB diagnostics could substantially improve the detection of TB in HIV co-infected children.
This holds promise for earlier TB-diagnosis in children, which might in turn have an impact on childhood
morbidity and mortality associated with TB. Additionally, clean sample collection methods to achieve a
high specificity have to be defined in more detail.
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Lipoarabinomannan (LAM), a cell wall component of mycobacteria, can be detected in 
the urine of tuberculosis (TB) patients. Advantages of this include the ease of sample 
collection and test conduction. However, as with most new TB diagnostics, the LAM 
tests were evaluated in well controlled laboratory settings and subsequently need 
assessment under real working conditions. Our experience has shown that the diagnosis 
of TB, using the detection of LAM in urine under field conditions, is prone to false 
positive results due to contamination. Dust and soil, but also stool seem to lead to 
increased OD values and thus false positive results of the enzyme-linked 
immunosorbent assay (ELISA) for MTB-LAM-ELISA, whereas contamination with 
blood, as well as bacterial or fungal organisms had no influence. The collection of urine 
for the detection of LAM should therefore follow strict collection criteria and avoid 
contamination. 
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Worldwide, tuberculosis (TB) causes significant morbidity and mortality, especially 
among people with human immunodeficiency virus (HIV) infection. Early diagnosis is 
a high priority for tuberculosisTB control and prevention of mortality. The use of 
lipoarabinomannan (LAM) detection in urine for TB diagnosis was first investigated in 
the late 1990s (1-3) but to date has not been introduced as a standard TB diagnostic. 
LAM is a 19 kilo Dalton (± 8.5 kD) sized lipopolysaccharide, specific to the cell wall in 
the genus Mycobacterium, and is released from metabolically active or degrading 
bacterial cells. The lipopolysaccharide is then filtered by the kidneys and can 
subsequently be detected in the urine. Advantages of TB diagnosis using LAM include 
the ease of specimen collection and test conduction, and higher sensitivity in patients 
with immunodeficiency (4-6). 
Since 2002, several trials conducted at the Mbeya Medical Research Centre in Tanzania 
evaluated the performance of the TB-LAM-ELISA. Boehme et al. assessed the non-
commercial first product generation of an ELISA for LAM (MTB-LAM-ELISA, 
Chemogen, Portland USA) in 231 TB suspects and 103 healthy volunteers and found 
high sensitivity and specificity in both HIV infected and uninfected individuals (7). The 
encouraging results of that study led to additional evaluations of the LAM-ELISA at 
our research centre.  
In a study on 291 TB suspects tested with the commercially available second generation 
MTB-LAM-ELISA from Chemogen, which utilizes a different polyclonal antibody 
compared to the test used by Boehme et al. (7), Reither et al. (4) demonstrated an 
overall sensitivity of only 50.7%, which was much lower than the previous results from 
Boehme, who reported a sensitivity of 81%. Surprisingly, the study showed a higher 
sensitivity, but lower specificity in female compared to male study subjects (66.7% 
versus 38.5% for sensitivity, 83.7 versus 93.9% for specificity, respectively), which had 
not been reported previously (4). However, higher sensitivity in HIV-positive (62.0%), 
compared to HIV-negative subjects (21.1%), was in concordance with other 
publications.  
 
In an attempt to evaluate the second generation MTB-LAM-ELISA (Chemogen, 
Portland, USA) as a TB screening tool in a large cohort, it was utilised in a general 
population study, which was conducted between 2006 and 2011 in the Mbeya Region in 
Tanzania. The EMINI project (Evaluate and Monitor the Impact of New Interventions), 
a population based cohort study, investigated the prevalence and incidence of HIV, TB 
Page 2 of 11
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Scandinavian Journal of Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 O
nly
and malaria in 9 selected communities with more than 170,000 community members. 
Geographically stratified random selection was used to select 10% of all households, 
which resulted in a cohort of more than 17,000 individuals of all age groups and both 
genders. From 2006 to 2008 study participants were visited annually for specimen and 
data collection, including blood for HIV testing which was performed using the 
Determine HIV 1/2 test (Abbott) rapid diagnostic test (RDT) in the first (2006/2007) 
and the HIV 1/2 STAT-PAK Dipstick Assay (Chembio) in the second round 
(2007/2008) of the survey. All positive results were confirmed using an ELISA HIV 
test (Enzygnost Anti HIV 1/2 Plus, DADE-Behring, Marburg, Germany) and 
subsequent Western blot in discordant cases. Negative RDTs from the first annual 
surveys which were confirmed by another negative RDT in the following survey were 
regarded as confirmed and not further tested. For all HIV incident cases in survey 2, the 
negative result of the previous round was confirmed by the above described testing 
algorithm (8). 
Sample collection during the survey further included morning and spot urine to perform 
the LAM-ELISA for the diagnosis of TB and in selected cases with positive symptom 
screening or clinical evidence of active tuberculosisTB , sputum was collected on three 
consecutive days.  
In the first year of the EMINI study, clean urine collection containers with separate lids 
were provided but no specific collection instructions were given. In the second survey 
round urine containers with closed lids were supplied, as well as instructions to provide 
a mid stream urine sample directly into the sample container. Immediately after 
collection in the households, the urine samples were stored at -20°C in portable 
freezers. The MTB-LAM-ELISA was performed on thawed samples and according to 
the manufacturer's instruction two to three weeks after collection in the field.  
In the first year of the survey, only 275 participants reported to be coughing during 
symptom screening or had clinical evidence of active tuberculosisTB . Smear 
microscopy (Ziehl-Neelsen-staining) was performed on collected sputum samples and 
only four participants had a positive smear. For 3 of these 4 TB cases, the urine test for 
LAM-ELISA was positive. All three were co-infected with HIV, whereas the smear 
positive case which was missed by the LAM-ELISA was HIV negative. However, with 
these low numbers, the sensitivity of the LAM-ELISA could not be reliably calculated. 
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In 2006 - the first year of our annual EMINI surveys - we found positive LAM 
screening results in 2,918 of 17,369 analysed urine samples (16.8%), which by far 
exceeded all reasonable expectations of detectable TB cases. The TB & Leprosy 
coordinator for the Mbeya region had reported 3,600 confirmed TB cases in an area 
with 2,000,000 inhabitants in 2006, which would translate to 31 culture-confirmed TB 
cases in a population of 17,369 participants. Even when adjusting this number for extra-
pulmonary and smear negative TB cases, our results were beyond any expectations. No 
difference between HIV positive (16.6%) and HIV negative participants (16.8%) was 
seen but similar to Reither et al (4) we found a significant difference in LAM-positivity 
between female and male study subjects (Table 1), with 23.3% versus 9.4% LAM 
positive participants, respectively (Prevalence Ratio (PR) = 2.49, 95%CI = 2.31 to 2.69, 
p<0.001). In addition, we found significantly less LAM positive urine samples in adults 
than in children, and lower numbers of LAM positive results were recorded in the rainy 
compared to the dry season. Suspecting dust as a possible contaminator, soil samples 
were taken from the area around the clinic in Mbeya. Two out of four soil samples were 
positive for non-tuberculous mycobacteria in smear or culture. Subsequently we 
concluded that dust contamination could explain the higher numbers of LAM positive 
results in the dry compared to the rainy season. Changes in sample collection 
procedures between the first and second round of the survey lead to significant 
reduction of positive LAM results (Table 1). However, despite the decline from 16.8% 
to 10.3% positive results, the results were still beyond reasonable expectations. During 
the second year we continued to find no differences between HIV positive (10.7%) and 
HIV negative individuals (10.3%), but strong differences in LAM positivity between 
women (13.6%) and men (4.1%) which were consistent with the first survey and the 
previously reported results from Reither et al. (4). Fungal and bacterial urinary tract 
infections, which are more common in women than in men (9), as well as 
contamination with menstrual blood could be potential causes for these differences. In 
order to systematically evaluate these hypotheses, the following investigations were 
conducted: 
 
Whole blood was added to previously LAM negative urine samples in a series of 
dilutions, from 1:1 up to 1:2,048. This led to insignificant changes in the optical density 
(OD) of the LAM result, but never reached the threshold for positivity. 
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Ten to 10 million units of Candida albicans were diluted in one ml of previously LAM 
negative urine samples. The maximum change of the OD was 0.03 above the 
uncontaminated urine, never reaching the cut-off for a positive result.  
 
One hundred and two participants with clinical symptoms of urinary tract infection 
(UTI) were examined to determine the effect of a bacterial UTI on the LAM result. 
Urine samples collected before and after antibiotic treatment were subjected to 
microbial testing and LAM-ELISA. Although 11 cases of UTI could be confirmed, with 
E. coli, K. pneumoniae and Proteus species as the underlying causes, the LAM ELISA 
was negative in 10 of 11 cases. One case of UTI due to Proteus species was initially 
LAM positive; however this urine sample was heavily contaminated with stool. Repeat 
testing on a clear urine sample prior to antibiotic treatment showed a negative LAM 
result. In concordance with these finding are the results of Boehme et al (7) who had 
already investigated possible cross-reactivity of LAM with different pathogens in the 
urinary tract and found no influence on the ELISA results.  
 
In order to explore the significance of stool as a contaminating factor, LAM negative 
urine samples of 13 individuals living in Mbeya, Tanzania with no signs or clinical 
suspicion of TB were mixed with 80 mg of stool from the respective individual. The 
solution was centrifuged and the supernatant diluted in a series of 1:1 up to 1:8, causing 
a significant increase of OD in 11 out of 13 individuals (Figure 1). The experiment was 
repeated using urine and stool samples from 12 individuals living in Munich, Germany. 
Again a significant increase of OD could be demonstrated. The presence of non-TB-
mycobacteria in stool specimen was already reported in 1990 by Colebunders et al. in a 
study conducted in Kinshasa, DRC (10). As the LAM ELISA will react positive with 
several mycobacteria, including M. fortuitum, M. kansasii, M. phlei and M. gordonae, 
as shown by Boehme et .al. (7), contamination of urine samples with stool containing 
any of the above mycobacteria could have contributed to the high number of positive 
test results for the MTB-LAM_ELISA within our study cohort. 
There are several limitations to our study. The EMINI survey was planned before data 
about the preferential use of the ELISA in patients with immune suppression became 
available (6, 11). The described specificity of 99% in the study by Boehme et al. (7), led 
to the idea of testing the LAM-ELISA in a field study, however with more data about 
the specific indication of the LAM-ELISA in immuno-compromised individuals it is 
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clear that a healthy general population is not the ideal target cohort for the use of this 
specific test. Furthermore, the study by Boehme et al.(7) was conducted with the non-
commercial version of the LAM-ELISA, whereas the commercial version of the LAM-
ELISA from Chemogen was used in the EMINI survey. Therefore, comparisons of the 
results are difficult to make. The TB screening method used in the EMINI project was 
too insensitive to find the potentially “real positive” TB cases among the LAM-positive 
results Lastly, no culture was performed on the stool-contaminated urine samples, 
therefore our conclusion that contamination with environmental mycobacteria could 
cause false positive results remains hypothetical as it is impossible to say which factor 
in the stool specimen lead to the documented increase of ODs. 
 
Conclusion 
The specificity of the MTB-LAM-ELISA was previously described as excellent (1, 6) 
with values above 97.5%. However, other publications reported lower specificities such 
as 88% to 94% (4-5). We found the performance of the commercially available MTB-
LAM-ELISA significantly influenced by different environmental factors. Dust and soil, 
but also stool seem to lead to increased OD values and thus false positive results of the 
MTB-LAM-ELISA, whereas contamination with blood, as well as bacterial or fungal 
organisms had no influence. As non-tuberculous mycobacteria such as M. gordonae 
and others are present worldwide in tap water and soil and have been described in 
human stool (10), it is possible that NTMs are the causative agent for false positive 
results. If urine is collected under field conditions, where unclean genital areas or 
additional collection devices could add stool particles or soil to the urine, false positive 
results due to contamination are likely. This can explain the varying results from 
different studies. The collection of urine for the detection of LAM should therefore 
follow strict collection criteria and avoid contamination. Nevertheless, under controlled 
sampling conditions and addressing the correct target population, LAM diagnosis 
remains a promising method to detect Mycobacterium tuberculosis.  
 
Ethical considerations: 
The study was approved by the National Ethical Committee/Medical Research 
Coordinating Committee of the National Institute for Medical Research, Tanzania. All 
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participants provided written informed consent prior to enrolment into the study, 
parents consented for their minors. 
 
References 
1. Hamasur B, Bruchfeld J, Haile M, Pawlowski A, Bjorvatn B, Kallenius G, et 
al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan 
in urine. J Microbiol Methods. 2001 May;45(1):41-52. 
2. Hamasur B, Kallenius G, Svenson SB. A new rapid and simple method for 
large-scale purification of mycobacterial lipoarabinomannan. FEMS Immunol Med 
Microbiol. 1999 May;24(1):11-7. 
3. Tessema TA, Hamasur B, Bjun G, Svenson S, Bjorvatn B. Diagnostic 
evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre. Scand J 
Infect Dis. 2001;33(4):279-84. 
4. Reither K, Saathoff E, Jung J, Minja LT, Kroidl I, Saad E, et al. Low 
sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC 
Infect Dis. 2009;9:141. 
5. Mutetwa R, Boehme C, Dimairo M, Bandason T, Munyati SS, Mangwanya D, 
et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in 
African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009 
Oct;13(10):1253-9. 
6. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, et al. Clinical 
utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients 
using urine and sputum samples. PLoS One. 2010;5(3):e9848. 
7. Boehme C, Molokova E, Minja F, Geis S, Loscher T, Maboko L, et al. 
Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in 
unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc 
Trop Med Hyg. 2005 Dec;99(12):893-900. 
8. Kroidl I, Clowes P, Mwalongo W, Maganga L, Maboko L, Kroidl AL, et al. 
Low specificity of determine HIV1/2 RDT using whole blood in south west Tanzania. 
PLoS One. 2012;7(6):e39529. 
9. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs. Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S. 
10. Colebunders R, Nembunzu M, Portaels F, Lusakumundu K, Kapita B, Piot P. 
Isolation of mycobacteria from stools and intestinal biopsies from HIV seropositive 
and HIV seronegative patients with and without diarrhea in Kinshasa, Zaire. Ann Soc 
belge Méd trop. 1990;70:S303-9. 
11. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the 
diagnosis of tuberculosis: current approaches, clinical applicability, and new 
developments. Curr Opin Pulm Med. 2010 May;16(3):262-70. 
 
Page 7 of 11
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Scandinavian Journal of Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 O
nly
 
Acknowledgement: 
We want to thank all EMINI participants for their willingness to be part of the study, as 
well as the EMINI field- and laboratory-teams for their contribution. Special thanks to 
Mr. Weston Assisya for the coordination of the field work and practical advice.  
 
This study was funded by the European Union (SANTE/2004/078-545 and 
SANTE/2006/129-931). 
 
Author contribution: IK wrote the initial draft of this manuscript, supervised the 
laboratory work for the EMINI study including the MTB-LAM-ELISA and performed 
the additional tests for possible contamination. MH designed the EMINI study, obtained 
funding and supervised its conduct. PC and LM were involved in the implementation of 
the EMINI study. PC was responsible for the overall conduct of the EMINI study and 
PC, JM and IK supervised the analysis of patients with urinary tract infections, for 
which AK performed the microbiology tests. KR, AR, AN and JJ were responsible for 
tuberculosis diagnosis. IK and ES did the statistical analysis. All authors read and 
critically revised the manuscript and approved the final version. 
 
Conflicts of Interest and Source of Funding:  
None of the authors has a conflict of interest regarding the contents of this manuscript.  
 
 
Page 8 of 11
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Scandinavian Journal of Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
0.01
0.1
1
10
N
C 1 2 3 4 5 6 7 8 9 1
0
1
1
1
2
1
3
N
C 1
4
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
1 ml urine + 80 mg stool
dilution 1:1
dilution 1:2
dilution 1:4
dilution 1:8
pure urine
Cutoff, 0.2  
Optical 
density 
Mbeya  
samples 
Munich  
samples 
Page 9 of 11
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Scandinavian Journal of Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 O
nly
 
 
Figure 1: LAM-ELISA results from 25 different subjects, with and without addition of 
stool in different concentrations 
 
 
Urine of 13 participants from Mbeya, Tanzania (samples 1-13), and urine of 12 
individuals from Munich, Germany (sample 14-25) was tested for the presence of LAM. 
Mean optical density (OD) for the negative control (NC) was 0.1 for both groups; cut-
off for LAM positivity was 0.2 (NC+0.1). None of the samples was tested LAM-positive, 
when testing the original urine sample (yellow bars). For the urine-stool-mix, eighty mg 
stool of each participant was mixed with 1ml urine of the respective individual and then 
diluted up to 1:16 (blue bars).  
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Table 1: Diagnostic test performance of LAM-ELISA by age and gender 
LAM-positivity defined as a positive result for at least one out of two urine samples 
 
 
 n LAM + 
prevalence 
 
 Prevalence Ratio 
(95% CI) 
LAM+ 
 
 HIV  
prevalence 
      
   Survey 2006 17,369 16.8%   7.1% 
   Male    8,106   9.4%   6.2% 
   Female   9,263 23.3% 2.49 
(2.31-2.69) 
 7.9% 
      
   Participants > 5 years  15,211 15.5% 
 
  7.8% 
   Children      < 5 years    2,158 26.3% 1.70 
(1.57-1.84) 
 2.3% 
      
   HIV neg  participants 
 
16,136 16.8%    
   HIV pos  participants 
 
  1,233 16.6% 0.98 
(0.86-1.12) 
  
      
   Survey 2007 
  (dust protection) 
 
 
12,668 
 
10.3% 
   
6.6% 
   Male (all ages)   5,833   5.3%   5.8% 
   Female (all ages)    6,835 14.6% 2.77 
(2.45-3.14) 
 7.2% 
      
   Participants > 5 years 10,965   9.3%   7.4% 
   Children      < 5 years   1,703 16.9% 1.82 
(1.62-2.06) 
 1.4% 
      
   HIV neg  participants 
 
11,837 10.3%    
   HIV pos  participants 
 
    831 10.7% 1.04 
(0.85-1.28) 
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QuantiFERONH-TB Gold In-Tube Performance for
Diagnosing Active Tuberculosis in Children and Adults in
a High Burden Setting
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Ib C. Bygbjerg1, Sayoki G. Mfinanga3, Pernille Ravn6
1 Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, 2 Clinical Research Centre, University Hospital
Hvidovre, Hvidovre, Denmark, 3 Muhimbili Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania, 4 NIMR-Mbeya Medical Research
Programme, Mbeya, Tanzania, 5 Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany, 6 Department for
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Abstract
Aim: To determine whether QuantiFERONH-TB Gold In-Tube (QFT) can contribute to the diagnosis of active tuberculosis (TB)
in children in a high-burden setting and to assess the performance of QFT and tuberculin skin test (TST) in a prospective
cohort of TB suspect children compared to adults with confirmed TB in Tanzania.
Methods: Sensitivity and specificity of QFT and TST for diagnosing active TB as well as indeterminate QFT rates and IFN-c
levels were assessed in 211 TB suspect children in a Tanzanian district hospital and contrasted in 90 adults with confirmed
pulmonary TB.
Results: Sensitivity of QFT and TST in children with confirmed TB was 19% (5/27) and 6% (2/31) respectively. In adults
sensitivity of QFT and TST was 84% (73/87) and 85% (63/74). The QFT indeterminate rate in children and adults was 27% and
3%. Median levels of IFN-c were lower in children than adults, particularly children ,2 years and HIV infected. An
indeterminate result was associated with age ,2 years but not malnutrition or HIV status. Overall childhood mortality was
19% and associated with an indeterminate QFT result at baseline.
Conclusion: QFT and TST showed poor performance and a surprisingly low sensitivity in children. In contrast the
performance in Tanzanian adults was good and comparable to performance in high-income countries. Indeterminate results
in children were associated with young age and increased mortality. Neither test can be recommended for diagnosing
active TB in children with immature or impaired immunity in a high-burden setting.
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Introduction
The aim of this study was to investigate the potential of the
interferon-c release assay (IGRA) QuantiFERONH-TB Gold In-
Tube (QFT) (Cellestis Limited Chadstone, Australia) as a reliable
diagnostic tool for physicians in Tanzania, a high TB burden
country, with considerable prevalence of HIV and malnutrition,
for diagnosing active TB in children.
TB is a major contributor to childhood morbidity and mortality,
with children ,5 years at highest risk and 40–50% of infected
infants developing disease within 1–2 years [1,2]. However
childhood TB is notoriously difficult to confirm, due to its pauci-
bacillary nature, and existing tools have limited performance [3].
In TB endemic countries, diagnosis is usually a clinical
diagnosis, relying on recognition of clinical features, suggestive
chest x-ray (CXR) and if available a positive tuberculin skin test
(TST) [4]. However it can be difficult to distinguish between the
signs and symptoms of TB, HIV and malnutrition, and CXRs and
TST results can be difficult to interpret [5,6].
QFT relies on M.tuberculosis (MTB) specific T-cell responses,
measuring levels of interferon-gamma (IFN-c) released in whole
blood in response to stimulation with the MTB specific antigens:
ESAT-6, CFP-10 and TB7.7, indicating past or present infection.
IGRAs are generally more specific than TST, since they do not
cross-react with the BCG vaccine, M.avium or most other non-
tuberculous mycobacteria (NTM). IGRAs are increasingly being
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used worldwide as an alternative to, or in conjunction with, TST
[7] for diagnosing latent TB and although not directly diagnostic
for active TB, IGRAs are often used by clinicians as an additional
tool in the diagnosis of active TB [8]. However there is a lack of
evidence of the performance in children, especially in young
children in a high burden setting [9].
In this study the performance of QFT was assessed in terms of
sensitivity, specificity, indeterminate rates, median IFN-c levels
and risk factor analysis for positive and indeterminate results.
Performance of TST for diagnosing active TB was included for
comparison. Considering the diagnostic challenges in children and
difficulties in assuring a gold standard of confirmed TB, adults
with confirmed active TB, from the same location, were included
as a measure of contrast.
Methods
Ethics Statement
The study protocol was approved by the Tanzanian Medical
Research Coordinating Committee (NIMR/HQ/R.8a/Vol IX/
584) and was evaluated by the Danish Central Ethical Committee
without any objections. Written informed consent was obtained
from the immediate caretaker, or next of kin, prior to inclusion, on
behalf of children participating in the study. The standards for
reporting diagnostic accuracy studies (STARD) criteria were
followed in reporting the results.
Study Setting and Population
The study participants were recruited prospectively at Muheza
designated district hospital, Tanga, Tanzania. Muheza is a rural
district with a population of 209.480, where 90% are engaged in
peasantry, fishery and small-scale business [10]. The TB
notification rate in the district in 2009 was 431/100.000 [11].
Children ,15 years with TB suspect signs and symptoms were
included consecutively from the paediatric ward and outpatients
departments, including the HIV, TB, and mother-child clinics.
Adults with active TB were included consecutively from the TB
clinic. Inclusion criteria are listed in Box S1.
A standardized questionnaire was used to record demographic
and clinical details of the participants, including age, weight,
height, TB specific signs and symptoms and presence of BCG scar.
For the children additional information was collected about
history of BCG vaccine, TB exposure, response to prior antibiotic
treatment and history of health facility visits.
All the study participants provided blood for QFT and HIV
testing. Chest x-rays and TST were performed and either sputum
or gastric wash samples were sent for microscopy and culture
examination. Follow-up of the children was conducted 2 and 6
months after inclusion, involving a standardised clinical examina-
tion and questionnaire concerning health status since last
examination. Children who did not return for follow-up were
traced within 7–12 months of inclusion.
Figure 1. Summary of recruitment and diagnostic classification of children. * Children without follow-up data were excluded since they
could not be classified according to the TB classifications. However one child had culture confirmed TB and could therefore be classified without
follow-up data. ** The first 61 QFT results were excluded, when the initial QFT analysis showed very poor response in all the QFT tubes, including the
mitogen. This was attributed to incorrect storage in a room reaching temperatures above 30uC. Subsequent tubes were all stored at 5–10uC.
doi:10.1371/journal.pone.0037851.g001
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Interferon Gamma Release Assay (IGRA)
Venous blood was collected in a syringe and immediately
dispensed into the QFT tubes, Nil (negative control coated with
saline), TB-Ag (coated with MTB specific antigens) and Mitogen
(positive control coated with phytohaemaggluttin), according to
the manufacturer’s instructions (Cellestis Ltd). The tubes were
taken to the laboratory within 4 hours and incubated at 37uC for
16–24 hours.
Immediately after incubation the samples were centrifuged and
the supernatants stored at minus 70uC, until IFN-c was measured
using the QFT ELISA at the NIMR-Mbeya Medical Research
Programme laboratory, Tanzania. The results were reported as
positive, negative or indeterminate according to the manufactur-
er’s instructions. In addition the raw quantitative results were
recorded.
The results of the first 61 QFT tests revealed that 82% of the
results were indeterminate with poor response in all the QFT
tubes. Thorough quality assurance of all the test procedures
indicated that the tubes had been stored under conditions with
temperatures reaching above 30uC. This was considered to be the
most likely the reason for the high number of indeterminate
results. All the tubes were replaced and new tubes were stored at
5–10uC, until the time they were used.
Tuberculin Skin Testing (TST)
Two units of purified protein derivate RT23 from Staten
Serum Institute, Denmark, were administered intradermally
using the mantoux technique recommended by the manufac-
turer. The transverse diameter of the induration was recorded
in millimetres after 48–72 hours. An induration of $5 mm was
considered positive in HIV positive children and adults whilst
an induration of $10 mm was considered positive for all others.
Chest X-Ray (CXR)
The children were chest x-rayed at inclusion. The CXRs were
read by three experts; the hospital radiologist and two independent
senior radiologists, who were unaware of the clinical status of the
child. Using a standardised recording form, the CXRs were
classified as either certain TB, highly suggestive TB, uncertain or
not TB, based on TB specific or suggestive features. CXRs from
202 children were included.
Microbiology
Sputum or gastric wash samples were collected from the
children on three consecutive mornings. Gastric wash samples
were collected in containers containing 100 mg sodium carbonate.
Ascites samples were included for 2 patients, whilst no cerebro-
spinal fluid or lymph node samples were included. The adults were
initially diagnosed with smear positive TB at the Muheza district
hospital laboratory using the Ziehl-Neelsen staining technique for
acid fast bacteria. An extra sputum sample was collected from the
adults for confirmation of diagnosis. All the gastric wash and
sputum samples were refrigerated, on average 4 days, until they
were sent for confirmatory microscopy and culture at the Central
TB Reference Lab, Dar es Salaam (CTRL) where auramine
staining was used for fluorescence microscopy and Löwenstein-
Jensen media for culture. Para-nitrobenzoic acid, which inhibits
MTB but not NTMs, was added in positive samples to exclude
NTMs.
Table 1. Characteristics of study population.
Children all Confirmed Possible Not TB Adults
N = 211 N = 33 N = 85 N = 93 N = 90
Age mean yrs (SD) 4.4 (3.8) 4.7 (3.7) 4.1 (3.9) 4.5 (3.7) 39.5 (14.9)
Age groups n (%)
,2 yrs 77 (37) 7 (21) 36 (42) 34 (37) – –
2–4.9 yrs 53 (25) 13 (40) 21 (25) 19 (20) – –
5–9.9 yrs 51 (24) 8 (24) 15 (18) 28 (30) – –
.10 yrs 30 (14) 5 (15) 13 (15) 12 (13) – –
Male n (%) 124 (59) 24 (73) 47 (55) 53 (57) 72 (80)
HIV Positive { n (%) 78 (37) 18 (55) 38 (45) 22 (24) 25 (28)
Z-score #22 { n (%) 109 (58) 15 (47) 45 (63) 49 (58) – –
BMI ,18.5 n (%) – – – – – – – – 57 (63)
History contact { n (%) 72 (35) 13 (39) 30 (36) 29 (32) – –
BCG history n (%) 196 (93) 30 (91) 81 (95) 85 (91) – –
BCG scar n (%) 192 (91) 28 (85) 75 (88) 89 (96) 70 (78)
Clinical TB * n (%) 76 (34) 33 (100) 43 (51) 0 0 90 (100)
Follow-up status{n (%)
Healthy 152 (72) 31 (97) 28 (33) 93 (100) – –
Still ill 19 (9) – – 19 (22) 0 0 – –
Dead 39 (19) 1 (3) 38 (45) 0 0 – –
{HIV test result available for 209 children, weight-for-age Z-score data available for 188 children, history of contact data available for 208 children (reported contact to
case of TB in last 2 years), 1 child with confirmed TB did not have follow-up data (follow-up status defined as health status of child 6 months after inclusion into study).
*Clinical TB in children defined as active TB diagnosed by local physician based on clinical examination, CXR and TST. Clinical TB in adults defined as active TB diagnosed
by local physician, all included adults had positive Ziehl-Neelsen smear microscopy as well as either positive culture and/or positive fluorescence microscopy.
doi:10.1371/journal.pone.0037851.t001
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TB Diagnosis and Classification
The clinical TB diagnosis in children and the decision to start
anti-TB treatment was made by the district TB medical doctor or
the medical doctor in charge of the paediatric ward. The study
team was not involved other than ensuring that the TB medical
doctor was consulted on each case and providing the results of
CXR, TST and HIV test. The results of the QFT test were not
available to the physicians responsible for diagnosing or treating
the children.
Each child was assigned to one of four predefined diagnostic
classifications; ‘‘Microbiologically confirmed TB’’, ‘‘Highly prob-
able TB’’, ‘‘Possible TB’’ and ‘‘Not TB’’. The classifications were
based on microscopy and culture data, CXR results, clinical
examination and follow-up data (Box S2). For data analysis
children with microbiologically confirmed TB and highly probable
TB were considered to have confirmed TB. Children without
follow-up data were excluded, unless they had microbiologically
confirmed TB. Adults with either positive culture or positive
fluorescence microscopy were classified as confirmed TB.
Data Management and Statistical Analysis
Data were double-entered into a data entry database using MS-
Access (Microsoft Corp, VA, USA) including error, range and
consistency check programs. Statistical analyses were performed
using StataTM v 10.0 (Stata Corp, TX, USA). Epi InfoTM 3.5.2
(CDC, USA) was used to generate weight-for-age z-scores to assess
nutritional status in children.
Indeterminate results were excluded in the sensitivity and
specificity analysis as well as in the risk factor analysis for a positive
QFT result. Student’s t-test was used to compare means,
Wilcoxon’s rank-sum test for comparing medians, using log
transformation for data that was not normally distributed.
Logistic regression analysis was used for univariable and
multivariable analysis of risk factors’ association with positive
Table 2. Median IFN-c U/ml in all three Quantiferon TB Gold
In-Tube tubes in children and adults.
Children Negative control Positive control TB antigens
IFN-c U/ml (IQR) IFN-c U/ml (IQR)
IFN-c U/ml
(IQR)
All (TB suspect) 0.15* (0.09–0.35) 2.05* (0.6–7.53) 0.19* (0.1–0.55)
Confirmed TB 0.15* (0.12–0.26) 3.8 (1.08–7.26) 0.17* (0.10–0.48)
Possible TB 0.13* (0.08–0.27) 1.69* (0.44–7.33) 0.17* (0.10–0.56)
Not TB 0.19* (0.09–0.38) 2.26 (0.80–7.61) 0.19* (0.11–0.55)
Adults
Confirmed TB 0.36 (0.22–0.59) 2.63 (1.29–8.09) 3.28(0.99–6.58)
Comparison of median IFN-c values in the three QFT tubes in children and
adults according to diagnostic TB classificaiton. There were significantly lower
levels* (p,0.05) in all subgroups of children compared to adults, except in the
positive control where median levels in children with confirmed and not TB
were not significantly different to levels in adults.
Wilcoxon’s rank-sum test used to test difference between median IFN-c in
children and adults.
IQR: interquartile range.
doi:10.1371/journal.pone.0037851.t002
Table 3. Comparison of median IFN-c responses in all TB suspect children.
Negative control Positive control TB antigens
IFN-c U/ml (IQR) p-value{ IFN-c U/ml (IQR) p-value{ IFN-c U/ml (IQR) p-value{
Age ,2 yrs 0.14 (0.07–0.21) – 1.32 (0.4–8.05) – 0.14 (0.08–0.35) –
$2 yrs 0.16 (0.1–0.44) 0.01 2.37 (1.01–7.33) 0.09 0.21 (0.12–0.64) 0.01
Sex Male 0.17 (0.09–0.45) – 2.18 (0.73–7.54) – 0.21 (0.12–0.57) –
Female 0.14 (0.09–0.24) 0.08 1.48 (0.49–7.53) 0.27 0.15 (0.09–0.39) 0.04
HIV status Pos 0.14(0.09–0.24) – 1.4 (0.47–5.61) – 0.15 (0.09–0.29) –
Neg 0.17 (0.09–0.52 0.09 2.49 (0.8–8.89) 0.07 0.2 (0.1–0.84) 0.01
Z-score #22 0.14 (0.09–0.37) – 1.75 (0.6–6.46) – 0.18 (0.09–0.49) –
.–2 0.15 (0.09–0.45) 0.45 2.49 (0.78–9–87) 0.32 0.21 (0.11–0.79) 0.20
History contact yes 0.17 (0.10–0.–36) 2.48 (0.99–7.39) 0.19 (0.10–0.56)
no 0.15 (0.09–0.37) 0.56 1.77 (0.53–8.18) 0.37 0.19 (0.10–0.54) 0.77
Living PTB+ * yes 0.12 (0.1–0.25) 1.91 (0.63–4.35) 0.17 (0.09–0.55)
no 0.15 (0.09–0.37) 0.51 1.77 (0.53–8.18) 0.51 0.19 (0.1–0.54) 0.79
Clinical TB** yes 0.15 (0.10–0.41) 2.28 (0.73–7.45) 0.18 (0.1–0.56)
no 0.15 (0.08–0.34) 0.69 1.91 (0.52–7.53) 0.56 0.19 (0.1–0.53) 0.68
Follow–up status Healthy*** 0.16(0.09–0.39) – 2.65 (0.95–8.8) – 0.19(0.11–0.55) –
Ill 0.16 (0.08–0.35) 0.59 1.08 ((0.33–2.68) 0.04 0.24 (0.1–0.58) 0.37
Died 0.11 (0.05–0.2) 0.01 1.02 (0.19–4.39) ,0.01 0.15 (0.07–0.4) 0.18
Comparison of median IFN-c in subgroups of children, finding lower median levels in response to specific TB antigens in children ,2 years, girls and HIV infected and
lower median mitogen responses in children who subsequently died.
{Wilcoxon’s rank-sum test used to test differences in median IFN-c between subgroups of children, p,0.05 considered significant.
IQR: interquartile range.
*Living PTB+ defined as living in the same household as a person with smear positive pulmonary TB.
**Clinically diagnosed with TB and put on anti-TB therapy.
***Subcategory ‘‘healthy’’ used for comparison both for ‘‘ill’’ and ‘‘died’’.
doi:10.1371/journal.pone.0037851.t003
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and indeterminate QFT results, using 95% confidence intervals to
quantify uncertainty. Risk factors that could potentially be
associated with the performance of the test were identified from
previous studies (age, sex, HIV status, nutritional status and
contact history).
Kaplan Meier failure estimates, odds ratios and log-rank test
were used to illustrate and quantify the difference in mortality
according to QFT results. A p-value of ,0.05 was considered
statistically significant.
Results
Study Population
From April 2008 to June 2010 4713 children were screened,
347 children were eligible according to our inclusion criteria and
211 children with TB suspect signs and symptoms were included
(figure 1). 107 Ziehl-Neelsen smear microscopy positive adults
were screened, 90 with either positive culture and/or positive
fluorescence microscopy were included. Characteristics of the
study populations are shown in table 1.
Four children were culture positive, two of whom were also
fluorescence microscopy positive. In adults 70 were culture and
fluorescence microscopy positive, whilst an additional 4 were
positive by culture only and 16 by microscopy only.
Based on the above and the criteria in box S2, 33/211 (16%) of
children were classified as ‘‘confirmed TB’’, 85/211 (40%)
‘‘possible TB’’ and 93/211 (44%) ‘‘not TB’’. All 90 adults were
classified as ‘‘confirmed TB’’.
TST Results
TST results were available for 197 children (6% positive) and 74
adults (85% positive). Two of four children with TST indurations
measuring 5–9 mm were considered TST positive because they
were HIV positive. The one adult with an induration of 5–9 mm
was HIV negative.
QFT Results
QFT results were positive in 26 (12%), negative in 128 (61%)
and indeterminate in 57 (27%) children. Amongst adults 73 (81%)
were QFT positive, 14 (16%) negative and 3 (3%) indeterminate.
One of the indeterminate results in children was due to high
negative control (.8 U/ml), the remaining indeterminate results
in children and adults were due to low response in the positive
control.
The median levels of IFN-c were significantly lower in children
compared to adults, especially in response to the TB antigens
(table 2). Even children with a positive QFT result had a lower
median IFN-c after antigen stimulation (2.08 U/ml) than adults
with a positive QFT (4.09 U/ml), p = 0.03 (data not shown). The
median IFN-c in response to TB antigens was significantly lower
in children under 2 years, in girls and HIV positive children
(table 3). Amongst children with a positive QFT test, HIV positive
children still had a significantly lower median IFN-c response to
TB antigens than HIV negative children (data not shown).
Children who died before discharge or during the follow-up
period, as well as those who were still ill at 6 month follow-up had
lower median IFN-c in the positive control at base-line compared
to those who had regained their health.
Sensitivity of QFT and TST for Diagnosing Active TB
Amongst children, clinically diagnosed with TB and started on
anti-TB treatment by the local physician, we found a sensitivity of
QFT and TST of only 18% and 12% respectively. Amongst
children with ‘‘confirmed TB’’ we found a sensitivity of QFT and
TST of 19% and 6% respectively. The sensitivity of QFT and
TST in children with ‘‘possible TB’’ was 24% and 9%, and in
children with ‘‘not TB’’ 10% and 3% (table 4).
The specificity of QFT and TST in children was 90% and 98%
respectively. The positive predictive value of QFT and TST in
children for having confirmed TB was 42% and 40%, whilst the
negative predictive value was 73% and 75% respectively.
In contrast, the diagnostic sensitivity of QFT and TST amongst
adults with confirmed TB was notably higher than in children at
86% and 89% (table 4). Sensitivity of QFT was significantly lower
in HIV positive adults 67% (16/24), compared to HIV negative
adults 91% (57/63), p = 0.007 (data not shown). The sensitivity of
TST in adults was not affected by HIV status. The specificity in
adults was not calculated since the inclusion criteria was confirmed
TB.
Risk Factors Association with Positive and Indeterminate
QFT Results
Logistic regression analysis was used in order to identify possible
causes for the low positivity rate and high indeterminate rate of
QFT in children (Table 5 and 6).
Neither sex, malnutrition nor HIV infection, were associated
with either positive or indeterminate QFT results in the
unadjusted or adjusted analysis. Surprisingly, history of TB
Table 4. Sensitivity of Quantiferon TB Gold In-Tube test and Tuberculin Skin test in children and adults.
QFT positive TST positive p-value{
Children n/all tested* (%) 95% CI n/all tested (%) 95% CI
Clinical TB diagnosis 11/60 (18.3) 8.4–28.3 8/69 (11.6) 3.9–19.3 0.28
Confirmed TB 5/27 (18.5) 3.4–33.6 2/31 (6) 22.4–15.3 0.16
Possible TB 14/59 (23.7) 12.7–34.8 7/77 (9.1) 2.6–15.6 0.02
Not TB 7/68 (10.3) 3.0–17.6 3/89 (3.4) 20.4–7.2 0.03
Adults
Confirmed TB 73/87 (83.9) 76.0–91.8 63/74 (85.1) 76.8–93.4 0.85
Sensitivity of QFT and TST according to TB status in children and adults, showing low sensitivity of both T-cell based test in children, irrespective of TB classification,
compared to adults with confirmed TB.
*Sensitivity analysis of QFT excludes indeterminate results.
{Difference between sensitivity in QFT and TST tested using two-sample test of proportion.
doi:10.1371/journal.pone.0037851.t004
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contact was not associated with a positive QFT result, even after
adjusting for confounders in the multivariable analysis.
Age seemed to influence the test performance as children ,2
years were more likely to have an indeterminate result (adjusted
OR 2.39, p = 0.01).
In adults HIV infection was negatively associated with a positive
QFT result (adjusted OR 0.25, p = 0.04) (table 7), whilst we found
no effect of age, sex or HIV status when analysing risk factors for
an indeterminate result (table 8). We were unable to determine
association with BMI as none with a BMI.18.5 had an
indeterminate result.
Mortality
Eleven children died during admission, whilst an additional 28
children died during the follow up period, resulting in an overall
mortality of 19%. An indeterminate QFT result at baseline was
associated with subsequent high childhood mortality (adjusted OR
3.87, p = 0.003, data not shown) and the cumulative mortality was
significantly higher in children with an indeterminate QFT result
(33%) compared to a determinate result (13%), p,0.001 (figure 2).
Discussion
The main findings of this study were a low sensitivity of both
QFT and TST for diagnosing active TB in children as well as a
high QFT indeterminate rate which was associated with high
subsequent mortality.
We found a surprisingly low sensitivity of QFT in children
with confirmed TB (19%) compared to adults with confirmed
TB (84%). The sensitivity of TST was similarly poor in children
(6%) compared to adults (85%). Using other criteria for
Table 5. Risk factors association with positive QFT results in children.
QFT positive (n)
(N) n/N (%) OR (95% CI) p-value{ Adj OR1 (95% CI) p-value{
Age $2 yrs 17/105 (16.2) 1 – 1 –
,2 yrs 9/49 (18.4) 1.16 (0.48–2.84) 0.73 0.93 (0.34–2.58) 0.89
Sex Female 11/62 (17.7) 1 – 1 –
Male 15/92 (16.3) 0.90 (0.38–2.12) 0.82 0.95 (0.37–2.43) 0.92
HIV status Neg 19/99 (19.2) 1 – 1 –
Pos 6/54 (11.1) 0.53 (0.20–1.41) 0.20 0.61 (0.21–1.77) 0.37
Z-score .22 11/60 (18.3) 1 – 1 –
#22 13/76 (11.9) 0.92 (0.38–2.23) 0.69 1.00 (0.39–2.59) 0.99
History contact No 15/93 (16.1) 1 – 1 –
Yes 11/60 (18.3) 1.17 (0.50–2.75) 0.72 1.37 (0.55–3.41) 0.49
Living PTB+ * No 15/93 (16.3) 1 – 1 –
Yes 7/27 (25.9) 1.82 (0.65–5.06) 0.25 2.83 (0.89–9.03) 0.08
Risk factor analysis using logistic regression analysis found no association between known risk factors and a positive QFT result in children.
OR: unadjusted odds ratio from univariable analysis.
Adj OR: adjusted odds ratio, adjusted for age, sex, HIV, z-score and contact TB case.
{p-value for the odds ratios.
*Compares living with a case of smear positive TB case to those reporting no contact at all.
doi:10.1371/journal.pone.0037851.t005
Table 6. Risk factors association with indeterminate QFT results in children.
QFT indeterminate (n)
(N) n/N (%) OR (95% CI) p-value{ Adj OR (95% CI) p-value{
Age $2 yrs 29/134 (21.6) 1 – 1 –
,2 yrs 28/77 (36.4) 2.07 (1.11–3.85) 0.02 2.39 (1.22–4.68) 0.01
Sex Female 25/87 (28.7) 1 – 1 –
Male 32/124 (25.8) 0.86 (0.47–1.59) 0.64 0.79 (0.40–1.54) 0.49
HIV status Neg 32/131 (24.4) 1 – 1 –
Pos 24/78 (30.8) 1.38 (0.74–2.57) 0.32 1.28 (0.63–2.63) 0.50
Z-score .22 19/79 (24.1) 1 – 1 –
#22 33/109 (30.3) 1.37 (0.71–2.65) 0.35 1.09 (0.53–2.21) 0.82
Risk factor analysis using logistic regression analysis found increased odds of an indeterminate result in children ,2 years.
OR: unadjusted odds ratio from univariable analysis.
Adj OR: adjusted odds ratio, adjusted for age, sex, HIV and z-score.
{p-value for the odds ratios.
doi:10.1371/journal.pone.0037851.t006
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diagnosing TB, such as the clinical TB diagnosis or by including
children with possible TB in the group of TB cases, did not
alter the overall picture of an extremely low sensitivity. In
addition the positive and negative predictive values of QFT in
children were low.
We found a high specificity ($ 90%) for both QFT and TST,
either suggesting that false positive results due to latent TB or
BCG vaccination did not influence the performance of the tests or
reflecting the overall poor performance of the test, with low
proportions of positive results in this population.
The few existing previous paediatric studies have reported QFT
sensitivity for active TB varying from 50%–100% [12]. To our
knowledge only one other study has evaluated QFT in a high
burden setting and they found only 8 children with confirmed TB
and a sensitivity of 63% [13]. Studies evaluating T-SpotH-TB,
another commercially available IGRA (Oxford Immunotec,
Abingdon, UK), in children in a high endemic setting are equally
few, one study in South Africa study with 10 culture confirmed
cases of TB, found a sensitivity of 50% [14].
We found only 12 children with a positive TST, which is
surprising given that 72 (35%) reported contact to person with TB
and 92.9% were BCG vaccinated. The sensitivity of TST (6%) was
even lower than QFT.
Infants are known to have poor production of cytokines, such as
IFN-c, even beyond infancy [15] and there is evidence that an
effective antigen specific response to the MTB infection is delayed
and less effective in infants compared to adults [16] which could
explain our comparatively low positivity rate. Not only young age
[13] but also HIV infection [17] and malnutrition, [18] were
expected to affect test sensitivity, due to immature immune
response or suppression of T-cell response. We found no clear
association in our risk factor analysis between these factors and the
QFT positivity rate, possibly due to small sample size, however we
did find reduced IFN-c responses in children ,2 years, HIV
infected and children who were still ill or had died by 6 month
follow-up. Children in low-income settings often present with
severe TB after a long period of illness, and consequent suboptimal
immune response [19,20]. These findings suggest that the
performance of QFT as well as TST, in these children with
chronic and severe illness, were affected by immature or impaired
immunity and progressive exhaustion of T-cells ability to react
adequately to antigen response [21].
Table 7. Risk factors association with positive QFT result in adults.
QFT positive (n)
(N) n/N (%) OR (95% CI) p-value{ Adj. OR (95% CI) p-value{
Age years* – 1.0 (0.96–1.04) 0.93 0.10 (0.95–1.04) 0.89
Sex Female 11/16 (68.8) 1 1
Male 62/71 (87.3) 3.13 (0.88–11.12) 0.08 2.07 (0.49–8.81) 0.33
HIV status Neg 57/63 (90.5) 1 1
Pos 16/24 (66.7) 0.21 (0.06–0.70) 0.01 0.25 (0.07–0.92) 0.04
BMI $18.5 28/33 (84.9) 1 1
,18.5 45/54 (83.3) 0.89 (0.27–2.94) 0.85 0.81 (0.23–2.84) 0.74
Risk factor analysis using logistic regression analysis found lower odds of a positive QFT result in HIV infected adults.
OR: odds ratio from univariable analysis.
Adj. OR: adjusted odds ratio adjusted for age, sex, HIV infection and BMI.
*Odds ratio calculated as per year increase in age.
{p-value for the odds ratios.
doi:10.1371/journal.pone.0037851.t007
Table 8. Risk factors association with indeterminate QFT result in adults.
QFT indeterminate (n)
(N) n/N (%) OR (95% CI) p-value{ Adj. OR (95% CI) p-value{
Age years* – 1.06 (0.99–1.15) 0.10 1.10 (0.99–1.22) 0.07
Sex Female 2/18 (11.1) 1 – 1 –
Male 1/72 (1.4) 0.11 (0.01–1.32) 0.08 0.02 (0.00–1.28) 0.07
HIV status Neg 2/65 (3.1) 1 – 1 –
Pos 1/25 ((4) 1.31 (0.11–15.15) 0.83 0.47 (0.01–17.02) 0.68
BMI ** $18.5 0/33 – – – –
,18.5 3/57 (5.3) – – – –
Risk factor analysis using logistic regression analysis found no association between suspected risk factors and an indeterminate QFT result in adults.
OR: odds ratio from univariable analysis.
Adj. OR: adjusted odds ratio adjusted for age, sex, HIV infection and BMI.
*Odds ratio calculated as per year increase in age.
**Logistic regression analysis not possible for association between BMI and indeterminate result, since there are no indeterminate results in those with BMI $18.5.
{p-value for the odds ratios.
doi:10.1371/journal.pone.0037851.t008
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Due to the lower levels of IFN-c in response to specific antigens
seen in HIV infected and young children it has been suggested that
a lower cut-off value for a positive QFT for children may be
relevant [22]. However applying a cut-off of 0.26 U/ml to our
data only increased the number of positives by two, both of whom
were classified ‘‘not TB’’. Thus our study does not indicate added
value of a lower cut-off in terms of sensitivity of QFT for active
TB.
The poor sensitivity of, not only QFT but also TST, could also
be explained by misclassification and over-diagnosis of TB
however we included microbiological confirmation, good clinical
response to treatment, in addition to either typical CXR or clinical
features, which is in accordance with the recommendations of the
recent expert consensus report on evaluating TB diagnostics in
children [23].
Like other studies including TB suspect children we found only
a small proportion of culture confirmed cases (2%). In the four
culture confirmed cases of TB there was only one QFT and one
TST positive result (in the same child), indicating that, rather than
a classification problem, the performance of T-cell based assays in
this particular group of children is suboptimal. Two of the
remaining children with culture confirmed TB, were both HIV
positive and severely malnourished, and it reasonable to conclude
that they were not able to mount an adequate immune response.
Our results highlight the difficulties in diagnosing TB in
children and we cannot conclude whether QFT suffers from
extremely low sensitivity in young children with active TB in a
high burden country or whether TB was over-diagnosed in these
very sick children. However in light of the review by Mandalakas
et al [12] which found that sensitivity of IGRAs and TST was
lower in children ,5 years, HIV positive children and in low-
middle income countries, our finding of low sensitivity is not
unlikely.
In adults we found a sensitivity of 84% which compares to the
pooled sensitivity of 80% in a recent review of IGRA studies [8]
and in line with another Tanzanian study [17] and the review by
Metcalfe [24], we also found a lower sensitivity amongst HIV
positive adults.
We found a high indeterminate rate in children (27%)
compared to adults (3%) (p,0.01) with higher rates amongst
children ,2 years and in children who subsequently died after
inclusion. Surprisingly our data did not support a significant
association with HIV infection or malnutrition possibly due to low
numbers.
Indeterminate rates in other paediatric QFT studies range from
0–35% [13,25], high rates correlated with young age [26],
immune suppression [25] and malnutrition [27]. Thomas et al
[27] found, in a study in Bangladesh that indeterminate results
were associated not only with malnutrition but also with helminth
infection, suggesting that children in a generally poor nutritional
state with added infections are less likely to have a determinate
QFT result. Hook worm and schistosomiasis are known to be
highly prevalent amongst school children in the study area [28]
and we can reasonably assume that many of the study participants
were co-infected, which may have influenced the performance of
QFT [29].
In our study 58% of children were defined as being
malnourished. Malnutrition leads to an impaired cellular immu-
nity which could affect the performance of the IGRA tests [18,30]
however several studies conducted in populations with significant
malnutrition [13,31], including the current study, did not find
malnutrition to be associated with reduced positivity rates or
increased indeterminate results. It is possible that weight-for-age z-
score is not the optimal measure for assessing the effect of
malnutrition on IGRA responses. A study of Peruvian adults found
that malnutrition as measured by corrected arm muscle area, but
not BMI or body fat, was associated with decreased TST positivity
[32].
No previous paediatric studies have shown that an indetermi-
nate result is a risk factor for death. To our knowledge only one
Figure 2. Childhood mortality according to Quantiferon TB Gold In-Tube result. Childhood mortality recorded during admission and at 6
month follow-up, according to QFT results. Children who did not attend scheduled follow-up at 6 months were traced and follow-up visits were
conducted in their homes within 7–12 months of inclusion. Both the mortality during admission and the overall mortality in children with an
indeterminate QFT result was significantly higher than in children with a determinate QFT result, p,0.001. * One of 154 children with a determinate
QFT result did not have follow-up data.
doi:10.1371/journal.pone.0037851.g002
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study in TB-suspect HIV positive adults in Uganda has shown that
mortality was higher in those with an indeterminate T-SPOT.TB
result [33]. It is reasonable to hypothesise that the children who
died after inclusion were severely ill and therefore unable to mount
an appropriate immune response. Thus, we suggest that the care
for children with indeterminate results should be intensified with
extensive diagnosis and treatment.
We found a low indeterminate rate of 3% amongst adults. Even
amongst the HIV positive adults, the indeterminate rate was only
4% which contrasts to other studies, including HIV infected
participants, where indeterminate rates reach as high as 21% [34].
HIV infection is known to be associated with lower positivity rates
[35] and our data support these findings.
The samples of both children and adults were taken and
processed concurrently, at the same hospital using the same staff,
procedures and equipment. As such, it is most unlikely that the
poor performance in children was due to technical errors.
Our study suggests that T-cell based assays, such as QFT and
TST, have poor performance in children with immature or
impaired immune systems and that indeterminate results are a
predictor for death. With a sensitivity of 19% amongst children
with confirmed TB and indeterminate rate of 27%, QFT is not the
answer for providing clinicians with a reliable tool for diagnosing
childhood TB in a high burden setting. This conclusion is in line
with recent reports that underline that IGRA cannot be used as a
test to exclude active TB in children [36], that use of IGRAs is not
recommended in children under 5 years [7] and according to
WHO should not be used in low and middle income countries at
all [37]. Whether low sensitivity is due to poor antigen response,
misclassification or over-diagnosis remains a major challenge for
the evaluation of any new diagnostic test for TB in children
however the evidence of high mortality in this vulnerable group
serves to underline the continued importance of research in this
field.
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